AU672583B2 - Recombinant infectious bovine rhinotracheitis virus - Google Patents
Recombinant infectious bovine rhinotracheitis virus Download PDFInfo
- Publication number
- AU672583B2 AU672583B2 AU23932/92A AU2393292A AU672583B2 AU 672583 B2 AU672583 B2 AU 672583B2 AU 23932/92 A AU23932/92 A AU 23932/92A AU 2393292 A AU2393292 A AU 2393292A AU 672583 B2 AU672583 B2 AU 672583B2
- Authority
- AU
- Australia
- Prior art keywords
- virus
- ibr
- gene
- dna
- glycoprotein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 241000701083 Bovine alphaherpesvirus 1 Species 0.000 title claims description 40
- 241000700605 Viruses Species 0.000 claims description 607
- 208000005562 infectious bovine rhinotracheitis Diseases 0.000 claims description 456
- 108020004414 DNA Proteins 0.000 claims description 335
- 108090000623 proteins and genes Proteins 0.000 claims description 223
- 238000000034 method Methods 0.000 claims description 186
- 108090000288 Glycoproteins Proteins 0.000 claims description 131
- 102000003886 Glycoproteins Human genes 0.000 claims description 130
- 238000012217 deletion Methods 0.000 claims description 112
- 230000037430 deletion Effects 0.000 claims description 112
- 229960005486 vaccine Drugs 0.000 claims description 112
- 241001465754 Metazoa Species 0.000 claims description 95
- 241000283690 Bos taurus Species 0.000 claims description 58
- 230000003053 immunization Effects 0.000 claims description 52
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 42
- 102000004169 proteins and genes Human genes 0.000 claims description 33
- 241000588724 Escherichia coli Species 0.000 claims description 32
- 101150108190 US2 gene Proteins 0.000 claims description 30
- 210000001124 body fluid Anatomy 0.000 claims description 21
- 239000010839 body fluid Substances 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 208000015181 infectious disease Diseases 0.000 claims description 20
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 15
- 101800000385 Transmembrane protein Proteins 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 241000711895 Bovine orthopneumovirus Species 0.000 claims description 13
- 241000702673 Bovine rotavirus Species 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 229920001184 polypeptide Polymers 0.000 claims description 11
- 101710170970 Leukotoxin Proteins 0.000 claims description 10
- 230000003612 virological effect Effects 0.000 claims description 10
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 9
- 108020001507 fusion proteins Proteins 0.000 claims description 8
- 101000807236 Human cytomegalovirus (strain AD169) Membrane glycoprotein US3 Proteins 0.000 claims description 7
- 108090001074 Nucleocapsid Proteins Proteins 0.000 claims description 7
- 108010046722 Thrombospondin 1 Proteins 0.000 claims description 7
- 230000002458 infectious effect Effects 0.000 claims description 7
- 102100036034 Thrombospondin-1 Human genes 0.000 claims description 6
- 102000037865 fusion proteins Human genes 0.000 claims description 6
- FBUKMFOXMZRGRB-UHFFFAOYSA-N Coronaric acid Natural products CCCCCC=CCC1OC1CCCCCCCC(O)=O FBUKMFOXMZRGRB-UHFFFAOYSA-N 0.000 claims description 5
- 238000007918 intramuscular administration Methods 0.000 claims description 4
- 230000000241 respiratory effect Effects 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 3
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 238000010253 intravenous injection Methods 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 230000007501 viral attachment Effects 0.000 claims description 3
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- 108010059722 Viral Fusion Proteins Proteins 0.000 claims description 2
- 206010051497 Rhinotracheitis Diseases 0.000 claims 3
- 230000000890 antigenic effect Effects 0.000 claims 2
- 206010044302 Tracheitis Diseases 0.000 claims 1
- 102000005936 beta-Galactosidase Human genes 0.000 claims 1
- 239000012634 fragment Substances 0.000 description 241
- 101710128479 Tail assembly protein G Proteins 0.000 description 139
- 101710125418 Major capsid protein Proteins 0.000 description 110
- 239000003550 marker Substances 0.000 description 85
- 239000013612 plasmid Substances 0.000 description 83
- 210000004027 cell Anatomy 0.000 description 72
- 241001529453 unidentified herpesvirus Species 0.000 description 72
- 108020005202 Viral DNA Proteins 0.000 description 69
- 239000013598 vector Substances 0.000 description 66
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 64
- 150000001413 amino acids Chemical group 0.000 description 54
- 101150066555 lacZ gene Proteins 0.000 description 38
- 239000000523 sample Substances 0.000 description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 34
- 108091026890 Coding region Proteins 0.000 description 33
- 108020004440 Thymidine kinase Proteins 0.000 description 33
- 239000000427 antigen Substances 0.000 description 33
- 108091007433 antigens Proteins 0.000 description 33
- 102000036639 antigens Human genes 0.000 description 33
- 239000002299 complementary DNA Substances 0.000 description 29
- 238000001890 transfection Methods 0.000 description 29
- 238000010367 cloning Methods 0.000 description 27
- 102000006601 Thymidine Kinase Human genes 0.000 description 26
- 238000011144 upstream manufacturing Methods 0.000 description 26
- 238000003780 insertion Methods 0.000 description 25
- 230000037431 insertion Effects 0.000 description 25
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 23
- 230000010076 replication Effects 0.000 description 23
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 22
- 229930193140 Neomycin Natural products 0.000 description 22
- 238000010276 construction Methods 0.000 description 22
- 229960004927 neomycin Drugs 0.000 description 22
- 108091008146 restriction endonucleases Proteins 0.000 description 22
- 241001045988 Neogene Species 0.000 description 21
- 210000003754 fetus Anatomy 0.000 description 21
- 230000000875 corresponding effect Effects 0.000 description 20
- 239000002609 medium Substances 0.000 description 20
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 19
- 244000309466 calf Species 0.000 description 19
- 230000006801 homologous recombination Effects 0.000 description 18
- 238000002744 homologous recombination Methods 0.000 description 18
- 244000005700 microbiome Species 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 101150091879 neo gene Proteins 0.000 description 17
- 239000008188 pellet Substances 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 230000014616 translation Effects 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- 230000008488 polyadenylation Effects 0.000 description 16
- 238000013519 translation Methods 0.000 description 16
- 239000007983 Tris buffer Substances 0.000 description 15
- 238000003752 polymerase chain reaction Methods 0.000 description 15
- 239000013615 primer Substances 0.000 description 15
- 238000002255 vaccination Methods 0.000 description 15
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 14
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 14
- 238000002105 Southern blotting Methods 0.000 description 14
- 101150003725 TK gene Proteins 0.000 description 14
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 14
- 108700026244 Open Reading Frames Proteins 0.000 description 13
- 238000010586 diagram Methods 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 241001293418 Mannheimia haemolytica Species 0.000 description 12
- 230000004927 fusion Effects 0.000 description 12
- 238000011081 inoculation Methods 0.000 description 12
- 239000013600 plasmid vector Substances 0.000 description 12
- 238000005304 joining Methods 0.000 description 11
- LINMATFDVHBYOS-MBJXGIAVSA-N (2s,3r,4s,5r,6r)-2-[(5-bromo-1h-indol-3-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C=C12 LINMATFDVHBYOS-MBJXGIAVSA-N 0.000 description 10
- 101000984570 Enterobacteria phage T4 Baseplate wedge protein gp53 Proteins 0.000 description 10
- 101000997743 Escherichia phage Mu Serine recombinase gin Proteins 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 230000029087 digestion Effects 0.000 description 10
- 230000002255 enzymatic effect Effects 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 101150008820 HN gene Proteins 0.000 description 9
- 108700002232 Immediate-Early Genes Proteins 0.000 description 9
- 108020004511 Recombinant DNA Proteins 0.000 description 9
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 230000001605 fetal effect Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 208000002289 Bovine Respiratory Disease Complex Diseases 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 101001002508 Homo sapiens Immunoglobulin-binding protein 1 Proteins 0.000 description 8
- 102100021042 Immunoglobulin-binding protein 1 Human genes 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 108010008529 bovine viral diarrhea virus gp53 Proteins 0.000 description 8
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 8
- 239000013599 cloning vector Substances 0.000 description 8
- 230000000120 cytopathologic effect Effects 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000003259 recombinant expression Methods 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 101100437498 Escherichia coli (strain K12) uidA gene Proteins 0.000 description 7
- 101150034814 F gene Proteins 0.000 description 7
- 102100034349 Integrase Human genes 0.000 description 7
- 101001056675 Klebsiella pneumoniae Ferric aerobactin receptor Proteins 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 238000013507 mapping Methods 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 238000012809 post-inoculation Methods 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 101710154606 Hemagglutinin Proteins 0.000 description 6
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 6
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 6
- 101710176177 Protein A56 Proteins 0.000 description 6
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 6
- 241000702670 Rotavirus Species 0.000 description 6
- 108091081024 Start codon Proteins 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 230000037452 priming Effects 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 230000000405 serological effect Effects 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 229920000936 Agarose Polymers 0.000 description 5
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 5
- 239000005695 Ammonium acetate Substances 0.000 description 5
- 101000942694 Bos taurus Clusterin Proteins 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- 101150027427 ICP4 gene Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 241000606860 Pasteurella Species 0.000 description 5
- 235000019257 ammonium acetate Nutrition 0.000 description 5
- 229940043376 ammonium acetate Drugs 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 239000013592 cell lysate Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 230000001018 virulence Effects 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 4
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 4
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 108010062697 pseudorabies virus glycoproteins Proteins 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- 210000004927 skin cell Anatomy 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 244000153158 Ammi visnaga Species 0.000 description 3
- 235000010585 Ammi visnaga Nutrition 0.000 description 3
- 102100026189 Beta-galactosidase Human genes 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000034354 Gi proteins Human genes 0.000 description 3
- 108091006101 Gi proteins Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 206010053459 Secretion discharge Diseases 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108091036066 Three prime untranslated region Proteins 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 206010000210 abortion Diseases 0.000 description 3
- 231100000176 abortion Toxicity 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000012224 gene deletion Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 101150028074 2 gene Proteins 0.000 description 2
- 101710154825 Aminoglycoside 3'-phosphotransferase Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000010711 Cattle disease Diseases 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 101710181600 Glycoprotein gp2 Proteins 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 101150039660 HA gene Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 241000948165 Milk vetch dwarf virus Species 0.000 description 2
- 241000711408 Murine respirovirus Species 0.000 description 2
- 241000282339 Mustela Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 2
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 2
- 208000007452 Plasmacytoma Diseases 0.000 description 2
- 208000008939 Pneumonic Pasteurellosis Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108700026226 TATA Box Proteins 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 206010051511 Viral diarrhoea Diseases 0.000 description 2
- 230000010530 Virus Neutralization Effects 0.000 description 2
- 101150003160 X gene Proteins 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- 230000000994 depressogenic effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 238000009585 enzyme analysis Methods 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 101150002378 gC gene Proteins 0.000 description 2
- 101150030521 gI gene Proteins 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 230000000521 hyperimmunizing effect Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 235000020030 perry Nutrition 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 2
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- PUMZXCBVHLCWQG-UHFFFAOYSA-N 1-(4-Hydroxyphenyl)-2-aminoethanol hydrochloride Chemical compound [Cl-].[NH3+]CC(O)C1=CC=C(O)C=C1 PUMZXCBVHLCWQG-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-OYDXRQHMSA-N 1-[(2r,4s,5s)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H]([14CH2]O)[C@@H](O)C1 IQFYYKKMVGJFEH-OYDXRQHMSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000030939 Bubalus bubalis Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 241000283716 Connochaetes Species 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- 241001649081 Dina Species 0.000 description 1
- 101150060442 EO gene Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 101710126486 Envelope glycoprotein D Proteins 0.000 description 1
- 101710126496 Envelope glycoprotein I Proteins 0.000 description 1
- 101900264058 Escherichia coli Beta-galactosidase Proteins 0.000 description 1
- 241001452028 Escherichia coli DH1 Species 0.000 description 1
- 101100004352 Escherichia coli lacZ gene Proteins 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 101150082239 G gene Proteins 0.000 description 1
- 101710112524 GDP-mannose transporter 2 Proteins 0.000 description 1
- 241000701047 Gallid alphaherpesvirus 2 Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101001129187 Homo sapiens Patatin-like phospholipase domain-containing protein 2 Proteins 0.000 description 1
- 101001077660 Homo sapiens Serine protease inhibitor Kazal-type 1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 101900276892 Human herpesvirus 2 Protein US2 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 101900208483 Human parainfluenza 3 virus Fusion glycoprotein F0 Proteins 0.000 description 1
- 241000712003 Human respirovirus 3 Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 241001460678 Napo <wasp> Species 0.000 description 1
- 101710118186 Neomycin resistance protein Proteins 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000282943 Odocoileus Species 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102100031248 Patatin-like phospholipase domain-containing protein 2 Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710088555 Probable GDP-mannose transporter 2 Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100039028 Protein SPO16 homolog Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000013616 RNA primer Substances 0.000 description 1
- 244000097202 Rathbunia alamosensis Species 0.000 description 1
- 235000009776 Rathbunia alamosensis Nutrition 0.000 description 1
- MJNIWUJSIGSWKK-UHFFFAOYSA-N Riboflavine 2',3',4',5'-tetrabutanoate Chemical compound CCCC(=O)OCC(OC(=O)CCC)C(OC(=O)CCC)C(OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-UHFFFAOYSA-N 0.000 description 1
- 102100037968 Ribonuclease inhibitor Human genes 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 101150108548 SPO16 gene Proteins 0.000 description 1
- 241000701062 Saimiriine gammaherpesvirus 2 Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102100025144 Serine protease inhibitor Kazal-type 1 Human genes 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 108010016200 Zinc Finger Protein GLI1 Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- ANAKGLHGKIVHLU-UHFFFAOYSA-N azanium;ethanol;acetate Chemical compound [NH4+].CCO.CC([O-])=O ANAKGLHGKIVHLU-UHFFFAOYSA-N 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- UFJPAQSLHAGEBL-RRKCRQDMSA-N dITP Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(N=CNC2=O)=C2N=C1 UFJPAQSLHAGEBL-RRKCRQDMSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 101150072564 gE gene Proteins 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- OBLBPUMQXLQMDZ-UHFFFAOYSA-N jjs-92 Chemical compound FC1=CC=CC=C1C(=O)N1C(C=2C3=CC=C(C=2)C=2C=C4OCOC4=CC=2)CC3CC1 OBLBPUMQXLQMDZ-UHFFFAOYSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- YFVGRULMIQXYNE-UHFFFAOYSA-M lithium;dodecyl sulfate Chemical compound [Li+].CCCCCCCCCCCCOS([O-])(=O)=O YFVGRULMIQXYNE-UHFFFAOYSA-M 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- KRZWEBVPFGCYMY-UHFFFAOYSA-M methylmercury(1+);hydroxide Chemical compound [OH-].[Hg+]C KRZWEBVPFGCYMY-UHFFFAOYSA-M 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229960001576 octopamine Drugs 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 229940037201 oris Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 108010024226 placental ribonuclease inhibitor Proteins 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- HJRIWDYVYNNCFY-UHFFFAOYSA-M potassium;dimethylarsinate Chemical compound [K+].C[As](C)([O-])=O HJRIWDYVYNNCFY-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 208000009305 pseudorabies Diseases 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000001944 turbinate Anatomy 0.000 description 1
- 101150101459 tx gene Proteins 0.000 description 1
- 101150101900 uidA gene Proteins 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16741—Use of virus, viral particle or viral elements as a vector
- C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Farming Of Fish And Shellfish (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
ECOW 1 ERION I Z3 4 c
I@~
PCT
Spages 140-152, claims, replaced by new pages 140-152 International uureau INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (51) International Patent Classification 5 (1 International Publication Number: WO 93/02104 C07K 7/10, C12N 7/01, 15/38 Al Cl2N 15/63 (43) International Publication Date: 4 February 1993 (04.02.93) (21) International Application Number: PCT/US92/06034 (72) Inventors; and Inventors/Applicants (for US only) COCHRAN, Mark, D.
(22) International Filing Date: 20 July 1992 (20.07.92) [US/US]; 4019 Crescent Point Road, Carlsbad, CA 92008 MACDONALD, Richard, D. [CA/US]; 6242 Snowbond Street, San Diego, CA 92120 (US).
Priority data: 732,584 18 July 1991 (18.07.91) US (74) Agent: WHITE, John, Cooper Dunham, 30 Rockefeller Plaza, New York, NY 10112 (US).
Parent Application or Grant (63) Related by Continuation (81) Designated States: AU, CA, HU, JP, KR, PL, RO, RU, US 732,584 (CIP) US, European patent (AT, BE, CH, DE, DK, ES, FR, Filed on 18 July 1991 (18.07.91) GB, GR, IT, LU, MC, NL, SE).
(71) Applicant (for all designated States except US): SYNTRO Published CORPORATION [US/US]; 9669 Lackman Road, Lene- With international search report.
xa, KS 66219 ulccii rcscov'c andor c.
cvc/oprici+ P^+-eBh 120 fi P;dcle, PorL DDrive Coonu 4 y of i' Santa char'a Call'o i'rola ASsli,.. /P Uni +cd Stcfcs of Amneic-c.
(54) Title: RECOMBINANT INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS (57) Abstract The present invention provides recombinant infectious bovine rhinotracheitis (IBR) viruses useful in vaccines to protect bovi- s from diseases particular to them, including infectious bovine rhinotracheitis and bovine respiratory disease complex. The present invention further provides methods for distinguishing an animal vaccinated with a vaccine of the present invention from an animal infected with a naturally-occurring IBR virus. The present invention also provides isolated DNA encoding the gpE glycoprotein, the gpG glycoprotein, and US2 genes of an IBR virus. The present invention further provides homology vectors for producing recombinant IBR viruses.
0 (Rlfrred to in PCTT Gazztue No. 09/1993, seciion II) WO 93/02104 PCT/ US92/06034 -1- RECOMBINANT INFECTIOUS BOVINE RHINOTRACHEITIS VIRUS Within this application several publications are referenced by arabic numerals within parentheses. Full citations for these publications may be found at the end of the specification immediately preceding the claims.
The disclosures of these publications are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.
Field of the Invention The present invention involves recombinant infectious bovine rhinotracheitis (IBR) viruses useful in vaccines to protect bovines from naturally-occurring infectious bovine rhinotracheitis virus and other bovine diseases.
Background of the Invention The ability to isolate viral DNA and clone this isolated DNA into bacterial plasmids has greatly expanded the approaches available to make viral vaccines. The methods used to make the present invention involve modifying cloned viral DNA sequences by insertions, deletions and single or multiple base changes. The modified DNA is then reinserted into the viral genome to render the virus non-pathogenic. The resulting live virus may then be used in a vaccine to elicit an immune response in a host animal and to protect the animal against a disease.
One group of animal viruses, the herpesviruses or Herpetoviridae, is an example of a class of viruses amenable to this approach. These viruses contain 100,000 to 200,000 base pairs of DNA as their genetic material.
Importantly, several regions of the genome have been WO 93/02104 PCT/US92/06034 -2identified that are nonessential for the replication of virus in vitro in cell culture. Modifications in these regions of the DNA may lower the pathogenicity of the virus, attenuate the virus. For example, inactivation of the thymidine kinase gene renders human herpes simplex virus non-pathogenic and pseudorabies virus of swine non-pathogenic (29).
Removal of part of the repeat region renders human herpes simplex virus non-pathogenic (30,31). A repeat region has been identified in Marek's disease virus that is associated with viral oncogenicity A region in herpesvirus saimiri has similarly been correlated with oncogenicity Removal of part of the repeat region renders pseudorabies virus non-pathogenic Patent No. 4,877,737, issued October 31, 1989). A region in pseudorabies virus has been shown to be deleted in naturally-occurring vaccine strains (11,3) and it has been shown that these deletions are at least partly responsible for the lack of pathogenicity of these strains.
It is generally agreed that herpesviruses contai nonessential regions of DN% in various parts of the genome, and that modifications of .hese regions can attenuate the virus, leading to a non-pathogenic strain from which a vaccine may be derived. The degree of attenuation of the virus is important to the utility of the virus as a vaccine. Deletions which cause too much attenuation of the virus will result in a vaccine that fails to elicit an adequate immune response. Although several examples of attenuating deletions are known, the appropriate ccmbination of deletions is not readily apparent.
Infectious bovine rhinotracheitis (IBR) virus, an alphaherpesvirus with a class D genome, is an important pathogen of cattle. It has been associated with WO 93/02104 PCT/US92/06034 -3respiratory, ocular, reproductive, central nervous system, enteric, neonatal, and dermal diseases (34).
Cattle are the normal hosts of IBR virus, however it also infects goats, swine, water buffalo, wildebeest, mink, and ferrets. Experimental infections have been established in mule deer, goats, swine, ferrets, and rabbits Conventional modified live virus vaccines have been widely used to dontrol diseases caused by IBR virus.
However, these vaccine viruses may revert to virulence.
More recently, killed virus IBR vaccines have been used, but their efficacy appears to be marginal.
IBR virus has been analyzed at the molecular level as reviewed in Ludwig A restriction map of the genome is available in this reference, which will aid in the genetic engineering of IBR according to the methods provided by the present invention.
As reported in the current literature, IBR virus has been engineered to contain a thymidine kinase deletion (43,44) and a deletion in the gill gene (45,46). However, no evidence has been presented for the deletions in the US2, repeat, gpG, or gpE regions. In the subject application, we demonstrate the usefulness of such deletions for both the attenuation of IBR virus and for the development of gene deleted marker vaccines.
As with other herpesviruses, IBR virus can become latent in healthy animals which makes them potential carriers of the virus. For this reason it is clearly advantageous to be able to distinguish animals vaccinated with nonvirulent virus from animals infected with disease-causing wild type virus. The development of differential vaccines and companion diagnostic tests has proven valuable in the management of pseudorabies disease (47).
WO 93/021041 PCT/US92/06034 -4- A similar differential marker vaccine would be of great value in the management of IBR disease. The construction of differential diagnostics has focused on the deletion of glycoproteins. Theoretically, the glycoprotein chosen to be the diagnostic marker should have the following characteristics: the glycoprotein and its gene should be non-essential for the production of infectious virus in tissue culture; the glycoprotein should elicit a major serological response in the animal; and the glycoprotein should not be one that makes a significant contribution to the protective immunity.
Four major IBR virus glycoproteins (gl, gII, gIll, and gIV) have been described in the literature Three of these genes, gI, gIII, and gIV, have been sequenced and shown to be homologous to the HSV glycoproteins gB, gC, and gD, respectively. Although it has been suggested that the glI protein is analogous to HSV gE, no sequence evidence has been presented to confirm that suggestion The gB and gD homologues are essential genes and would not be appropriate as deletion marker genes. The gC gene of herpesviruses has been shown to make a significant contribution to protective immunity as a target of neutralizing antibody (49) and as a target of cell-mediated immunity Therefore, the gC gene is not desirable as a deletion marker gene. As indicated above, Kit et al. (45) have described the deletion of the IBR virus gIll as a marker gene. It would be expected that such a deletion would compromise the efficacy of an IBR vaccine.
For pseudorabies virus (PRV) the criteria for a deletion marker gene are best met by the glycoprotein X (51).
Wirth et al. (52) suggests the existence of a "gX homologue of HSV-1" in the IBR virus. It is not clear what is meant by this because although there is a PRV gX gene, there is no reported HSV-1 gX gene or gX homologous gene. In any case, no sequence evidence is presented to WO 93/02104 PCT/US92/06034 support this suggestion. WA present clear evidence of homologues of PRV gX (HSV-2 g, and PRV gI (HSV gE) in IBR virus and demonstrate their usefulness as diagnostic markers.
The present invention provides a method of producing a fetal-safe, live recombinant IBR virus which comprises treating viral T- from a naturally-occurring live IBR virus so as to delete from the virus DNA corresponding to the US2 region of the naturally-occurring IBR virus. The present invention also provides viruses in which DNA corresponding to the US2 region of naturally-occurring IBR virus has been deleted, and DNA encoding gpG and/or gpE has been altered or deleted. Such viruses are useful in vaccines which need diagnostic markers and are safe for use in pregnant animals.
The ability to engineer DNA viruses with large genomes, such as vaccinia virus and the herpesviruses, has led to the finding that these recombinant viruses can be used as vectors to deliver immunogens to animals The herpesviruses are attractive candidates for development as vectors because their host range is primarily limited to a single target species and they have the capacity for establishing a latent infection (55) that could provide for stable in vivo expression of a desired cloned polypeptide. Herpesviruses have been engineered to express a variety of foreign gene products, such as bovine growth hormone human tissue plasminogen activator and E. coli B-galactosidase (58,59). In addition, possible immunogenic polypeptides have been expressed by herpesviruses. Whealy et al. (60) expressed portions of the human immunodeficiency virus type 1 envelope glycoprotein in pseudorabies virus (PRV) as fusions to the PRV glycoprotein III. The hepatitis B virus surface antigen (61) and a hybrid human malaria antigen from Plasmodium falciparum have been expressed in WO 93/02104 PCr/US92/06034 -6herpes simplex virus type 1 (HSV-1) The IBR viruses described above may be used as vectors for the insertion of genes encoding antigens from microorganisms causing important cattle diseases. Such recombinant viruses would be multivalent vaccines protecting against IBR as well as other diseases. Kit et al. (63) have described the expression of a Foot and Mouth disease antigen in IBR virus. In some of the prior applications from which the subject application claims priority (which precedes the Kit publication by at least three years), we described the use of IBR virus to express several foreign genes including the E. coli B-galactosidase (lacZ) gene, the TN5 neomycin resistance gene, and antigens from bovine rota virus, and parainfluenza type 3 virus (see U.S. Serial No. 06/933,107, filed November 20, 1986 and U.S. Serial No. 07/078,519, filed July 27, 1987). These applications precede the Kit publication by at least three years. The viruses described in this application provide a combination of attenuation, differentiation and multivalency. These properties make such viruses useful as vaccines for the management of cattle diseases.
WO 93/02104 PCVTUS92/06034 -7- Summarv of the Invention The present invention provides recombinant infectious bovine rhinotracheitis (IBR) viruses useful in vaccine.
to protect bovines from infectious bovine rhinotracheitis and other bovine diseases. The present invention further provides methods for distinguishing an animal vaccinated with the vaccine of the present invention from an animal infected with a naturally-occurring IBR virus. The present invention also provides isolated DNA encoding the gpE glycoprotein of IBR virus and isolated DNA encoding the gpG glycoprotein of IBR virus. The present invention also provides a method of producing a fetal-safe, live recombinant IBR virus which comprises treating viral DNA from a naturally-occurring live IBR virus so as to delete from the virus DNA corresponding to the US2 region of the naturally-occurring IBR virus.
The present invention also provides isolated DNA encoding the US2 gene of an IBR virus. The present invention further provides a homology vector for producing a recombinant IBR virus by inserting foreign DNA into the genomic DNA of an IBR virus which comprises a doublestranded DNA molecule consisting essentially of doublestranded foreign DNA encoding RNA which does not naturally occur in an animal into which the recombinant IBR is introduced and at one end of the foreign DNA, double-stranded IBR viral DNA homologous to genomic DNA located at one side of a site on the genomic DNA which is not essential for replication of the IBR virus and at the other end of the foreign DNA, double-stranded IBR viral DNA homologous to genomic DNA located at the other side of the same site on the genomic DNA.
The present invention also provides for a homology vector for producing a recombinant IBR virus by deleting DNA which encodes a detectable marker which had been inserted WO 93/02104 PCT/US92/06034 -8into the genomic DNA of an IBR virus comprising a doublestranded DNA molecule consisting essentially of doublestranded IBR viral DNA homologous to the genomic DNA which flanks on each side the DNA to be deleted. The present invention further provides a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus from which DNA from the US2 gene, the gpE glycoprotein gene and the gpG glycoprotein gene has been deleted so that upon replication, the recombinant IBR virus produces no gpE glycoprotein and no gpG glycoprotein. The invention also provides a vaccine which comprises an effective immunizing amount of a recombinant virus protective against bovine respiratory disease complex and a suitable carrier.
WO 93/02104 /Cr/US92/06034 -9- Brief Description of the Figures Figure 1 Details of the IBR Cooper Strain. Diagram of IBR genomic DNA showing the unique long, internal repeat, unique short, and Terminal repeat regions. Restriction maps for the enzymes HindIII, EcoRI, and XbaI are indicated Fragments are lettered in order of decreasing size. The unique short region is also expanded for inclusion of more detail.
The location of several genes is also indicated, they are unique short 2 (TTS2), immediate early genes (IE) glycoprotein G (gpG), glycoprotein IV (gpIV) (17), glycoprotein E (gpE). Note that due to the inversion of the short region, which includes the unique short, internal, and terminal repeats, four half molar HindXII fragments are present (HindIII D, C, F, and H).
Details of S-IBR-002. Diagram of S-IBR-002 Q'enomic DNA showing the unique long, internal repeat, unique short, and Terminal repeat regions. Restriction maps for the enzymes HindIII, EcoRI, and Xbal are indicated Fragments are lettered in order of decreasing size. The EcoRI B and F fragments are expanded for inclusion of more detail. The "800 BP repeat deletions are indicated by deltas. Note that due to the inversion of the short region, which includes the unique short, internal, and terminal repeats, four half molar HindIII fragments are present (HindIII D, C, F, and H).
DNA sequence of the IBR Unique Short 2 gene.
The sequence of the first 1080 base pair's of the HindIII K fragment, reading from the Figure 2 Figure 3 WO 93/02104 PCIS/US92!06034 Figure 4 HindIII K/HindIII 0 junction, are shown. The unique short 2 (US2) gene is transcribed toward the HindIII K/HindIII 0 junction as indicated in Figure 1. The sequence has been reversed and complemented in order to show the translation start and termination of US2 gene.
Homology between the IBR US2 protein and the US2 proteins of HSV-1, PRV, HSV-2, and MDV.
Matrix plot of the amino acid sequence of the IBR US2 protein (309) against the amino acid sequence of the HSV-1 US2 protein (291) Alignment of the conserved region between IBR US2 protein, HSV-1 US2 protein, PRV US2 protein (256 amino acids, HSV-2 US2 protein (291) and MDV US2 protein (270 amino acids) Details of the Nasalgen deletion. Diagram of IBR genomic DNA showing the unique long, internal repeat, unique short, and terminal repeat regions. A restriction map for the enzyme HindIII is indicated. Fragments are lettered in order of decreasing size. The unique short region is expanded for inclusion of more detail. The location of the deletion in the Nasalgen HindIII K fragment is shown.
Three regions of DNA sequence are also shown.
The first line shows the first 60 base pairs upstream of the HindIII 0/HindIII D junction in the IBR Cooper strain. The second line shows the first 60 base pairs upstream of the HindIII K/HindIII D junction in the Nasalgen strain.
The third line shows 60 base pairs flanking the DNA encoding amino acid 59 of the IBR US2 gene in the IBR Cooper strain.
Figure 5 WO 93/02104 PC1 US92/06034 -11- Figure 6 Details of S-IBR-027. Diagram of S-IBR-027 genomic DNA showing the unique long, internal repeat, unique short, and terminal repeat regions. Restriction maps for the enzymes HindIII, EcoRI, and XbaI are indicated Fragments are lettered in order of decreasing size. The unique short region is also expanded for inclusion of more detail. The location of several genes is also indicated, they are unique short 2 (US2), immediate early genes (IE) glycoprotein G (gpG), glycoprotein IV (gpIV) glycoprotein E (gpE). The unique short region and repeat region deletions are indicated by deltas. The location of the approximately 1200 BP deletion of the US2 gene is shown in the expanded region. Note that due to the inversion of the short region, which includes the unique short, internal, and terminal repeats, four half molar HindIII fragments are present (HindIII D, C, F, and H).
Detailed description of the DNA insertion in Homology Vector 129-71.5. Diagram showing the orientation of DNA fragments assembled in plasmid 129-71.5. The origin of each fragment is indicated in the table. The sequences located at each of the junctions between fragments is also shown. The restriction sites used to generate each fragment as well as synthetic linker sequences which were used to join the fragments are described for each junction. The synthetic linker sequences are underlined by a heavy bar. The location of several gene coding regions and regulatory elements i: also given. The following two conventions are used: numbers in parentheses, refer to amino acids, and restriction sites Figure 7 WO 93/02104 PCIr/U S92/06034 Figure 8 Figure 9 -12in brackets, indicate the remnants of sites which were destroyed during construction. The following abbreviations are used: polyadenylation signal infectious bovine rhinotracheitis virus (IBR), Herpes simplex virus type 1 (HSV-1), thymidine kinase (TK), neomycin resistance (NEO), bacterial transposon DNA sequence of the IBR glycoprotein G gene.
The sequence of approximately 1400 base pairs of the HindIII K fragment, starting approximately 2800 base pairs downstream of the HindIII K/HindIII 0 junction, are shown. The glycoprotein G (gpG) gene is transcribed away from the HindIII K/HindIII 0 junction as indicated in Figur2 1. The translational start and termination of the gpG gene are indicated.
Homology between the IBR gpG protein, the gpX protein of PRV and the gpG protein of HSV-2.
Matrix plot of the amino acid sequence of the IBR gpG protein (441) against the amino acid sequence of the PRV gpX protein (498) Alignment of the conserved region between IBR gpG protein, PRV gpX protein, and HSV-2 gpG protein (699) Note that IUPAC- IUB Biochemical Nomenclature Commission conventions are used.
Western blot of proteins released into the medium of IBR and PRV infected cells, showing the absence of gpG in S-PRV-013, S-IBR-035, S- IBR-036, S-IBR-037, and S-IBR-038 but its presence in S-PRV-160 and wild type S-IBR-000.
Lanes 0.5 gg purified gpG, blank lane, S-PRV-160, S-PRV-013, pre-stained Figure 10 WO 93/02104 W 2Cr/ LUS92/06034 Figure 11 -13molecular weight markers, 0.5 gg purified gpG, S-IBR-038, S-IBR-037, S-IBR- 036, S-IBR-035, S-IBR-000, (L) uninfected MDBK cells, pre-stained molecular weight markers. Media samples were prepared as described in the PREPARATION OF HERPESVIRUS CELL LYSATES. The concentrated media from the infection of one 6 cm dish of infected cells was loaded in each sample lane except for samples S-PRV-013 and S-PRV-160 for which the media from two 6 cm dishes were loaded.
Detailed description of the DNA insertion in Plasmid 459-12.6. Diagram showing the orientation of DNA fragments assembled in plasmid 459-12.6. The origin of each fragment is indicated in the table. The sequenres located at each of the junctions between fragments is also shown. The restriction sites used to generate each fragment as well as synthetic linker sequences which were used to join the fragments are described for each junction. The synthetic linker sequences are underlined by a heavy bar. The location of several gene coding regions and regulatory elements is also given. The following two conventions are used: numbers in parentheses, refer to amino acids, and restriction sites in brackets, indicate the remnants of sites which were destroyed during construction. The following abbreviations are used: unique glycoprotein G (gpG), glycoprotein III (gpIII), glycoprotein X (gpX), polyadenylation signal infectious bovine rhinotracheitis virus (IBR), pseudorabies virus (PRV), and human cytomegalovirus (HCMV).
WO 93/02104 W 0c6r/US92/6034 -14- Figure 12 Detailed description of the DNA insertion in Homology Vector 439-01.31. Diagram showing the orientation of DNA fragments assembled in plasmid 439-01.31. The origin of each fragment is indicated in the table. The sequences located at each of the junctions between fragments is also shown. The restriction sites used to generate each fragment as well as synthetic linker sequences which were used to join the fragments are described for each junction. The synthetic linker sequences are underlined by a heavy bar. The location of several gene coding regions and regulatory elements is also given. The following two conventions are used: numbers in parentheses, refer to amino acids, and restriction sites in brackets, indicate the remnants of sites which were destroyed during construction. The following abbreviations are used: unique short 2 (US2), glycoprotein G (gpG), glycoprotein IV (gpIV), polyadenylation signal infectious bovine rhinotracheitis virus (IBR), pseudorabies virus (PRV), and human cytomegalovirus (HCMV).
Detailed description of the DNA insertion in Homology Vector 439-21.69. Diagram showing the orientation of DNA fragments assembled in plasmid 439-21.69. The origin of each fragment is indicated in the table. The sequences located at each of the junctions between fragments is also shown. The restriction sites used to generate each fragment as well as synthetic linker sequences which were used to join the fragments are described for each junction. The synthetic linker sequences are underlined by a heavy bar. The location of Figure 13 WO 93/02104 9I'/20rI S92/06034 several gene coding regions and regulatory elements is also given. The following two conventions are used: numbers in parentheses, refer to amino acids, and restriction sites in brackets, indicate the remnants of sites which were destroyed during construction. The following abbreviations are used: unique short 2 (US2), glycoprotein G (gpG), glycoprotein IV (gpIV), polyadenylation signal infectious bovine rhinotracheitis virus (IBR), pseudorabies virus (PRV), and human cytomegalovirus (HCMV).
Figure 14 Detailed description of the DNA insertion in Homology Vector 439-70.4. Diagram showing the orientation of DNA fragments assembled in plasmid 439-70.4. The origin of each fragment is indicated in the table. The sequences located at each of the junctions between fragments is also shown. The restriction sites used to generate each fragment as well as synthetic linker sequences which were used to join the fragments are described for each junction. The synthetic linker sequences are underlined by a heavy bar. The location of several gene coding regions and regulatory elements is also given. The following two conventions are used: numbers in parentheses, refer to amino acids, and restriction sites in brackets, indicate the remnants of sites which were destroyed during construction. The following abbreviations are used: glycoprotein G (gpG), glycoprotein IV (gpIV), and infectious bovine rhinotracheitis virus (IBR).
Figure 15 DNA sequence of the IBR glycoprotein E gene.
The sequence of 2038 base pairs of the IBR WO 93/02104 PCT/US92/06034 Figure 16 -16unique short region, starting approximately 1325 base pairs upstream in the HindIII K/HindIII F junction in the HindIII K fragment, are shown. The glycoprotein E (gpE) gene is transcribed toward the HindIII K/HindIII F junction as indicated in Figure 1. The translation start and termination of the gpE gene are indicated. Note that IUPAC-IUB Biochemical Nomenclature Commission conventions are used.
Homology between the IBR gpE protein and the gpE protein of HSV-1, the gpl protein of VZV, and the gI protein of PRV. Matrix plot of the amino acid sequence of the IBR gpE protein (617) against the amino acid sequence of the PRV gI protein (577) Alignment of the conserved region between IBR gpE protein, PRV gI protein, and VZV gpl protein (37).
Detailed description of a plasmid containing the gpE gene. Diagram showing the orientation of DNA fragments to be assembled in the gpEcontaining plasmid. The origin of each fragment is indicated in the table. The sequences located at each of the junctions between fragments are also shown. The restriction sites used to generate each fragment are described for each junction. The location of several gene coding regions and regulatory elements is also given. The following tvo conventions are used: numbers in parentheses, refer to amino acids, and restriction sites in brackets, indicate the remnants of sites which were destroyed during construction. The following abbreviations are used: unique glycoprotein E (gpE), Figure 17 WO 93/02104 PC1'/US92/06034 Figure 18 -17glycoprotein IV (gpIV), and infectious bovine rhinotracheitis virus (IBR).
Detailed description of the DNA insertion in the homology vector 536-03.5. Diagram showing the orientation of DNA fragments to be assembled in the homology vector. The origin of each fragment is indicated in the table.
The sequences located at each of the junctions between fragments is also shown. The restriction sites used to generate each fragment as well as synthetic linker sequences which were used to join the fragments are described for each junction. The synthetic linker sequences are underlined by a heavy bar.
The location of several gene coding regions and regulatory elements is also given. The following two conventions are used: numbers in parentheses, refer to amino acids, and restriction sites in brackets, indicate the remnants of sites which were destroyed during construction. The following abbreviations are used: glycoprotein E (gpE), immediate early promoter infectious bovine rhinotracheitis virus (IBR), and pseudorabies virus (PRV).
Construction of Recombinant S-IBR-004 Virus.
S-IBR-004 is an IBR recombinant virus carrying an inserted foreign gene (NEO) under the control of the PRV gpX promoter. A new XbaI site was created at the short unique region and the original SacI site was deleted.
Figure 19 Figure 20 Construction of Recombinant S-IBR-008 Virus.
S-IBR-008 is a recombinant IBR virus that has a bovine rotavirus glycoprotein gene and the WO 93/02104 WICI'/ US92/06034 -18plasmid vector inserted in the XbaI site on the unique long region. A site specific deletion was created at the [SacI] site due to the loss of NEO gene in the small unique region.
Figure 21 Sequence of the PI-3 (SF-4 Strain) HN Gene.
Note that IUPAC-IUB Biochemical Nomenclature Commission conventions are used.
Figure 22 Details of S-IBR-018 Construction.
A. First line shows the IBR (Cooper Strain) BamHI- C fragment map. Second line shows the construction of the alpha-4 promoter on the PI- 3 HN gene and its insertion into the HindIII site in BamHI-C. Also shown are the beta-gal and neomycin (NEO) gene constructions under the control of the gX promoter that were put into the XbaI site and used as selectable markers to purify the recombinant virus.
B. The BamHI-C fragment map of S-IBR-018 after insertion of the PI-3 HN, beta-gal, and neomycin genes.
C. The S-IBR-018 genome showing the location of the three inserted foreign genes.
Legend: B BamHI; H HindIII; X Xbal; S Stul; UL unique long region; US unique short region; IR internal repeat region; TR terminal repeat region.
Figure 23 Details of S-IBR-019 Construction.
A. First line shows the IBR (Cooper Strain) BamHI- C fragment map. Second line shows the WO 93/02104 PCr/US92/06034 -19construction of the alpha-4 promoter on the PI- 3 F gene and its insertion into the HindIII site in BamHI-C. Also shown are the beta-gal and neomycin (NEO) gene constructions under the control of the gX promoter that were put into the XbaI site and used as selectable markers to purify the recombinant virus.
B. The BamHI-C fragment map of S-IBR-019 after insertion of the PI-3 F, beta gal, and neomycin genes.
C. The S-IBR-019 genome showing the location of the three inserted foreign genes.
Figure 24 Detailed description of the DNA insertion in Homology Vector 591-21.20. The diagram shows the orientation of DNA fragments assembled in plasmid 591-21.20. The origin of each fragment is described in the MATERIALS AND METHODS section. The sequences located at the junctions between each fragment are shown. The restriction sites used to generate each fragment as well as synthetic linker sequences which were used to join the fragments are described for each junction. The synthetic linker sequences are underlined by a double bar. The location of the Tk gene coding region is also given. The following two conventions are used: numbers in parenthesis refer to amino acids, and restriction sites in brackets indicate the remnants of sites which were destroyed during construction. The following abbreviation is used, infectious bovine rhinotracheitis virus (IBR).
WO 93/0/(2104- PCIA S92/06034 Figure 25 Detailed description of the marker gene insertion in Homology Vector 591-46.12. The diagram shows the orientation of DNA fragments assembled in the marker gene. The origin of each fragment is described in the MATERIALS AND METHODS section. The sequences located at the junctions between each fragment and at the ends of the marker gene are shown. The restriction sites used to generate each fragment are indicated at the appropriate junction. The location of the uidA gene coding region is also given. The following two conventions are used: numbers in parenthesis refer to amino acids, and restriction sites in brackets indicate the remnants of sites which were destroyed during construction. The following abbreviations are used, pseudorabies virus (PRV), uronidase A gene (uidA), Escherichia coli coli), herpes simplex virus type 1 (HSV-1), poly adenylation signal and glycoprotein X (gpX).
Legend: B BamHI; H HindIII; X XbaI; S StuI; UL unique long region; US unique short region; IR internal repeat region; TR terminal repeat region.
WO 93/02104 I'CY/US92/06034 -21- Detailed Description of the Invention The present invention provides a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus in which DNA encoding gpG glycoprotein has been altered or deleted so that upon replication the recombinant IBR virus produces no gpG glycoprotein. The DNA encoding gpG glycoprotein may be deleted or foreign DNA may be inserted into the DNA encoding gpG glycoprotein. The DNA encoding gpG glycbprotein may be deleted and foreign DNA may be inserted in place of the deleted DNA encoding gpG glycoprotein.
The present invention further provides a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus in which DNA encoding gpG glycoprotein has been altered or deleted and DNA encoding the gpE glycoprotein has been altered or deleted so that upon replication the recombinant IBR virus produces no gpG glycoprotein and no gpE glycoprotein. The DNA encoding gpE glycoprotein may be deleted or foreign DNA may be inserted into the DNA encoding gpE glycoprotein. The DNA encoding gpE glycoprotein may be deleted and foreign DNA may be inserted in place of the deleted DNA encoding gpE glycoprotein.
The present invention further provides a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus in which DNA encoding gpG glycoprotein has been altered or deleted so that upon replication the recombinant IBR virus produces no gpG glycoprotein, DNA corresponding to the US2 region of the naturallyoccurring IBR virus has been deleted, and DNA encoding the gpE glycoprotein has been altered or deleted.
The present invention also provides a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR WO 93/02104 WI'Y UiS92/0603.1 -22virus in which DNA corresponding to the US2 region of the naturally-occurrAng IBR virus has been deleted, and DNA encoding gpG glycoprotein has been altered or deleted. The DNA encoding the gpG glycoprotein may be deleted or foreign DNA may be inserted in place of the deleted DNA encoding gpG glycoprotein. Foreign DNA may be inserted in place of the deleted DNA corresponding to the US2 region of the naturally-occurring IBR virus.
The present invention also provides S-IBR-037, a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus in which DNA corresponding to the US2 region of the naturallyoccurring IBR virus has been deleted, and DNA encoding gpG glycoprotein has been deleted. S-IBR-037 was deposited on April 16, 1991 pursuant to the Budapest Treaty on the International Deposit of Microorganisms for the Purposes of Patent Procedure with the Patent Culture Depository of the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852 U.S.A. under ATCC Accession No. VR 2320.
The present invention also provides a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus in which DNA corresponding to the US2 region of the naturally-occurring IBR virus has been deleted and a foreign DNA sequence ch encodes Escherichia coli 8galactosidase has beer. .aserted in place of the deleted DNA encoding gpG glycoprotein, and DNA encoding gpG glycoprotein has been altered or deleted. The present invention also provides two examples of such viruses, S- IBR-035 and S-IBR-036.
The present invention further provides a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus in which DNA encoding gpE glycoprotein has been altered or deleted so that upon replication the WO 93/02104 PCT/US92/06034 -23recombinant IBR virus produces no gpE glycoprotein. The DNA encoding gpE glycoprotein may be deleted or foreign DNA may be inserted in the DNA encoding gpE glycoprotein.
The DNA encoding gpE glycoprotein may be deleted and foreign DNA may be inserted in place of the deleted DNA encoding gpE glycoprotein.
The present invention further provides a recombinant IBR virus comprising virzl DNA from a naturally-occurring IBR virus in which DNA encoding gpE glycoprotein has been altered or deleted so that upon replication the recombinant IBR virus produces no gpE glycoprotein and DNA corresponding to the US2 region of the naturallyoccurring IBR virus has been deleted.
The present invention further provides a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus from which DNA in the unique short region of the naturally-occurring IBR virus has been deleted. Foreign DNA may be inserted into the DNA of the recombinant IBR virus. The foreign DNA wmy be inserted into the Xbal site in the ong unique region. The foreign DNA may be a sequence which encodes bovina rotavirus glycoprotein 38; this sequence may be inserted into the XbaI site in the long unique region.
The present invention provides S-IBR-008, a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus from which DNA corresponding to the US2 region of the naturally-occurring IBR virus has been deleted and in which a foreign DNA sequence which encodes bovine rotavirus glycuprotein 38 has been inserted into the Xbal site in the long unique region. S-IBR-008 was deposited on June 18, 1986 pursuant to the Budapest Treaty on the International Deposit of Microorganisms for the Purposes of Patent Procedure with the Patent Culture Depository of the American Type Culture Collection, 12301 Parklawn WO 93/02104 PCT/US92/06034 -24- Drive, Rockville, Maryland 20852 U.S.A. under ATCC Accession No. VR 2141.
The present invention further provides a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus from which DNA corresponding to the US2 region of the naturally-occurring IBR virus has been deleted and at least a portion of both repeat sequences has been deleted. The present invention further provides an example of such a recombinant virus, designated S-IBR- 027. S-IBR-027 was deposited on April 17, 1991 pursuant to the Budapest Treaty on the International Deposit of Microorganisms for the Purposes of Patent Procedure with the Patent Culture Depository of the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852 U.S.A. under ATCC Accession No. VR 2322.
The present invention further provides a recombinant IBR virus comprising viral DNA from a naturally-occurring 1,R virus from which at least a portion of both repeat sequences has been deleted.
The present invention further provides a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus from which at least a portion of both repeat sequences has been deleted and DNA encoding one or re EcoRV restriction sites has been deleted. The sent invention further provides an example of such a recombinant vir's, designated S-IBR-002. S-IBR-002 was deposited on June 18, 1986 pursuant to the Budapest Treaty on the International Deposit of Microorganisms for the Purposes of Patent Procedure with the Patent Culture Depository of the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852 U.S.A. under ATCC Accession No. VR 2140.
WO 93/02104 I)C/US92/0603 The present invention further provides a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus from which at least a portion of both repeat sequences has been deleted and wherein foreign DNA has been inserted into the DNA of the recombinant IBR virus. The foreign DNA may be a sequence which encodes the Tn5 NEO gene.
The present invention further provides S-IBR-020, a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus from which at least a portion of both repeat sequences has been deleted and (2) wherein a foreign DNA sequence which encodes the Tr-- EO gene has been inserted into the DNA of the recombinant IBR virus.
The present invention also provides a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus from which at least a portion of both repeat sequences has been deleted, wherein a foreign DNA sequence which encodes the Tn5 NEO gene has been inserted into the DNA of the recombinant IBR virus, and (3) wherein at least a portion of the thymidine kinase gene has been deleted.
The present invention also provides a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus from which at least a portion of both repeat sequences has been deleted, wherein a foreign DNA sequence which encodes the Tn5 NEO gene has been inserted into the DNA of the recombinant IBR virus, and (3) wherein at least a portion of the thymidine kinase gene has been deleted. The subject invention provides an example of such a recombinant virus, designated S-IBR- 028. S-IBR-028 was deposited on May 14, 1991 pursuant to the Budapest Treaty on the International Deposit of Microorganisms for the Purposes of Patent Procedure with WO 93/02104 W9/09/ US92/06034 -26the Patent Culture Depository of the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852 U.S.A. under ATCC Accession No. VR 2326.
The present invention further provides a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus in which a foreign DNA sequence which encodes the NEO gene has been inserted into the viral DNA. The NEO gene may be under the control of an inserted, upstream, pseudorabies virus glycoprotein X promoter.
The subject invention further provides an example of a recombinant virus wherein the Tn5 NEO gene is under the control of an inserted, upstream, pseudorabies virus glycoprotein X promoter, designated S-IBR-004. S-IBR-004 was deposited on May 23, 1986 pursuant to the Budapest Treaty on the International Deposit of Microorganisms for the Purposes of Patent Procedure with the Patent Culture Depository of the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852 U.S.A. under ATCC Accession No. VR 2134.
The subject invention further provides a recombinant IBR virus compr.'-Ing viral DNA from a naturally-occurring IBR virus in which a foreign DNA sequence which encodes the Escherichia coli 8-galactosidase and Tn5 NEO genes, and the parainfluenza type 3 virus hemagglutinin gene, HN, has been inserted into the viral DNA. The subject invention provides an example of such a recombinant virus, designated S-IBR-018.
The subject invention further provides a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus in which a foreign DNA sequence which encodes the Escherichia coli B-galactosidase and Tn5 NEO genes, and the parainfluenza type 3 virus fusion gene, F, has been inserted into the viral DNA. The subject invention WO 93/02104 PCT/U S92/06034 -27provides an example of such a recombinant virus, designated S-IBR-019.
The recombinant viruses of the subject invention were derived from the Cooper Strain. However, other IBR viruses, such as the LA strain or the 3156 strain, may also be used.
The subject invention also provides a vaccine which comprises a suitable carrier and an effective immunizing amount of any of the recombinant viruses of the present invention. The vaccine may contain either inactivated or live recombinant virus.
Suitable carriers for the recombinant virus are well known in the art and include proteins, sugars, etc. One example of such a suitable carrier is a physiologically balanced culture medium containing one or more stabilizing agents such as hydrolyzed proteins, lactose, etc. Preferably, the live vaccine is created by taking tissue culture fluids and adding stabilizing agents such as stabilized, hydrolyzed proteins. Preferably, the inactivated vaccine uses tissue culture fluids directly after inactivation of the virus.
The subject invention also provides a vaccine which comprises a suitable carrier and an effective immunizing amount of a recombinant virus comprising viral DNA from a naturally-occurring IBR virus in which DNA encoding gpG glycoprotein has been altered or deleted so that upon replication the recombinant IBR virus produces no gpG glycoprotein.
The subject invention provides a vaccine which comprises a suitable carrier and an effective immunizing amount of a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus in which DNA encoding gpG WO 93/02104 W /jCl'/jJS92/0603-1 -28glycoprotein has been altered or deleted and DNA encoding the gpE glycoprotein has been altered or deleted so that upon replication the recombinant IBR virus produces no gpG glycoprotein and no gpE glycoprotein.
The subject invention also provides a vaccine which comprises a suitable carrier and an effective immunizing amount of a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus in which DNA encoding gpG glycoprotein has been altered or deleted so that upon replication the recombinant IBR virus produces no gpG glycoprotein, DNA corresponding to the US2 region of the naturally-occurring IBR virus has been deleted, and DNA encoding the gpE glycoprotein has been altered or deleted.
The subject invention further provides a vaccine which comprises a suitable carrier and an effective immunizing amount of a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus in which DNA corresponding to the US2 region of the naturallyoccurring IBR virus has been deleted, and DNA encoding gpG glycoprotein has been altered or deleted.
The subject invention also provides a vaccine which comprises a suitable carrier and an effective immunizing amount of a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus in which DNA encoding gpE glycoprotein has been altered or deleted so that upon replication the recombinant IBR virus produces no gpE glycoprotein.
The subject invention provides a vaccine which comprises a suitable carrier and an effective immunizing amount of a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus in which DNA encoding gpE glycoprotein has been altered or deleted so that upon WO 93/02104 IICT/ US92/06034 -29replication the recombinant IBR virus produces no gpE glycoprotein and DNA corresponding to the US2 region of the naturally-occurring IBR virus has been deleted.
The subject invention also provides a vaccine which comprises a suitable carrier and an effective immunizing amount of a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus from which DNA corresponding to the US2 region of the naturallyoccurring IBR virus has been deleted.
The subject invention provides a vaccine which comprises a suitable carrier and an effective immunizing amount of a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus from which at least a portion of both repeat sequences has been deleted.
The subject invention further provides a vaccine which comprises a suitable carrier and an effective immunizing amount of a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus in which a foreign DNA sequence which encodes the Tn5 NEO gene has been inserted into the viral DNA.
The subject invention also provides a vaccine which comprises a suitable carrier and an effective immunizing amount of a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus in which a foreign DNA sequence which encodes the Escherichia coli Bgalactosidase and Tn5 NEO genes, and the parainfluenza type 3 virus hemagglutinin gene, HN, has been inserted into the viral DNA.
The subject invention also provides a vaccine which comprises a suitable carrier and an effective immunizing amount of a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus in which a foreign WO 93/02104 PCT/US92/06034 DNA sequence which encodes the Escherichia coli 8galactosidase and Tn5 NEO genes, and the parainfluenza type 3 virus fusion gene, F, has been inserted into the viral DNA.
All of the vaccines described hereinabove and hereinbelow may contain either inactivated or live recombinant virus.
The vaccines may be administered by any of the methods well known to those skilled in the art, for example, by intramuscular, subcutaneous, intraperitoneal, or intravenous injection. Alternatively, the vaccine may be administered intranasally or orally.
The present invention also provides a method of immunizing an animal against infectious bovine rhinotracheitis virus which comprises administering to the animal an effective immunizing dose of any of the vaccines of the present invention. The animal may be a bovine.
The subject invention also provides a method for distinguishing an animal vaccinated with a vaccine which comprises an effective immunizing amount of a recombinant virus of the present invention from an animal infected with a naturally-occurring IBR virus which comprises analyzing a sample of a body fluid from the animal for the presence of gpG glycoprotein of IBR virus and at least one other antigen normally expressed in an animal infected by a naturally-occurring IBR virus, identifying antigens which are present in the body fluid, and determining whether gpG glycoprotein is present in the body fluid. The presence of antigens which are normally expressed in an animal by a naturally-occurring IBR virus and the absence of gpG glycoprotein in the body fluid is indicative of an animal vaccinated with the vaccine and not infected with a naturally-occurring IBR virus. The presence of antigens and gpG glycoprotein in the body WO 93/02104 PCr/US92/06034 -31fluid may be determined by detecting in the body fluid antibodies specific for the antigens and gpG glycoprotein.
One of the vaccines that is useful in this method is a vaccine which comprises a suitable carrier and an effective immunizing amount of a recombinant virus comprising viral DNA from a naturally-occurring IBR virus in which DNA encoding gpG glycoprotein has been altered or deleted so that upon replication the recombinant IBR virus produces no gpG glycoprotein. Another vaccine that is useful in this method is a vaccine which comprises a suitable carrier and an effective immunizing amount of a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus in which DNA encoding gpG glycoprotein has been altered or deleted and DNA encoding the gpE glycoprotein has been altered or deleted so that upon replication the recombinant IBR virus produces no gpG glycoprotein and no gpE glycoprotein. Yet another vaccine that is useful in this method is a vaccine which comprises a suitable carrier and an effective immunizing amount of a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus in which DNA encoding gpG glycoprotein has been altered or deleted so that upon replication the recombinant IBR virus produces no gpG glycoprotein, DNA corresponding to the US2 region of the naturally-occurring IBR virus has been deleted, and DNA encoding the gpE glycoprotein has been altered or deleted. Still another vaccine that is useful in this method is a vaccine which comprises a suitable carrier and an effective immunizing amount of a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus in which DNA corresponding to the US2 region of the naturally-occurring IBR virus has been deleted, and DNA encoding gpG glycoprotein has been altered or deleted.
WO 93/02104 PCT/US92/06034 -32- The present invention also provides a method for distinguishing an animal vaccinated with a vaccine which comprises an effective immunizing amount of a recombinant virus of the present invention from an animal infected with a naturally-occurring IBR virus which comprises analyzing a sample of a body fluid from the animal for the presence of gpE glycoprotein of IBR virus and at least one other antigen normally expressed in an animal infected by a naturally-occurring IBR virus, identifying antigens which are present in the body fluid and determining whether gpE glycoprotein is present in the body fluid. The presence of antigens which are normally expressed in an animal by a naturally-occurring IBR virus and the absence of gpE glycoprotein in the body fluid is indicative of an animal vaccinated with the vaccine and not infected with a naturally-occurring IBR virus. The presence of antigens and gpE glycoprotein in the body fluid may be determined by detecting in the body fluid antibodies specific for the antigens and gpE glycoprotein.
One of the vaccines useful in this method is a vaccine which comprises a suitable carrier and an effective immunizing amount of a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus in which DNA encoding gpG glycoprotein has been altered or deleted and DNA encoding the gpE glycoprotein has been altered or deleted so that upon replication the recombinant IBR virus produces no gpG glycoprotein and no gpE glycoprotein. Another vaccine that is useful in this method is a vaccine which comprises a suitable carrier and an effective immunizing amount of a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus in which DNA encoding gpG glycoprotein has been altered or deleted .so that upon replication the recombinant IBR virus produces no gpG glycoprotein, DNA corresponding to the US2 region of the naturally- WO 93/02104 PCT/US92/06034 -33occurring IBR virus has been deleted, and DNA encoding the gpE glycoprotein has been altered or deleted. Yet another vaccine that is useful in this method is a vaccine which comprises a suitable carrier and an effective immunizing amount of a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus in which DNA encoding gpE glycoprotein has been altered or deleted so that upon replication the recombinant IBR virus produces no gpE glycoprotein. Still another vaccine that is useful in this method is a vaccine which comprises a suitable carrier and an effective immunizing amount of a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus in which DNA encoding gpE glycoprotein has been altered or deleted so that upon replication the recombinant IBR virus produces no gpE glycoprotein and DNA corresponding to the US2 region of the naturally-occurring IBR virus has been deleted.
The present invention also provides isolated DNA encoding the gpG glycoprotein of IBR virus. The subject invention also provides purified recombinant gpG glycoprotein encoded by the DNA encoding the gpG glycoprotein of IBR virus. The subject invention further provides a recombinant cloning vector which comprises the DNA encoding the gpG glycoprotein of IBR virus. The subject invention also provides a recombinant expression vector which comprises the DNA encoding the gpG glycoprotein of IBR virus. The subject invention provides a host cell which comprises the recombinant expression vector which comprises the DNA encoding the gpG glycoprotein of IBR virus.
The subject invention also provides a method of producing a polypeptide which comprises growing the host cell which comprises the recombinant expression vector which comprises the DNA encoding the gpG glycoprotein of IBR WO) 93/02104 PCT/US92/06034 -34virus under conditions such that the recombinant expression vector expresses gpG glycoprotein and recovering the gpG glycoprotein so expressed.
The subject invention also provides an antibody directed to an epitope of the purified gpG glycoprotein of IBR virus encoded by the DNA encoding the gpG glycoprotein of IBR virus. The antibody may be a monoclonal antibody.
The subject invention also provides a method of detecting the presence or absence of gyG glycoprotein of IBR virus in a sample which comprises contacting the sample with an antibody directed to an epitope of the purified gpG glycoprotein of IBR virus encoded by the DNA encoding the gpG glycoprotein of IBR virus under conditions such that the antibody forms a complex with any gpG glycoprotein present in the sample and detecting the presence or absence of such complex. The sample may be bovinederived.
The subject invention also provides isolated DNA encoding the gpE glycoprotein of IBR virus. The subject invention also provides purified recombinant gpE glycoprotein encoded by the DNA encoding the gpE glycoprotein of IBR virus. The subject invention further provides a recombinant cloning vector which comprises the DNA encoding the gpE glycoprotein of IBR virus. The subject invention provides a recombinant expression vector which comprises the DNA encoding the gpE glycoprotein of IBR virus. The subject invention also provides a host cell which comprises the recombinant expression vector which comprises the DNA encoding the gpE glycoprotein of IBR virus.
The subject invention also provides a method of producing a polypeptide which comprises growing the host cell which comprises the recombinant expression vector which WO 93/02104 WO CTI/ 11US92/0603-; comprises the DNA encoding the gpE glycoprotein of IBR virus under conditions such that the recombinant expression vector expresses gpE glycoprotein and recovering the gpE glycoprotein so expressed.
The subject invention also provides an antibody directed to an epitope of the purified gpE glycoprotein of IBR virus encoded by the DNA encoding the gpE glycoprotein of IBR virus. The antibody may be a monoclonal antibody.
The subject invention also provides a method of detecting the presence or absence of gpE glycoprotein of IBR virus in a sample which comprises contacting the sample with an antibody directed to an epitope of the purified gpE glycoprotein of IBR virus encoded by the DNA encoding the gpE glycoprotein of IBR virus under conditions such that the antibody forms a complex with any gpE glyccprotein present in the sample and detecting the presence or absence of such compclx. The sample may be bovinederived.
The subject invention also provides a method of producing a fetal-safe, live recombinant IBR virus which comprises treating viral DNA from a naturally-occurring live IBR virus so as to delete from the virus DNA corresponding to the US2 region of the naturally-occurring IBR virus.
The subject invention also provides a recombinant pseudorabies virus designated S-PRV-160. The subject invention also provides an antibody which directed to an epitope of the recombinant pseudorabies virus designated S-PRV-160.
The subject invention also provides isolated DNA encoding the US2 gene of an IBR virus. The present invention further provides a homology vector for producing a recombinant IBR virus by inserting foreign DNA into the WO 93/02104 icr/ LIS92/06034 -36genomic DNA of an IBR vi,rus which comprises a doublestranded DNA molecule consisting essentially of doublestranded foreign DNA encoding 1. which does not naturally occur in an animal into ch the reccombinant IBR is introduced, with at one end of the foreign DNA, double-stranded IBR viral DNA homologous to genomic DNA located at one side of a site on the genomic DNA which is not essential for replication of the IBR virus and at the other end of the foreign DNA, double-stranded IBR viral DNA homologous to genomic DNA located at the other side of the same site on the genomic DNA. The double-stranded foreign DETA may further comprise a promoter. The promoter can be from HSV-1 a 4 immediate early gene, Human cytomegalovirus immediate early gene or pseudorabies virus glycoprotein X gene. The doublestranded foreign DNA may futher comprise a polyadenylation signal. The polyadenylation signal may be from HSV-1 thymidine kinase gene or pseudorabies virus glycoprotein X gene. The subject invention also provides a homology vector wherein the RNA encodes a polypeptide.
The polypeptide may be a detectable marker such as Fscherichia coli B-galactosidase oX bacterial transposon neomycin resistance protein. The DNA which encodes the polypeptide may be flanked on each side by restriction sites permitting said DNA to be cut out with a restriction endonuclease which cuts at a limited number of sites on the genome. The subject invention further provides for a homology vector wherein the upstream double-stranded IBR viral DNA is homologous to genomic DNA present within the approximately 860 bp NcoI to BamHI subfragment of the HindIII A fragment of IBR virus and the downstream double-stranded IBR viral DNA is homologous to genomic DNA present within the approximately 1741 bp BglII to StuI subfragment of the HindIII A fragment of IBR virus.
WO 93/01104 WO 93/210 CTI/ US92/0603.1 The subject inventioin, iurther provides a homology vector wherein u',..streaz double-stranded f oreign DNA which comprises a promoter and downstream double-stranded forei' n DNA which comprises a polyadenylation signal flank on each side double-stranded foreign DNA which encodes a detectable marker, The invention further a honology vector wherein t~he upstreari promoter is homologous to genomic DNA prese~nt, within the approximately 490 bp PvuII to BamHI subfragment. of the BamHII N fragment of HSV-1 and the downstream pc'lyadenylation signal is homologous to V.nom;,c DINA present within the approximately 784 bp SinaI to SinaI subfragment of the BaDjHI Q fragment of HSV-l. The invention further provides a homology vector wherein the 1.1 DNA which e,,Icodes a detectable marker is homologous to the approxxatelty 1541L bp.; gill to BainHI fragment of Tme subject inventioz;n aloo provides a homology vector whnerein the upstrez' double-stranded IBR viral DNA is homologoixs to genomic DNA present within the approximately 3593 bp HindXJII to XihoI subfragment of the HindIII K fragment of MR! vir-o8 -and -the downstream double-9tranded IBR viral DNA is homologous to genomic Dn pvesent within the approximately 7E5 bp XhoI to NdeI subfrt&,gment of the IiindIII K fragment of IBR virus. The invention further provides a homology vector ,wherein upstreeam double-stranded foreign DNA which comprises a prootei and downstream double-stranded foreign DNA which comprises a polyadenylation signal, flank on each side double-stranded foreign DNA which otncodes a detectable marker. This upstream promoter i6 homologous to genomio DNA present within the approximately 1191 bp Avail to PstI subfragment of the XbaI B fragment of HOW~ and the downstream plyadcriylation sequence is homolo~gous to genomic DNA present within the approximately 753 bp Sall to NdeI subfragmerAL of the BainHI 17 fragment of PRy. The DNA whizh encodes a detectable marker is homologous to WO 93/02104 PCI', 1992/000434 -38the approximately 3347 bp Ball to BamHI fragment of pJF751.
The invention further provides a homology vector wherein the upstream double-stranded IBR viral DNA is homologous to genomic DNA present within the approximately 888 bp Mlul to Smal subfragment of the HindIII K fr?,gment of IBR virus and the downstream double-stranded IBR viral DNA is homologous to genomic DNA present within the approximately 785 bp XhoI to NdeI subfragment of the HindIII K fragment of IBR virus. The upstream doublestranded foreign DNA may comprise a prcsot-er and doublestranded foreign DNA which comprise a polyadenylation signal flank on each side double-stranded foroeign DNA which encodes a detectable marker. The subject in ,tAion also provides a homology vector wherein the upa.ream promoter is homologous to genomic DNA present within the approximately 1191 bp Avail to PstI subfragment of the XbaI B fragment of HCMV and the downstream polyadenylation signal is homologous to genomic DNA present within the approximately 753 bp Sail to NdeI subfragment of the BamHI #7 iragment of PRV. The DNA which encodes a detectable marker is homologous to the appro .mately 3347 bp Ball to BamHI fragment of pJF57;L.
The present invention further provides a homology vector wherein the upstream double-stranded IBR viral DNA is homologous to genomic DNA present within the approximately 1704 bp Smal to Smal subfragment of the HindllI K fragment of IBR virus rand the downstream double-stranded IBR viral DNA is homologous to genomic DNA present within the approximately 742 bp Ns.eI to BglI subfragment of the SmaI 2.5KB fragment of IBR virus. The present invention further provides a homology vector wherein upstream double-stranded foreign DNA which comprises a promoter and downstream double-stranded foreign DNA which comprises a polyadenylation signal WO) 93/021040 WP0Cr'/ US92/06034 -39flank on each side double-stranded foreign DNA which encodes a detectable marker. The upstream promoter is homologous to genomic DNA present within the approximately 413 bp SalI to BamHI subfragment of the BamHI #10 fragment of PRV and the downstream polyadenylation signal is homologous to genomic DNA present within the approximately 754 bp NdeI to SalI subfragment of the BamHI #7 fragment of PRV. The detectable marker is homologous to the approximately 3010 bp BamHI to PvuII'fragment of p7F751.
The present invention provides for a homology vector for producing a recombinant IBR virus by deleting DNA which encodes a detectable marker which had been inserted into the genomic DNA of an IBR virus comprising a doublestranded DNA molecule consisting essentially of doublestranded IBR viral DNA homologous to the genomic DNA which flank on each side the DNA to be deleted. The subject invention further provides a homology vector wherein the upstream double-stranded IBR viral DNA is homologous to genomic DNA present within the approximately 888 bp Klul to SmaI subfragment of the HindIII K fragment of IBR -Irus and the downstream double-stranded IBR viral DOA is homologous to genomic DKA present within the aryz-Aimately 785 bp Xhol to Ndel subfragment of the HindIII K fragment of IBR virus.
The present invention also provides a method of immunizing an animal against infectious bovine rhinotracheitis virus which comprises administering to the animal an effective immunizing dose of any of the vaccines of the present invention. The animal may be a bovine. The subject invention also provides a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus from which at least a portion of both repeat sequences have been deleted, specifically, wherein DNA encoding one or more EcoRV WO 93/02104 PCI'/US92/06034 restriction sites has be-n deleted, and wherein foreign DNA has been inserted into the DNA of the recombinant virus. The foreign DNA may be a DNA sequence which encodes bovine viral diarrhea virus glycoprotein gp53.
The subject invention provides an example of such a recombinant IBR virus, designated S-IBR-032.
The subject invention provides a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus from which DNA from the US2 gene, the gpE glycoprotein gene and the gpG glycoprotein gene have been deleted so that upon replication, the recombinant IBR virus produces no gpE glycoprotein and no gpG glycoproteir, A Foreign DNA sequence may be inserted in place of the deleted DNA which encodes gpE glycoprotein. The foreign DNA sequence that may be inserted can be a foreign DNA sequence which encodes Escherichia coli B-galactosidase. The subject invention provides an example of such a recombinant virus, designated S-IBR-039.
The subject invention further provides a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus in which DNA from the US2, gpE glycoprotein gene, the gpG glycoprotein gene and the thymidine kinase gene has been deleted so that upon replication, the recombinant IBR virus produces no gpE glycoprotein, no gpG glycoprotein and no thymidine kinase. The subject invention provides an example of such a recombinant virus, designated S-IBR-045. A foreign DNA sequence may be inserted in place of the deleted DNA encoding gpE glycoprotein. The foreign DNA sequence may encode Escherichia coli B-galactosidase. The subject invention provides an example of such a recombinant virus, designated S-IBR-044. The foreign DNA sequence may encode bovine viral diarrhea virus gp53 glycoprotein.
The subject invention provides an example of such a recombinant virus, designated S-IBR-046. The foreign DNA WVO 9a/02104 W CIUS92/06034 -41sequence may encode Parainfluenza virus type 3 fusion protein and Parainfluenza virus type 3 hemagglutinin protein. The subject application provides an example of such a virus, designated S-IBR-047. The foreign DNA sequence may encode Bovine respiratory syncytial virus fusion protein, Bovine respiratory syncytial virus attachment protein and Bovine respiratory syncytial virus nucleocapsid protein. The subject invention provides an example of such a recombinant virus, designated S-IBR- 049. The foreig DNA sequence may encode Pasteurella haemolvtica leukotoxin and Pasteurella haemolvtica iron regulated outer membrane proteins. The subject invention provides an example of such a recombinant virus, designated S-IBR-051.
The subject invention also provides a recombinant IBR virus comprising viral DNA from a naturally-occurring IBR virus from which DNA from the US2 gene, the gpE glycoprotein gene, the gpG glycoprotein gene and the thymidine kinase gene have been deleted so that upon replication, the recombinant IBR virus produces no gpE glycoprotein, no gpG glycoprotein and no thyiidine kinase. The subject invention provides for a foreign DNA sequence inserted in place of the DNA which encodes thymidine kinase. The foreign DNA sequence may encode Escherichia coli B-glucuronidase. The present invention further provides a recombinant virus wherein a foreign DNA sequence is inserted in place of the DNA encoding gpE glycoprotein. The foreign DNA sequence may encode Escherichia coli 8-galactosidase. The present invention further provides an example of such a recombinant virus, designated S-IBR-043.
The subject invention also provides a vaccine which comprises an effective immunizing amount of any of the recombinant viruses of the present invention and a WO 93/021(04 0PCr/US92/06034- -42suitable carrier. The vaccine may contain either inactivated or live recombinant virus.
The present invention provides a vaccine which comprises an effective immunizing amount of recombinant virus protective against bovine respiratory disease complex and a suitable carrier. A recombinant virus may be a recombinant IBR virus and the recombinant virus can consist essentially of any or all of the recombinant viruses of the present invention.
The subject invention also provides for a vaccine which comprises an effective immunizing amount of a recombinant virus and non-recombinant virus protective against bovine respiratory disease complex and a suitable carrier.
The subject invention further provides a vaccine which comprises an effective immunizing amount of a recombinant IBR virus and non-recombinant virus protective against bovine respiratory disease complex and a suitable carrier. The recombinant IBR virus can consist essentially of any or all of the recombinant viruses of the subject invention.
For purposes of this invention, the infectious diseases that contribute to bovine respiratory disease complex include infectious bovine rhinotracheitis, parainfluenza type 3 virus, bovine viral diarrhea virus, bovine respiratory syncytial virus and Pasteurella haemolytica.
For purposes of the present invention, non-recombinant viruses can include, but are not limited to, conventionally derived viruses which include killed virus, inactivated bacterins, and modified live viruses.
The subject invention further provides for a method of irnunizing an animal against infectious bovine WO 93/02104 W /ICI'/ US92/06034 -43rhinotracheitis which comprises administering to the animal an immunizing dose of any of the vaccines of the present invention. The subject invention further provides a method of immunizing an animal against Parainfluenza type 3 which comprises administering to the animal an immunizing dose of the vaccine of the present invention that contains the IBR virus encoding antigens for Parainfluenza type 3 virus. The subject invention further provides a method of immunizing an animal against bovine viral diarrhea which comprises administering to the animal an immunizing dose of the vaccine of the present invention that contains the IBR virus encoding antigens for bovine viral diarrhea virus. The subject invention further provides a method of immunizing an animal against bovine respiratory syncytial virus disease which comprises administering to the animal an immunizing dose of the vaccine of the present invention that contains the IBR virus encoding antigens for bovine respiratory syncytial virus. The subject invention further provides for a method of immunizing an animal against Pneumonic pasteurellosis which comprises administering to the animal an immunizing dose of the vaccine of the present invention that contains the IBR virus encoding antigens for Pasteurella haemolytica.
The invention further provides a method of immunizing an animal against bovine respiratory disease complex which comprises administering to an animal an immunizing dose of the vaccine containing the recombinant IBR viruses of the present invention or the recombinant viruses of the present invention and non-recombinant viruses. For purposes of this invention, the animal may be a bovine.
The invention further provides a method for distinguishing an animal vaccinated with a vaccine which comprises an effective immunizing amount of a recombinant virus of the present invention from an animal infected with a naturally-occurring IBR virus which comprises WO 93/02104 PCf/UjS92/0034 -44analyzing a sample of a body fluid from the animal for the presence of gpE glycoprotein of IBR virus and at least one other antigen normally expressed in an animal infected by a naturally-occurring IBR virus, identifying antigens which are present in the body fluid and determining whether gpE glycoprotein is present in the body fluid, the presence of antigens which are normally expressed in an animal by a naturally-occurring IBR virus and the absence of gpE glycoprotein in the body fluid being indicative of an animal vaccinated with the vaccine and not infected with a naturally-occurring IBR virus.
WO 93/02104 PCT/US92/0603-4 Materials and Methods PREPARATION OF IBR VIRUS STOCK SAMPLES. IBR virus stock samples were prepared by infecting MDBK cells at a multiplicity of infection of 0.01 PFU/cell in Dulbecco's Modified Eagle Medium (DMEM) containing 2 mM glutamine, 100 units/ml penicillin, 100 units/ml streptomycin (these components were obtained from Irvine Scientific or an equivalent supplier, and hereafter are referred to as complete DME medium) plus 1% fetal bovine serum. After cytopathic effect was complete, the medium and cells were harvested and the cells were pelleted at 3000 rpm for minutes in a clinical centrifuge. Cells were resuspended in 1/10 the original volume of medium, and an equal volume of skim milk skim milk powder in H 2 0 weight/volume) was added. The virus sample was frozen at 0 C. The titers were usually about 108 PFU/ml.
PREPARATION OF HERPESVIRUS DNA. For herpesvirus DNA preparation, a confluent monolayer of cells (MDBK for IBR virus or Vero for PRV) in a 25 cm 2 flask or 60 mm petri dish was infected with 100 gl of virus sample. After overnight incubation, or when the cells were showing 100% cytopathic effect, the cells were scraped into the medium. The cells and medium were centrifuged at 3000 rpm for 5 minutes in a clinical centrifuge. The medium was decanted, and the cell pellet was gently resuspended in 0.5 ml of solution containing 0.5% NONIDET P-40" (NPpurchased from Sigma Chemical Co., St. Louis, MO).
The sample was incubated at room temperature for minutes. Ten Al of a stock solution of RNase A (Sigma) was added (stock was 10 mg/ml, boiled for 10 minutes to inactivate DNAse). The sample was centrifuged to pellet nuclei. The DNA pellet was removed with a pasteur pipette or wooden stick and discarded. The supernatant fluid was decanted into a 1.5 ml Eppendorf tube containing 25 gl of 20% sodium dodecyl sulfate (Sigma) WO) 93/02 104 3I'f/ 'S92/06034 -46and 25 pl proteinase-K (10 mg/ml; Boehringer Mannheim).
The sample was mixed and incubated at 37 0 C for 30-60 minutes. An equal volume of water-saturated phenol was added and the sample was mixed briefly. The sample was centrifuged in an Eppendorf minifuge for 5 minutes at full speed. The upper aqueous phase was removed to a new Eppendorf tube, and two volumes of absolute ethanol were added and the tube put at -20 0 C for 30 minutes to precipitate nucleic acid. The sample was centrifuged in an Eppendorf minifuge for 5 minutes. The supernatant was decanted, and the pellet was washed with -300 ul of ethanol, followed by centrifugation in an Eppendorf minifuge for 5 minutes. The supernatant was decanted, and the pellet was air dried and rehydrated in -16 Al H 2 0.
For the preparation of larger amounts of DNA, the procedure was scaled up to start with a 850 cm 2 roller bottle of MDBK cells. The DNA was stored in 0.01 M tris pH 7.5, 1 mM EDTA at 4 0
C.
PREPARATION OF HERPESVIRUS CELL LYSATES. For cell lysate preparation, serum free medium was used. A confluent monolayer of cells (MDBK for IBR virus or Vero for PRV) in a 25 cm 2 flask or a 60 mm petri dish was infected with 100 Al of virus sample. After cytopathic effect was complete, the medium and cells were harvested and the cells were pelleted at 3000 rpm for 5 minutes in a clinical centrifuge. For media samples medium was concentrated approximately 10-fold by filtration with a microconcentrator (Amicon). For call samples the cell pellet was resuspended in 250 pl of disruption buffer sodium dodecyl sulfate, 2% 8mercaptoethanol). The samples were sonicated for seconds on ice and stored at -20 0
C.
WESTERN BLOTTING PROCEDURE. Samples of lysates, controls and protein standards were run on a polyacrylamide gel according to the procedure of Laemmli After gel WO 93/02104 'CI/t'892/06034 -47electrophoresis the proteins were transferred according Sambrook The primary antibody was a mouse hyper-immune serum raised against chemically-synthesized gpG peptides (amino acids 232-252 and 267-287) linked to keyhole limpet hemocyanin. The secondary antibody was a goat anti-mouse alkaline phosphatase coupled antibody.
MOLECULAR BIOLOGICAL TECHNIQUES. Techniques for the manipulation of bacteria and DNA, including such procedures as digestion with restriction endonucleases, gel electrophoresis, extraction of DNA from gels, ligation, phosphorylation with kinase, treatment with phosphatase, growth of bacterial cultures, transformation of bacteria with DNA, and other molecular biological methods are described by Maniatis Except as noted, these were used with minor variation.
LIGATION. DNA was joined together by the action of the enzyme T4 DNA ligase (BRL). Ligation reactions contained various amounts of DNA (from 0.2 to 20Ig), 20mM Tris pH 10mM MgCl 2 10mM dithiothreitol (DTT), 200 MM ATP and 20 units T4 DNA ligase in 10-20 Al final reaction volume. The ligation proceeded for 3-16 hours at 15 0
C.
DNA SEQUENCING. Sequencing was performed using the BRL Sequenase Kit and 35 S-dATP (NEN). Reactions using both the dGTP mixes and the dITP mixes were performed to clarify areas of compression. Alternatively, compressed areas were resolved on formamide gels. Templates were double-stranded plasmid subclones or single stranded M13 subclones, and primers were either made to the vector just outside the insert to be sequenced, or to previously obtained sequence. Sequence obtained was assembled and compared using Dnastar software. Manipulation and comparison of sequences obtained was performed with Superclone and Supersee programs from Coral Software.
WO 93/02104 7I'I'/ U S92/06034 -48- SOUTHERN BLOTTING OF DNA. The general procedure for Southern blotting was taken from Maniatis DNA was blotted to nitrocellulose filters and hybridized to appropriate, labeled DNA probes. Probes for southern blots were prepared using either the Nonradioactive DNA Labeling and Detection Kit of Boehringer Mannheim or the nick translation kit of Bethesda Research Laboratories (BRL). In both cases the manufacturers' recommended procedures were followed.
DNA TRANSFECTION FOR GENER. 'ING RECOMBINANT VIRUS. The method is based upon the calcium phosphate procedure of Graham and Van der Eb (24) with the following modifications. Virus and/or plasmid DNA were diluted to 298 gl in 0.01 M 6ris pH 7.5, 1mM EDTA. Forty pl 2M CaCl2 was added followed by an equal volume of 2X HEPES buffered saline (10g N-2-hydroxyethyl piperazine N'-2ethanesulfonic acid (HEPES), 16g NaCl, 0.74g KC1, 0.25g Na 2 HP0 4 -2H 2 0, 2g dextrose per liter H 2 0 and buffered with NaOH to pH The mixture was then incubated on ice for 10 minutes, and then added dropwise to an confluent monolayer f MDBK or rabbit skin (RS) cells growing in a 60 mm petri dish under 5 ml of medium (DME plus 2% fetal bovine serum). The cells were incubated 4 hours at 37 0 C in a humidified incubator containing 5% CO,.
The cells were then washed with three 5 ml aliquots of 1XPBS (1.15g Na 2
HPO
4 0.2g KH 2
PO
4 0.8g NaCI, 0.2g KC1 per liter H 2 and fed with 5 ml of medium (DME plus 2% fetal bovine serum). The cells were incubated at 37 0 C as above for 3-7 days until cytopathic effect from the virus was 50-100%. Virus was harvested as described above for the preparation of virus stocks. This stock was referred to as a transfection stock and was subsequently screened for recombinant virus by the BLUOGAL" SCREEN FOR RECOMBINANT IBR VIRUS.
WO 93/02104 W['/11S92/0603.1 -49- HOMOLOGOUS RECOMBINATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS. This method relies upon the homologous recombination between herpesvirus DNA and plasmid homology vector DNA which occurs in tissue culture cells co-transfected with these elements. From 0.1-1.0 Ag of plasmid DNA containing foreign DNA flanked by appropriate herpesvirus cloned sequences (the homology vector) were mixed with approximately 0.3 pg of intact herpesvirus DNA. The DNAs were diluted to 298 Al in 0.01 M Tris pH 7.5, ImM EDT and transfected into MDBK cells according to the DNA TRANSFECTION FOR GENERATING RECOMBINANT VIRUS (see above).
DIRECT LIGATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS. Rather than using homology vectors and relying upon homologous recombination to generate recombinant virus, we have also developed the technique of direct ligation to engineer herpesviruses. In this instance, a cloned foreign gene did not require flanking herpesvirus DNA sequences but only required that it have restriction sites available to cut out the foreign gene fragment from the plasmid vector. A compatible restriction enzyme was used to cut herpesvirus DNA. A requirement of the technique was that the restriction enzyme used to cut the herpesvirus DNA must cut at a limited number of sites. We have used Xbal, which cuts IBR virus DNA in one place. We have also used EcoRV which cuts IBR virus DNA in two places. For PRV we have used Xbal and HindIII, both of which cut in two places.
Restriction sites previously introduced into herpesviruses by other methods may also be used. The herpesvirus DNA was mixed with a 30-fold molar excess of plasmid DNA (typically 5pg of virus DNA to 10pg of plasmid DNA), and the mixture was cut with the appropriate restriction enzyme. The DNA mixture was phencl extracted and ethanol precipitated to remove restriction enzymes, and ligated together according to WO 93/02 i (0! WO CI/t'892/0603.4 the ligation procedvre detailed above. The*ligated DNA mixture was then resuspended in 298 pA 0.01 M Tris pH 1mM EDTA and transfected into cells (MDBK or RS for IBR virus and Vero for PRV) according to the DNA TRANSFECTION FOR GENERATING RECOMBINANT VIRUS (see above). The direct ligation procedure may also be used to delete DNA from herpesviruses. Non-essential DNA which is flnked by appropriate restriction enzyme sites may be deleted by digesting the virus DNA with such enzymes and religation. The frequency of engineered viruses generated by the direct ligation procedure is high enough that screening can be accomplished by restriction enzyme analyss of randomly picked plaques from the transfection stock.
BLUOGAL" SCREEN FOR RECOMBINANT HERPESVIRUS. When the E.coli B-galactosidase (lacZ) marker gene was incorporated into a recombinant virus the plaques containing re-ombinants were visualized by a simple assay. The chemical BLUOGAL" (GIBCO-Bethesda Research Labs) was incorporated (200 Ag/ml) into the agarose overlay during the plaque assay, and plaques that expressed active B-galactosidase turned blue. The blue plaques were then picked onto fresh cells (MDBK for IBR virus and Vero for PRV) and purified by further blue plaque isolations. In recombinant virus strategies in which the E.coli B-galactosidase marker gene is removed, the assay involves plaque purifying white plaques from a background of parental blue plaques. In both cases 2" viruses were typically purified with three rounds of plaque purification.
SCREEN FOR RECOMBINANT HERPESVIRUS EXPRESSING ENZYMATIC MARKER GENES. When the E. coli B-galactosidase (lacZ) or B-glucuronidase (uidA) marker gene was incorpor&' 4 into a recombinant virus the plaques containing recombL..an,.s were visualized by a simple assay. The enzymatic WO 93/02104 "CI/ US92/06034 -51substrate was incorporated (300 Ag/ml) into the agarose ov.L. y during the plaque assay. For the lacZ marker gene the substrate BLUOGAL" (halogenated indolyl-B-Dgalactosidase, Bethesda Research Labs) was used. For the uidA marker gene the substrate X-Glucuro Chx (5-bromo-4chloro-3-indolyl-B-D-glucuronic acid Cyclohexylammonium salt, Biosynth AG) was used. Plaques that epressed active marker enzyme turned blue. The blue plaques were then picked onto fresh cells and purified by further blue plaque isolation. In recombinant virus strategies in which the enzymatic marker ge ,e is removed the assay involves plaque purifying white plaques from a background of parental blue plaques. In both cases viruses were typically purified with three rounds of plaque purification.
ANTIBODY SCRE' FOR RECOMBINANT HERPESVIRUS. A third method for screening the recombinant virus stock was to look directly for the expression of the foreign gene with antibodies. Herpesvirus plaques were spotted and picked by inserting a toothpick through the agarose above the plaque and scraping the plaque area on the dish. Viruses weie then rinsed from the toothpick by inserting the toothpick into a well of a 96-well micro-titer dish (Falcon Plastics) containing a confluent monolayer of tiseue culture cells that had been washed 3 times in DME medium without serum. It was important for the virus to grow without serum at this stage to allow the immunological procedure to work. After cytopathic effect was complete, the plates were put at -700C to freeze and lyse the cells. The medium was thawed, and the freeze/thaw prccedure was repeated a second time. Then 50-100 microliters of medium were removed from each well and filtered under vacuum through a nitrocellulose membrane (S&S BA85) using a DotBlot- apparatus (BRL).
The filter blots were soaked in a blocking solution of 0.01 M Tri. pH 7.5, 0.1 M NaCl, 3% bovine serum albumin WO 93/02104 JCI'/US92/06034 -52at room temperature for two hours with shaking. The filter blots were then placed in a sealable bag (Sears SEAL-A-MEAL" or equivalent), and 10 mis of the blocking solution that contained 10 mLcroliters of antibody specific for the foreign protein were added. After overnight incubation at room temperature with shaking, the blot wanr washed 3 times with 100 mis 0.01 M Tris, pH 0.1 M NaCI, 0 Tween 20 detergent (Sigma). The blot was put in an, salable bag and 10 mls blocking solution containing .unts per minute of 1 2 A (New England Nuclear) were added. After allowing the protein A to bind to the antibody for 2 hours at roora t -nerature with shaking, the blot was washed as above, dr. ed, and overlayed with an X-ray film and an intensifying screen (Dupont) and autoradiographed for 1-3 days at -70°C. The film was developed by standard procedures. Virus from the positive wells which contained the recombinant virus was further purified.
SELECTION OF G418 RESISTANT IBR VIRUS. The antibiotic G418 (GIBCO) has a wide range of inhibitory activity on protein synthesis. However, recombinant viruses expressing the aminoglycosidase 3'-phosphotransferase, encoded by the NEO gene of the transposable element are resistant to G418. The transfection stocks of recombinant viruses were grown on MDBK cells in the presence of 500 pg/ml G418 in complete DME medium plus 1% fetal bovine serum. After one or two days at 37 0
C,
plaques from the dishes inoculated with the highest dilution of virus were picked for virus stocks. The selection was repeated a second or third time. The virus stocks generated from the G418 selection were tested for NEO gene insertion by the SOUTHERN BLOTTING OF DhA hybridizatior procedure described above.
CONSTRUCTION OF DELETION VIRUSES. The strategy used to construct deletion viruses involved the use of either WO 3/021044 I Ci' US92/06034 -53homologous recombination and/or direct ligation techniques. Initially a virus was constructed via homologous recombination, in which the DNA to be deleted was replaced with a marker gene such as E.coli Bgalactosidase (lacZ) or B-glucuronidase (uidA). A second virus was then constructed in which the marker gene was deleted either by homologous recombination or via direct ligation. The advantage of this strategy is that both viruses may be purified by the SCREEN FOR RECOMBINANT HERPE'VIRUS EXPRESSING ENZYMATIC MARKER GENES. The first virus is purified by picking blue plaques from a white plaque background, the second virus is purified by picking white plaques from a blue plaque background.
Several homology vectors were constructed for the purpose of deleting the gpG, gpE and Tk gene coding regions. A detailed description of these homology vectors follows.
HOMOLOGY VECTOR 129-71.5. The plavsmid 129-71.5 was constructed for the purpose of deleting a portion of the TK gene coding region from the IBR virus. It incorporates a selectable marker, the bacterial transposon neomycin resistance gene, flaiked by IBR virus DNA. Upstream of the marker gene is an approximately 860 base pair fragment of IBR virus DNA which ends with sequences encoding amino acids 1-62 of the TK primary translation product. Downstream of the marker gene is an approximately 1741 base pair fragment of IBR virus DNA which begins with sequences encoding amino acids 156-367 of the TK primary translation product. When this plasmid is used according to the HOMOLOGOUS RECOMBINATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS, it will replace the DNA coding for amino acids 63-155 of the TK primary translation product with DNA coding for the marker gene. Note that the marker gene will be under the control of the herpes simplex type 1 alpha-4 immediate early gene promoter A detailed description of the WO 93/021 04 CI2IA /LS92/06034 -54plasmid is given in Figure 7. It was constructed from the indicated DNA sources utilizing standard recombinant DNA techniques It may be constructed by joining restriction fragments from the following sources with the synthetic DNA sequences indicated in Figure 7. The plasmid vector is derived from an approximately 2975 base pair SmaI to HindII7 restriction fragment of (Promega). Fragment 1 is an approximately 860 base pair NcoI tc BamHI restriction fragment of the IBR virus HindIII restriction fragment A This fragment is located on an approximately 5500 base pair ClaI to Nrul fragmernt contained in the IBR virus HindIII A fragment.
Fragment 2 is an approximately 490 base pair PvuII to BamHI restriction sub-fragment of the HSV-1 BamHi restriction fragment N Note that the HSV-1 oriS region has been removed from this fragment by deletion of the sequences between the Sina sites located 1483 and 128 base pairs away from the PvuII end Fragment 3 is an approximately 1541 base pair BglII to BamHI restriction fragment of plasmid pNEO Biochemicals, Inc.). Fragment 4 is an approximately 784 base pair SmaI to SmaI restriction sub-fragment of the HSV-1 BamHI restriction fragment Q Note that this fragment is oriented such that the polyadenylation sequence (AATAAA) is located closest to junction D. Fragment 5 is an approximately 1741 base pair BglII to StuI restriction sub-fragment from the IBR HindIII restriction fragment A PLASMID 459-12.6. The plasmid 459-12.6 was generated for the purpose of constructing a recombinant cloning vector wh 4 ch expresses the IBR virus glycoprotein G. This was accomplished by inserting the IBR virus gpG gene into S- PRV-013 Serial No. 07/823,102 filed January 27, 1986). Plasmid 459-12.6 contains a chimeric gene under the control of the IBR virus gpG promoter. The chimeric gene expresses a fusion protein consisting of the first WO 93/02104 WPCI'/US92/06034 362 amino acids of IBR virus gpG fused to amino acids 421-467 of the PRV gpIII (13) followed by amino acids 480-498 of the PRV gpX The chimeric gene is flanked by HindIII restriction sites. When this plasmid is used with S-PRV-013 and the restriction enzyme HindIII according to the DIRECT LIGATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS the esulting recombinant will express the IBR virus gpG. A detailed description of the plasmid is given in Figure 11. It was constructed from '.he indicated DNA sources utilizing standard recombinant DNA techniques It may be constructed by joining restriction fragments from the following sources with the synthetic DNA sequences indicated in Figure 11. The plasmid vector is derived from an approximately 2999 base pair XbaI to XbaI restriction fragment of a hybrid cloning vector derived from pSP64 and pSP65 (Promega).
The hybrid cloning vector was constructed by joining approximately 1369 base pair Pvul to SmaI fragment from pSP64 with the approximately 1652 base pair PvuI to SmaI fragment from pSP65. Fragment 1 is an approximately 182 base pair PstI to EcoRV restriction sub-fragment of the HCMV XbaI restriction fragment B Fragment 2 is an approximately 2121 base pair MluI to XhoI restriction sub-fragment of the IBR virus MindIII restriction fragment K Fragment 3 is an approximately 121 base pair XhoI to BamHI restriction sub-fragment of the PRV BamHI restriction fragment #2 Fragment 4 is an approximately 760 base pair NdeI to Sail restriction subfragment of the PRV BamHI restriction fragment #7 HOMOLOGY VECTOR 439-01.31. The plasmid 439-01.31 was constructed for the purpose of deleting a portion of the gpG gene coding region from the IBR virus. It incorporates an 5.coli B-galactosidase marker gene flanked by IBR virus DNA. Downstream of the marker gene is an approximately 3593 base pair fr-zment of IBR virus DNA which ends with sequences encoding the first 262 WO 93/02104 1T/US92/60034 -56amino acids of the gpG primary translation product.
Upstream of the marker qesn is an approximately 785 base pair fragment of IBR virus DNA which begins with sequences encoding the last 80 amino acids of the gpG primary translation product. When this plasmid is used according to the HOMULOGOUS RECOMBINATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS it will replace the DNA coding for amino acids 263-361 of the gpG primary translation product with DNA coding for the marker gene.
Note that the B-galactosidase (lacZ) marker gene will be under the control of the human cytomegalovirus immediate early gene promoter. A detailed description of the plasmid is given in Figure 12. It was constructed from the indicated DNA sources utilizing standard recombinant DNA techniques It may be constructed by joining restriction fragments from the following sources with the synthetic DNA sequences indicated in Figure 12. The plasmid vector is derived from an approximately 2965 base pair HindIII to Smal restriction fragment of pSP64 (Promega). Fragment 1 is an approximately 3593 base pair HindIII to XhoI restriction fragment of the IBR HindIII restriction fragment K Fragment 2 is an approximately 753 base pair Sal to NdeI restriction fragment of the PRV BamHI restriction fragment #7 Note that this fragment was resected with Exonuclease III/S1 nuclease digestion such that approximately 57 base pairs were removed from the NdeI end. Fragment 3 is an approximately 3347 base pair Ball to BamHI restriction fragment of plasmid pJF751 Fragment 4 is an approximately 1191 base pair Aval to PstI restriction fragment from the HCMV XbaI restriction fragment E (16).
Fragment 5 is an approximately 785 base pair XhoI to YdeI restriction fragment from the IBR HindIII restriction fragment K Note that the lacZ marker gene is flanked by XbaI sites located at Junction B and Junction E in this plasmid permitting the marker gene to be cut out with Xbal.
WO 93/02104 PCT/US92/06034 -57- HOMOLOGY VECTOR 439-21.69. The plasmid 439-21.69 was constructed for the purpose of deleting a portion of the gpG gene coding region from the IBR virus. It incorporates an E.coli B-galactosidase (lacZ) marker gene flanked by IBR virus DNA. Downstream of the marker gene is an approximately 888 base pair fragment of IBR virus DNA which begins approximately 1042 base pairs upstream of the initiation codon of the gpG gene and ends approximately 154 base pairs upstream of the initiation codon of the gpG gene. Upstream of the marker gene is an approximately 785 base pair fragment of IBR virus DNA which begins with sequences encoding the last 80 amino acids of the gpG primary translation product. When this plasmid is used according to the HOMOLOGOUS RECOMBINATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS it will replace the DNA coding for amino acids 1-361 of the gpG primary translation product with DNA coding for the marker gene. Note that the B-galactosidase (lacZ) marker gene will be under the control of the human cytomegalovirus immediate early gene promoter. A detailed description of the plasmid is given in Figure 13. It was constructed from the indicated DNA sources utilizing standard recombinant DNA techniques It may be constructed by joining restriction fragments from the following sources with the synthetic DNA sequences indicated in Figure 13. The plasmid vector is derived from an approximately 2965 base pair HindIII to SmaI restriction fragment of pSP64 (Promega). Fragment 1 is an approximately 3593 base pair HindIII to XhoI restriction fragment of the IBR HindIII restriction fragment K Fragment 2 is an approximately 753 base pair Sall to NdeI restriction fragment of the PRV BamHI restriction fragment #7 Note that this fragment was resected with Exonuclease III/Sl nuclease digestion such that approximately 57 base pairs were removed from the NdeI end. Fragment 3 is an approximately 3317 base pair Ball to BamHI restriction fragment of plasmid pJF751 WO 93/02104 P07LI/ S92/06034 -58- Fragment 4 is an approximately 1191 base pair Aval to PstI restriction fragment from the HCMV XbaI restriction fragment E Fragment 5 is an approximately 785 base pair XhoI to NdeI restriction fragment from the IBR HindIII restriction fragment K Note that the lacZ marker gene is flanked by Xbal sites located at Junction B and Junction E in this plasmid permitting the marker gene to be cut out with XbaI.
HOMOLOGY VECTOR 439-70.4. The plasmid 439-70.4 was constructed for the purpose of deleting the E.coli Bgalactosidase (lacZ) marker gene from S-IBR-035 virus.
It incorporates two regions of IBR viral DNA which flank the marker gene in S-IBR-035. The first region is an approximately 888 base pair fragment of IBR virus DNA which begins approximately 1042 base pairs upstream of the initiation codon of the gpG gene and ends approximately 154 base pairs upstream of the initiation codon of the gpG gene. The second region is an approximately 785 base pair fragment of IBR virus DNA which begins with sequences encoding the last 80 amino acids of the gpG primary translation product. When this plasmid is used in conjunction with S-IBR-035 DNA according to the HOMOLOGOUS RECOMBINATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS it will delete the DNA coding for the E.coli B-galactosidase (lacZ) marker gene.
A detailed description of the plasmid is given i: Figure 14. It was constructed from the indicated DNA sources utilizing standard recombinant DNA techniques It may be constructed by joining restriction fragments from the following sources with the synthetic DNA sequences indicated in Figure 14. The plasmid vector is derived from an approximately 2965 base pair HindIII to SmaI restriction fragment of pSP64 (Promega). Fragment 1 is an approximately 3593 base pair HindIII to XhoI restriction fragment of the IBR HindIII restriction fragment K Fragment 2 is an approximately 785 base WO 93/021041 I)CT'/ US92/06034 -59pair XhoI to NdeI restriction fragment from the IBR HindIII restriction fragment K IBR VIRUS gpE PLASMID. A plasmid may be generated for the purpose of constructing a recombinant cloning vector which expresses the IBR virus glycoprotein E (gpE). This plasmid may be used to insert the IBR virus gpE gene into S-PRV-002 Patent No. 4,877,737). The plasmid will contain the gpE gene flanked by XbaI restriction sites.
When this plasmid is used with S-PRV-002 and the restriction enzyme Xbal according to the DIRECT LIGATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS the resulting recombinant will express the IBR virus gpE. A detailed description of the plasmid is given in Figure 17. It may be constructed, utilizing standard recombinant DNA techniques by joining restriction fragments from the following sources. The plasmid vector is derived from an approximately 2999 base pair XbaI to Xbal restriction fragment of a hybrid cloning vector derived from pSP64 and pSP65 (Promega). The hybrid cloning vector was constructed by joining an approximately 1369 base pair Pvul to SmaI fragment from pSP64 with the approximately 1652 base pair PvuI to SmaI fragment from pSP65. Fragment 1 is an approximately 3647 base pair NdeI to HindIII restriction sub-fragment of the IBR virus HindIII restriction fragment K Fragment 2 is an approximately 832 base pair HindIII to Sacd restriction sub-fragment of an IBR virus 2400 base pair SmaI restriction fragment. This SmaI fragment has been cloned into the SmaI site of the plasmid pSP64 (Promega).
This plasmid is designated PSY1645. PSY1645 was deposited on July 16, 1991 pursuant to the Budapest Treaty on the International Deposit of Microorganisms for the Purposes of Patent Procedure with the Patent Culture Depository of the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852 U.S.A. under ATCC Accession No. 68650. Note that the lacZ marker gene WO 93/02104 WCrI US92/06031 is flanked by XbaI sites located at Junction B and Junction E in this plasmid permitting the marker gene to be cut out with XbaI.
HOMOLOGY VECTOR 536-03.5. The plasmid 536-03.5 was constructed for the purpose of deleting a portion of the gpE gene coding region from the IBR virus. It incorporates an E.coli B-galactosidase (lacZ) marker gene flanked by IBR virus DNA. Upstream of the marker gene is an approximately 1704 base pair fragment of IBR virus DNA which ends with sequences encoding amino acids 1-76 of the gpE primary translation product. Downstream of the marker gene is an approximately 742 base pair fragment of IBR virus DNA which begins with sequences encoding amino acids 548-617 of the gpE primary translation product.
When this plasmid is used according to the HOMOLOGOUS RECOMBINATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS, it will replace the DNA coding for amino acids 77-547 of the gpE primary translation product with DNA coding for the marker gene. Note that the Bgalactosidase (lacZ) marker gene will be under the control of the PRV gpX. A detailed description of the plasmid is given in Figure 18. It may be constructed utilizing standard recombinant DNA techniques by joining restriction fragments from the following sources with the synthetic DNA sequences indicated in Figure 18.
The plasmid vector is derived from an approximately 2975 base pair Smal to HindIII restriction fragment of (Promega). Fragment 1 is an approximately 1704 base pair SmaI to SmaI restriction sub-fragment of the IBR HindIII restriction fragment K Fragment 2 is an approximately 413 base pair Sall to BamHI restriction fragment #7 Fragment 5 is an approximately 742 base pair NheI to BglI sub-fragment of an IBR virus 2400 base pair SmaI fragment. This SmaI fragment has been cloned into the SmaI site of the plasmid pSP64 (Promega). This plasmid is designated PSY1645. PSY1645 was deposited on WO 93/02104 PCf/US92/06034 -61- July 16, 1991 with the American Type Culture Collection.
Note that the lacZ marker gene is flanked by XbaI sites located at Junction B and Junction E in this plasmid permitting the marker gene to be cut out with XbaI.
VACCINATION STUDIES IN CALVES WITH INACTIVATED IBR VIRUS.
Calves, seronegative to IBR virus, were housed in facilities secure from IBR virus exposure. Groups of four calves were vaccinated intramuscularly with vaccines containing 107.3 or 108.0 plaque forming units of inactivated IBR virus formulated with an oil adjuvant.
A second vaccination was given 21 days later; four calves were maintained as unvaccinated controls. At 21 days after the second vaccination, animals were challenged intranasally with virulent wild-type IBR virus. After vaccination and challenge, animals were observed and the injection site was palpated weekly. Blood samples were taken on days 0, 7, 21, 28, and 42 post vaccination.
After challenge, animals were observed daily for clinical signs of IBR. Blood samples were taken on days 7 and 13 post challenge. Nasal swabs were collected on days 3, 6, 9, and 12 post challenge.
PURIFICATION OF IBR VIRUS gpG. gpG was purified from the tissue culture medium of infected MDBK cells. Confluent MDBK cells in serum-free medium were infected at a multiplicity of infection equal to 5, with wild-type, Cooper strain of IBR virus. The cells and media were harvested at approximately twenty-two hours after infection, when the cells showed considerable cytopathic effect and the fluids were centrifuged at 5000 rpm for minutes.
The supernatant fluid was concentrated approximately fold by ultrafiltration through an Amicon ym-30 membrane, and dialyzed against 10mM NaPO 4 pH 7.2. The dialysate was treated for 20 minutes at 0 0 C with 70% perchloric acid to WO 93/02104 IPCI'/US92/06034 -62a final concentration of 0.2M perchloric acid, then centrifuged at 12,000 rpm for 20 minutes. The supernatant fluid was then dialyzed against 20mM Tris pH The acid-soluble proteins were separated by column chromatography on a DEAE-Sephacel anion exchange column using a liner gradient elution 0 to 100% A to B where A 20mM Tris pH 9.5 and B 20mM Tris pH 9.5/800 mM NaCl. The gpG eluted at approximately 35-40% B. Peak fractions were assayed by Western blot using anti gpG peptide sera. Reactive fractions were combined arnd dialyzed against 5 mM Tris pH 7.0. The sample was then concentrated 10-fold by lyophilization and stored at ELISA ASSAY. A standard enzyme-linked immunosorbent assay (ELISA) protocol was used to determine the immune status of cattle following vaccination and challenge.
A purified gpG antigen solution (100 Al at 1 ng/. in PBS) was allowed to absorb to the wells of microtiter dishes for 18 hours at 4 0 C. The coated wells were rinsed one time with PBS. Wells were blocked by adding 250 Ml of PBS containing 1% BSA (Sigma) and incubating 1 hour at 37 0 C. The blocked wells were rinsed one time with PBS containing 0.02% Tween 20. 50 Al of test serum (previously diluted 1:2 in PBS containing 1% BSA) were added to the wells and incubated 1 hour at 37 0 C. The antiserum was removed and the wells were washed 3 times with PBS containing 0.02% Tween 20. 50 Al of a solution containing anti-bovine IgG coupled to horseradish peroxidase (diluted 1:500 in PBS containing 1% BSA, Kirkegaard and Perry Laboratories, Inc.) was added to visualize the wells containing antibody against the specific antigen. The solution was incubated 1 hour at 37 0 C, then removed and the wells were washed 3 times with WO 93/02104 39PCTS2/06034 -63- PBS containing 0.02% Tween 20. 100 Al of substrate solution (ATBS, Kirkegaard and Perry Laboratories, Inc.) were added to each well and color was allowed to develop for 15 minutes. The reaction was terminated by addition of 0.1M oxalic acid. The color was read at absorbance 410nm on an automatic plate reader.
PROCEDURE FOR GENERATING MONOCLONAL ANTIBODIES. To produce monoclonal antibodies, 8 to 10 week old BALB/c female mice were vaccinated intraperitoneally seven times at two to four week intervals with 107 PFU of S-PRV-160.
Three weeks after the last vaccination, mice were injected intraperitoneally with 40 Ag of purified gpG.
Spleens were removed from the mice three days after the last antigen dose.
Splenocytes were fused with mouse NSl/Ag4 plasmacytoma cells by the procedure modified from Oi and Herzenberg, Splenocytes and plasmacytoma cells were pelleted together by centrifugation at 300 x g for 10 minutes.
One ml of a 50% solution of polyethylene glycol (m.w.
1300-1600) was added to the cell pellet with stirring over one minute. Dulbecco's modified Eagles's medium ml) was added to the cells over three minutes. Cells were pelleted by centrifugation at 300 x g for 10 minutes and resuspended in medium with 10% fetal bovine serum and containing 100 MM hypoxanthine, 0.4 pM aminopterin and 16 MM thymidine (HAT). Cells (100 pl) were added to the wells of eight to ten 96-well tissue culture plates containing 100 Al of normal spleen feeder layer cells and incubated at 37°C. Cells were fed with fresh HAT medium every three to four days.
Hybridoma culture supernatants were tested by the ELISA ASSAY in 96-well microtiter plates coated with 100 ng of purified gpG. Supernatants from reactive hybridomas were further analyzed by black-plaque assay and by Western WO 93/02104 O4C['/ S92/06034 -64- Blot. Selected hybridomas were cloned twice by limiting dilution. Ascetic fluid was produced by intraperitoneal injection of 5 X 106 hybridoma cells into pristane-treated BALB/c mice.
METHOD FOR cDNA CLONING BOVINE ROTAVIRUS gp38 GENE. The Calf Nebraska strain of bovine rotavirus (USDA) was propagated on MA-104 cells (Rhesus monkey kidney cells from MA Bioproducts). Confluent monolayers were infected at a multiplicity of infectionx of greater than 10 in DMEM containing 5 micrograms/ml trypsin. Cells were incubated with virus for 48 hours or until a cytopathic effect was obtained. Media and cell debris were collected and centrifuged at 10,000 x g for 20 minutes at 40C. The supernatant containing the rotavirus was then centrifuged at 10,000 x g in a preparative Beckman Ti45 rotor at Virus pellets were resuspended in SM medium (50 mM Tris- HC1 pH 7.5, 100 mM KC1, 10 mM MgCl 2 and homogenized lightly in a Dounce-type homogenizer. The resuspended virus was centrifuged at 10,000 x g for 10 minutes then loaded onto 25-50% CsCl gradients in SM buffer.
Gradients were centrifuged at 100,000 x g for 4 hours at 0 C. The two blue-white bands representing intact virions and cores of rotavirus were collected, diluted, and the CsCl gradient procedure was repeated a second time. Virus obtained from the second gradient was dialyzed overnight against SM buffer at 4 0
C.
Dialyzed bovine rotavirus 4as twice extracted with an equal volume of SDS/ph,. then twice more with chxoroform: isoamylalcohol The double stranded RNA was precipitated with ethanol in the presence of 0.2 M sodium acetate, centrifuged and resuspended in water.
The yield was typically 100 micrograms from 1,000 cm 2 of infected cells.
.WO 93/02104 PCI/ L'S92/06034 160 micrograms of double-stranded bovine rotavirus RNA obtained from the above piocedure was mixed with one microgram each of two synthetic oligonucleotide primers in a volume of 160 microliter (sequences of primers were: 5'-GGGAATTT2GCAGGTCACATCATACAATTCTAATCTAAG-3' and -GGGAATTCTGCAGGCTTTAAAAGAGAGAATTTCCGTTTGGCTA-3') derived from the published sequence of bovine rotavirus The RNA-primer mixture was boiled for 3 minutes in a water bath then chilled on ice. Additions of microliters of 1 M Tris-HCl pH 8.3, 35 microliters of 1 M KC1, 10 microi.ters of 0.25 M MgCl 2 7 microliters of 0.7 M 2-mercaptoethanol, 7 microliters of 20 mM dNTP's, and 6 microliters of reverse transcriptase (100 units) were made sequentially. The reaction was incubated at 42 0 C for 1.5 hours then 10 microliters of 0.5 M EDTA pH was added and the solution was extracted once with chloroform:phenol The aqueous layer was removed and to it 250 microliters of 4 M ammonium acetate and ml of 95% ethanol was added, the mixture was frozen in dry ice and centrifuged in the cold. The resulting pellet was resuspended in 100 microliters of 10 mM Tris- HCl pH 7.5 and the ammonium acetate precipitation procedure was repeated. The pellet was resuspended in 100 microliters of 0.3 M KOH and incubated at r.-om temperature overnight, then at 370C for 2 hours. The solution was brought to neutral pH by addition of microliters of 3.0 M HC1 and 25 microliters of 1.0 M Tris-HC1 pH 7.5 The resulting single-stranded cDNA was then precipitated two times by the above-described ammo: ,am acetate-ethalAol procedure. The pellet obtained was resuspended in 50 microliters of 10 mM Tris-HCl pH 100 mM NaCI, 1 mM EDTA, boiled in a water bath for 2 minutes, then incubated at 59 0 C Zor 16 hours. The solution was lyophilized to a volume of 15 microliters and the resulting double-stranded cDNA was run on a agarose gel (Sigma agarose Type II). The ethidium bromide-stained DNA migrating at 1,000-1,100 base pair WO 93/02104 W 0Cr/US92/06034 -66length was excised from the -gel and electroeluted in a CBS electroeluter device. The solution was lyophilized, and the cDNA was resuspended in 25 microliters of water.
To this solution was added 2 microliters of 1.0 M Tris- HC1 pH 7.5, 2 microliters &1 1 M KCl, 1 microliter of 0.25 M MgC1 2 1 microliter of 20 mM dNTP's and 5 units of E. coli DNA polymerase I. The reaction was incubated at room temperature for 15 minutes, then chloroform/phenol extracted and ammonium acetate-ethanol precipitated as described above. The resulting cDNA was tailed with dCTP using terminal deoxynucleotide transferase (BRL buffer and enzyme used). The reaction was stopped 'ith 2 microliters of 0.5 M EDTA, chloroform/phenol extracted and precipitated with sodium acetate in the presence of 10 micrograms of carrier tRNA. The resuspended cDNA was mixed with 200 ng of dGMP-tailed Pst I cut pBR322 (BRL catalog #5355SA) in 200 microliters of 10 mM Tris-HC1 pH 100 mM NaC1, 1 mM EDTA, heated to 65°C for minutes, then 57 0 C for 2 hours. The annealed cDNA-vector pBR322 was transformed onto E. coli DH-1 cells prepared for high efficiency transformation. Colonies that showed sensitivity to ampicillin and tetracycline resistance were grown and DNA was prepared and cut with Pst I to determine the size of the cDNA insert. Several clones having Pst I inserts of 1,050-1,100 base pairs were analyzed and found to have identical restriction enzyme digest patterns. For one of these clones, the 1,100 base pair PstI insert was subcloned into a M13 phage sequencing vector. Part of the DNA sequence of this clone was determined and was found to be identical to the published sequence cDNA CLONING. cDNA cloning refers to the i. hods used to convert RNA molecules into DNA molecules following state of the art procedures. Applicants' methods are described in Gubler and Hoffman Bethesda Research Laboratories (Gaithersburg, MD) have designed a cDNA WO 93/0210" 0ClT/US92/06034 -67- Cloning Kit that is very similar to the procedures used by applicants and contains the best set of reagents and protocols to duplic. e our results.
For cloning virus sE'A species, a host cell line sensitive to infection by the virus was infected at 5-10 plaque forming units per cell. When cytopathic effect was evident, but before total destruction, the medium was removed and the cells were lysed in 10 mis lysis b"ffer (4 M guanidine thiocyanate, 0.1% antifoam A, 25 mM sodium citrate pH 7.0, 0.5% N-lauroyl sarcosine, 0.1 M betamercaptoethanol). The cell lysate was poured into a sterilized Dounce homogenizer and homogenized on ice 3-10 times until the solution was homogenous. For RNA purification, 8 mis of cell lysate were gently layered over 3.5 mis of CsCl solution (5.7 M CsCl, 25 mM sodium citrate pH 7.0) in a Beckman SW41 centrifuge tube. The samples were centrifuged for 18 hours at 20 0 C at 36,000 rpm in a Beckman SW41 rotor. The tubes were put on ice and the supernatants from the tubes were carefully removed by aspiration to leave the RNA pellet undisturbed. The pellet was resuspended in 400 microliters glass distilled water, and 2.6 mls of guanidine solution (7.5 M guanidine-HC1, 25 mM sodium citrate pH 7.0, 5 mM dithiothreitol) were added. Then 0.37 volumes of 1 M acetic acid were added, followed by 0.75 volumes of cold ethanol and the sample was put at 0 C for 18 hours to precipitate RNA. The precipitate was collected by centrifugation in a SorveUl crntrifuge for 10 min at 4 0 C at 10,000 rpm in an SS34 rotor. The pellet was dissolved in 1.0 ml distilled water, recentrifuged at 13,000 rpm, and the supernatant saved.
RNA was reextracted from the pellet 2 more times as above with 0.5 ml distilled water, and the supernatants were pooled. A 0.1 volume of 2 M potassium acetate solution was added to the sample followed by 2 volumes of cold ethanol and the sample was put at -20 0 C for 18 hours.
WO 93/02104 PCIT/US92/06034 -68- The precipitated RNA was collected by centrifugation in the SS34 rotor at 4 0 C for 10 minutes at 10,000 rpm. The pellet was dissolved in 1 ml distilled water and the concentration taken by absorption at A260/280. The RNA was stored at -70 0
C.
mRNA containing polyadenylate tails (poly-A) was selected using oligo-dT cellulose (Pharmacia #27 5543-0). Three milligrams of total RNA was boiled and chilled and applied to a 100 mg oligo-dT cellulose column in binding buffer (0.1 M Tris pH 7.5, 0.5 M LiCI, 5 mM EDTA pH 0.1% lithium dodecyl sulfate). The retained poly-A RNA was eluted from the column with elution buffer (5 mM Tris pH 7.5, 1 mM EDTA pH 8.0, 0.1% sodium dodecyl sulfate).
This mRNA was reapplied to an oligo-dT column in binding buffer and eluted again in elution buffer. The sample was precipitated with 200 mM sodium acetate and 2 volumes cold ethanol at -20oC for 18 hours. The RNA was resuspended in 50 microliters distilled water.
Ten micrograms poly-A RNA was denatured in 20 mM methyl mercury hydroxide for 6 minutes at 22°C. Betamercaptoethanol was added to 75 mM and the sample was incubated for 5 min at 22 0 C. The reaction mixture for first strand cDNA synthesis in 0.25 ml contained 1 microgram oligo-dT primer (P-L Biochemicals) or 1 microgram synthetic primer, 28 units placental ribonuclease inhibitor (Bethesda Research Labs #5518SA), 100 mM Tris pH 8.3, 140 mM KC1, 10 mM MgCl,, 0.8 mM dATP, dCTP, dGTP, and dTTP (rharmacia), 100 microcuries 32
P-
labelled dCTP (New England Nuclear #NEG-013H), and 180 units AMV reverse transcriptase (Molecular Genetics Resources #MG 101). The reaction was incubated at 42 0
C
for 90 minutes, and then was terminated with 20 mM EDTA pH 8.0. The sample was extracted with an equal volume of phenol/chloroform and precipitated with 2 M ammonium acetate and 2 volumes of cold ethanol -20 0 C for WO 93/02104 PC/ US92/06034 -69- 3 hours. After precipitation and centrifugation, the pellet was dissolved in 100 microliters distilled water.
The sample was loaded onto a 15 ml G-100 Sephadex column (Pharmacia) in buffer (100 mM Tris pH 7.5, 1 mM EDTA pH 8.90, 100 mM NaCl). The leading edge of the eluted DNA fractions were pooled, and DNA was concentrated by lyophilization until the volume was about 3.00 microliters, then the DNA was precipitated with ammonium acetate plus ethanol as above.
The entire first strand sample was used for second strand reaction which follow the Gubler and Hoffman (23) method except that 50 micrograms/ml dNTP's, 5.4 units DNA polymerase I (Boehringer Mnnheim #642-711), and 100 units/ml E. coli DNA ligase (New England Biolabs #205) in a total volume of 50 microliters were used. After second strand synthesis, the cDNA was phenol/chloroform extracted and precipitated. The DNA was resuspended in microliters distilled water, treated with 1 microgram RNase A for 10 minutes at 22 0 C, and electrophoresed through a 1% agarose gel (Sigma Type II agarose) in 40 mM Tris-acetate buffer pH 6.8R. The gel was stained with ethidium bromide, and DNA in the expected size range wan excised from the gel and electroeluted in 8 mM Trisacetate pH 6.85. Electroeluted DNA was lyophilized to about 100 microliters, and precipitated with ammonium acetate and ethanol as above. The DNA was resuspended in microliters water.
Oligo-dC tails were added to the DNA to facilitate cloning. The reaction contained the DNA, 100 mM potassium cacodylate pH 7.2, 0.2 mM dithiothreitol, 2 mM CaCl 2 80 micromoles dCTP, and 25 units terminal deoxynucleotidyl transferase (Molecular Genetic Resources #S1001) in 50 microliters. After 30 minutes at 37 0 C, the reaction was terminated with 10 mM EDTA, and the sample WO 93/02104 PCT/US92/06034 was phenol/chloroform extracted and precipitated as above.
The dC-tailed DNA sample was annealed to 200 ng plasmid vector pBR322 that contained oligo-dG tails (Bethesda Research Labs #5355 SA/SB) in 200 microliters of 0.01 M Tris pH 7.5, 0.1 M NaCl, 1 mM EDTA pH 8.0 at 65 0 C for 2 minutes and then 57 0 C for 2 hours. Fresh competent E.
coli DH-1 cells were prepared and transformed as described by Hanahan (41) using half the annealed cDNA sample in twenty 200 microliter aliquots of cells.
Transformed cells were plated on L-broth agar plates plus micrograms/ml tetracycline. Colonies were screened for the presence of inserts into the ampicillin gene using Ampscreen (Bethesda Research Labs #5537 UA), and the positive colonies were picked for analysis.
POLYMERASE FILL-IN REACTION. DNA was resuspended in buffer containing 50 mM Tris pH 7.4, 50 mM KC1, 5 mM MgCl 2 and 400 micromolar each of the four deoxynucleotides. Ten units of Klenow DNA polymerase (BRL) were added and the reaction was allowed to proceed for 15 minutes at room temperature. The DNA was then phenol extracted and ethanol precipitated as above.
HOMOLOGY VECTOR 523-78.72. The plasmid 523-78.72 was constructed for the purpose of deleting a portion of the gpE gene coding region from the IBR virus. It may also be used to insert foreign DNA into IBR. Plasmid 523- 78.72 may be constructed by digestion of the plasmid 536- 03.5 with the enzyme XbaI followed by religation to remove the lacZ marker gene.
HOMOLOGY VECTOR 591-21.20. The plasmid 591-21.20 was constructed for the purpose of deleting a portion of the thymidine kinase gene. It may also be used to insert WO 93/02104 PCT/US92/06034 -71foreign DNA into IBR. It contains a unique BglII restriction enzyme site into which foreign DNA may be inserted. It may be constructed utilizing standard recombinant DNA techniques 14) by joining restriction fragments from the following sources with the synthetic DNA sequences indicated in figure 24. The plasmid vector is derived from an approximately 2999 base pair SalI to Sall restriction fragment of pSP64 (Promega). Fragment 1 is an approximately 1400 base pair SalI to NarI restriction subfragment contained on the approximately 2700 base pair SalI-SalI restriction subfragment of the IBR HindIII restriction fragment A Fragment 2 is an approximately 1215 base pair BglIII to Sall restriction subfragment contained on the approximately 2700 base pair SalI-SalI restriction subfragment of the IBR HindIII restriction fragment A (72).
HOMOLOGY VECTOR 552-46.12. The plasmid 591-46.12 was constructed for the purpose of deleting a portion o the Tk gene coding region from the IBR virus. It incorporates an E. coli B-glucuronidase (uidA) marker gene flanked by IBR virus DNA. The uidA marker gene was inserted into the homology vector 591-21.20 at the unique BglII site. The marker gene is oriented in the same direction as the Tk gene in the homology vector. A detailed description of the marker gene is given in figure 25. It may be constructed utilizing standard recombinant DNA techniques 14) by joining restriction fragments from the following sources with the synthetic DNA sequences indicated in figure 25. Fragment 1 is an approximately 404 base pair Sall to EcoRI restriction subfragment of the PRV BamHI restriction fragment Note that the EcoRI site was introduced at the location indicated in figure 12 by PCR cloning. Fragment 2 is an approximately 1823 base pair EcoRI to SmaI fragment of the plasmid pRAJ260 (Clonetech). Note that the EcoRI and SmaI sites were introduced at the locations WO 93/02104 W CI'/ US92/06034 -72indicated in figure 25 by PCR cloning. Fragment 3 is an approximately 784 base pair Smal to SmaI restriction subfragment of the HSV-1 BamHI restriction fragment Q Note that this fragment is oriented such that the polyadenylation sequence (AATAAA) is located closest to junction C.
CLONING OF BOVINE VIRAL DIARRHEA VIRUS gp53 GENE. The bovine viral diarrhea (BVDV) gp53 gene was cloned essentially as described earlier (see cDNA CLONING) using the random priming method Viral RNA prepared from BVDV Singer strain grown in MADIN-DARBY bovine kidney (MDBK) cells was converted to cDNA using the random priming method. The cDNA was used for second strand reaction (23) and the resulting double stranded DNA was used cloned as described in the cDNA CLONING procedure.
From this procedure a series of clones were obtained that comprised parts of the genome of BVDV. The location of the gene for gp53 gene has been published (66) and this sequence information was used to locate and isolate the gp53 encoding region from the 449 kilodalton primary translation product open reading frame contained in the complete cDNA clone.
The gp53 encoding gene of BVDV was also cloned essentially as described by Katz et al. for the HA gene of human influenza virus. Viral RNA prepared from the Singer strain of BVDV virus grown in MDBK cells was first converted to cDNA utilizing an oligo nucleotide primer specific for the target gene. The cDNA was then used as a template or polymerase chain reaction (PCR) cloning (67) of the gp53 gene. The PCR primers were designed to incorporate restriction endonuclease enzyme sites that permit the cloning of the amplified coding region into vectors that contain the appropriate signals for gene expression in IBR. The gp53 gene of the Singer strain of BVDV was cloned using the following oligo nucleotide WO 93/02104 PC17US92/06034 -73primers: 5'-CATAGATCTTGTGGTGCTGTCCGACTTCGCA-3' for cDNA priming and was combined with CGTGGATCCTCAATTACAAGAGGTATCGTCTAC-3' for PCR amplification. Note that this general strategy may be used to clone the gp53 coding region from BVDV strains other than Singer.
CLONING OF BOVINE RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEIN AND NUCLEOCAPSID PROTEIN GENES. The bovine respiratory virus (BRSV) fusion attachment an nucleocapsid protein genes may be cloned essentially as described by Katz et al. for the HA gene of human influenza. Viral RNA prepared from virus grown in bovine nasal turbinate (BT) cells is first converted to cDNA utilizing an oligo nucleotide primer specific for the target gene. The cDNA is then used as a template for polymerase chain reaction (PCR) cloning (67) of the targeted region. The PCR primers are designed to incorporate restriction sites which permit the cloning of the amplified coding regions into vectors containing the appropriate signals for expression in IBR. One pair of oligo nucleotides will be required for each coding region. The N gene coding region from the BRSV strain A51908 (or 391-2??) would be cloned utilizing the following p r i m e r s: 5' AAAAGATCTTAGCAAGGTCAAACTAAATGACACTTTCAAC-3' for cDNA priming and combined with CGTGGATCCAACTCACAATTCCACATCATTATCTTTGGGATT-3' for PCR.
The G gene coding region from the BRSV strain A51908 (or 391-2??) would be cloned utilizing the following primers: '-TATAGATCTTCATACCCATCATCTTAAATTCAAGACATTA-3 for cDNA priming and combined with 5' CGTGGATCCATAATTAGATGTTATATGGAGGTGTGTTG-3' for PCR. The F gene from strain A51908 (or 391-2??) of BRSV would be cloned utilizing the following primers: TATAGATCTAACAGCCATGAGGATGATCATCAGCATTATC-3' for cDNA priming and combined with WO 93/02104 PCr/US92/06034 -74- CGTGGATCCTTCTGAGGTTTAGATTGTAAACATTATGCA-3' for PCR. Note that this general strategy may be used to clone the coding region of F and N genes from other strains of
BRSV..
CLONING OF PASTEURELLA HAEBLYTICA LEUKOTOXIN AND IRON REGULATED OUTER MEMBRANE PROTEIN(S). The Pasteurella haemolytica strain Al leukotoxin gene may be cloned from a genomic DNA sample. Genomic DNA is prepared from P.
haemolytica Al cells grown in culture (68) by the methods described in Maniatis et al. (1982). The purified P.
haemolytica DNA is then used as a template for polymerase chain reaction (PCR) cloning (67) of the targeted leukotoxin gene. The PCR primers are designed so that restriction endonuclease sites are incorporated that allow the cloning of the 102 kilodalton toxin portion of the gene into vectors containing the appropriate signals for expression in IBR. The P. haemolytica Al (ATTC 43279 biotype A, serotype 1) leukotoxin gene woud be cloned utilizing the following primers: TATAGATCTTAGACTTACAACCCTAAAAAC-3' and CGTGGATCCAACTCTATAATGTGTGCAACAATATAG-3' for PCR. Note that this general strategy may be used to clone the coding regions for the leukotoxin gene of all P.
haemolytica serotypes.
The P. haemolytica Al iron regulated outer membrane proteins (IRP) of 3 major polypeptides with molecular weights of 35, 70 and 100 kilodaltons. The DNA coding for the array of P. haemolytica genes can be cloned in Escherichia coli using plasmid vectors essentially as described in Maniatis et al. (1982). The clone library is constructed by partial digestion of the genomic DNA.
The IRP genes can be isolated from this library of P.
haemolytica clones by screening for the production of iron regulated outer membrane antigens by a colony enzyme-linked immunosorbent assay blot method with WO 93/02104 PCI'/US92/06034 antiserum that is specific to the IRPs. This antiserum may be obtained by eluting antibodies derived from polyclonal antiserum raised against whole P. haemolytica or membrane enriched fractions but selectively bound to the IRPs on Western blots The specificity of the antibodies can be verified by immunoblot screening of P.
haemolytica polypeptides from iron restricted and iron induced cultures.
WO 93/02104 WI C1L'S92/06034 -76- Example 1 S-IBR-002 S-IBR-002 is an IBR virus that has a deletion of approximately 800 bp in the repeat region of the genome.
This deletion removes the only two EcoRV restriction sites on the virus genome and an adjacent BglII site (Figure 2).
To construct this virus, the DIRECT LIGATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS was performed.
Purified IBR virus DNA (Cooper strain) digested with EcoRV restriction enzyme was mixed with Dral-restriction enzyme-digested plasmid DNA containing the E.coli Bgalactosidase (lacZ) gene under the control of the HSV-1 TX promoter. After ligation the mixture was used to transfect animal cells and the transfection stock was screened for recombinant IBR virus by the SOUTHERN BLOTTING OF DNA procedure. The final result of the purification was the recombinant IBR virus designated S- IBR-002. It was shown by Southern hybridization that this virus does not carry any foreign genes. Restriction enzyme analysis also showed that the insertion sites (EcoRV) in both repeats were deleted. Figure 2 shows the restriction map of the EcoRI B fragment which contains the EcoRV restriction sites and the map of S-IBR-002 which lacks the EcoRV rites. S-IBR-002 was deposited on June 18, 1986 pursuant to the Budapest Treaty on the International Deposit of Microorganisms for the Purposes of Patent Procedure with the Patent Culture Depository of the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852 U.S.A. under ATCC Accession No. VR 2140.
WO 93/021043 PCr/LIS92/06034 -77- A study was conducted to determine the safety and serological response of young calves following intramuscular administration of S-IBR-002. These results are presented in Table 1. Three calves were inoculated intramuscularly with 10 7 PFU of S-IBR-002. Clinical signs of IBR and febrile response were absent in these calves, as well as in the contact control calf. All three calves developed significant neutralizing antibody to IBR virus but the contact control remained seronegative. These results suggest that S-IBR-002 is useful as a vaccine against IBR disease.
WO 93/02104 9302104PCT/US92/06034 -78- Table 1. Serologic and IBR-002 Clinical Response of Young Calves Following Vaccination with S.- Virus Calf Clinical Virus Antibody Titer Construct and Isolation" Days Post Inoculation Febrile -77 -4 2 response 0 7 1 1 2 28 NONE <2 <4 6 5 3 S-IBR-002 30 NONE <2 <4 6 <2 6 94 NONE <2 <4 6 3 8- IControl 32 NONE <4 <4 <4 <2 <4 f- M woman== 'From nasal swabs and peripheral blood leukocytes.
WO 93/02104 PCT/US92/06034 -79- Example 2 Uniaue Short 2 aene The unique short region of IBR virus contains a gene homologous to the US2 gene of several other herpesviruses. In the studies described below we show that deletion of the IBR unique short 2 gene (US2) may render the virus safe for use in pregnant cows, as determined by direct fetal inoculation.
Observing that the Nasalgen IBR vaccine strain will not cause abortion when used in IBR-susceptible pregnant cows at various stages of gestation (18,65), we attempted to determine the genomic lesion responsible for this property. We characterized the genome of this virus by restriction mapping and DNA sequence analysis. It was determined that a major portion of the IBR virus US2 gene was deleted from the Nasalgen virus. Restriction mapping of the Nasalgen virus indicated that the HindIII K fragment contained an approximately 800 base pair deletion. The deletion was localized to the end of the HindIII K Fragment located next to the HindIII 0 fragment (see Figure Therefore, the HindIII K fragment from the Cooper strain was subcloned and this region was sequenced. The first 1080 base pairs of the fragment were found to contain an open reading frame (ORF) coding for 309 amino acids (see Figure The ORF is 68% G+C and encodes a protein with a predicted molecular weight of 46,094. Comparison of the sequence of the predicted protein with sequences of gene products of HSV-1, PRV, HSV-2, and MDV in the unique short region indicated that this ORF is homologous to the herpesvirus US2 gene (see Figure Although the function of the herpesvirus US2 gene is not known, the gene has been shown to be nonessential for growth of HSV in cell culture (4,19).
WO 93/02104 PCT!JS92/06034 The US:; gene has also been shown to be deleted in the PRV vaccine strains Norden and Bartha (11).
The HindIII K fragment from the Nasalgen virus was subcloned and the deletion region was sequenced. When the sequence obtained from the Nasalgen strain was compared to the sequence obtained from the Cooper strain (see Figure it was possible to determine that amino acids 59 to 309 of the US2 gene had been deleted. It was also determined that most of the HindIII 0 fragment had also been deleted.
Cattle studies have shown that the Nasalgen virus will not cause abortion when used in IBR-susceptible pregnant cows at various stages of gestation Since the only major difference between the wild-type IBR strain and the Nasalgen strain resides in the deletion of the US2 gene, this gene may be involved in the fetal virulence observed for the wild type virus.
WO 93/02104 W CT1/US92/06034 -81- Example 3 S-IBR-027 S-IBR-027 is an IBR virus that has a deletion of approximately 800 bp in the repeat regions and approximately 1200 bp in the short unique region of the genome. The deletion in the short unique region removes the US2 gene (Figure The repeat deletion was derived from the parental virus S-IBR-002 and is described in Example 2.
To construct this virus, the HOMOLOGOUS RECO'3INATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS was performed. A homology vector containing the bacterial transposon Tn5 NEO (aminoglycosidase 3'phosphotransferase) gene under the control of the HSV a4 promoter flanked by sequences from the IBR virus TX gene was constructed. The IBR virus homology regions were derived from the TK gene. The upstream homology included the first amino acid of the TK gene (15) and extended approximately 800 base pairs upstream of the TK coding region. The downstream homology included amino acids 156 to 357 and extended downstream of the TK coding region approximately 60 base pairs. S-IBR-002 DNA was mixed with the homology vector and transfected into rabbit skin cells as indicated in the methods. The transfection stock was selected according to the SELECTION OF G418 RESISTANT IBR VIRUS. Individual clones were picked after one round of selection and analyzed by the SOUTHERN BLOTTING OF DNA procedure. When a probe derived from the SEO gene was used in this analysis, one clone .was found which did not hybridize to the NEO probe but had a HindIII restriction digestion pattern clearly distinct from the parental S-IBR-002. Further analysis indicated that the NEO had not been inserted into the TK region, WO 93/02104 PCT/US92/06034 -82however an approximately 1200 base pair deletion had occurred in the HindIII K fragment.
In order to characterize the HindIII K deletion, that fragment was subcloned and subjected to restriction mapping. Utilizing a series of oligonucleotide probes derived from the wild type sequence it was determined that approximately 1200 base pairs were deleted from the end of the HindIII K fragment adjacent to the HindIII K/HindIII 0 junction (see Figure This deletion removes the entire coding region of the US2 gene. S-IBR- 027 was deposited on April 17, 1991 pursuant to the Budapest Treaty on the International Deposit of Microorganisms for the Purposes of Patent Procedure with the Patent Culture Depository of the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852 U.S.A. under ATCC Accession No. VR 2322.
Direct fetal inoculation is the most sensitive test for determining the safety of live, IBR vaccines as regards their use in pregnant cows or in calves nursing pregnant cows. Three virus constructs were tested for fetal safety by inoculating directly into the bovine fetus, following laparotomy to expose the uterus. Abortion occurring within seven days after inoculation was considered to be surgically-induced. If fetuses aborted after this time, tissue samples were removed and cultured for the presence of the IBR constrp Caesarean sections were performed on cows with fetuses surviving for greater than 30 days post-inoculation. Fetal tissue was removed for virus culturing and blood samples were taken for evaluation of serum antibody to IBR virus.
The S-IBR-027 construct described above was tested, as well as two other constructs, S-IBR-020 and S-IBR-028.
The S-IBR-020 construct was derived from the Cooper WO 93/02104 PCT/US92/06034 -83strain of IBR virus by making deletions in the repeat regions of the DNA and by inserting the Tn5 NEO gene.
The S-IBR-028 construct was derived from the Cooper strain of IBR virus by making deletions in the repeat region of the DNA and in the TK gene. The Tn5 NEO gene was also inserted into the TK deletion.
The following results were obtained from studies with the three virus constructs. In the studies with S-IBR-020, two fetuses were inoculated, one at approximately 130-140 days gestation and the other at approximately 170-180 days gestation. The younger fetus aborted twenty days after inoculation, but virus could not be recovered from tissue samples of this fetus (Table The other fetus was live and appeared normal when it was surgically removed 60 days post-inoculation. In studies with S-IBR- 027, four fetuses, ranging in age from 125 days to >250 days, were inoculated (Table All fetuses survived and appeared normal. In studies with S-IBR-028, three fetuses, ranging in age from 140 days to >250 days, were inoculated. The youngest and eldest fetuses survived and appeared normal, however the fetus inoculated at 160-170 days gestation aborted nine days after inoculation.
Direct fetal inoculation is the most sensitive test for measuring the safety of live, IBR viruses used in pregnant cows. To date, the gene(s) involved in fetal virulence has not been reported. We have engineered IBR viruses with deletions in three different regions of IBR virus DNA and then determined the effect of the gene deletion. All three virus constructs tested have a deletion in the repeat region of the DNA Aid- two constructs do not have TK activity. One fetus inoculated with each of the TK- constructs has aborted. In contrast, the construct with deletions in the repeat regions and the US2 gene (S-IBR-027) has been inoculatdd into four fetuses with no adverse reactions.
WO 93/02104 PCT/US92/06034 -84- Table 2. Safety of IBR Viruses for Bovine Fetuses Construct Fetal Age" Results Fetus aborted Day 20 post- 130-140 Days inoculation; no virus isolated S-IBR-020 Normal, live fetus 60 days post- 170-180 Days inoculation Normal, live fetus 60 days post- 125-135 Days inoculation Normal, live calf born 56 days 150-160 Days post-inoculation S-IBR-027 Normal, live calf born 30 days 220-240 Days post-inoculation Normal, live calf born 30 days >250 Days post-inoculation Normal, live fetus 60 days post- 140-150 Days inoculation Fetus aborted Day 9 post- S-IBR-028 160-170 Days inoculation; no virus isolated Normal, live calf born 12 days 250 Days post-inoculation "Approximate age at time of virus inoculation WO 93/02104 PCT/US92/06034 We have shown that S-IBR-027 is safe for fetal inoculation in contrast to S-IBR-020 and S-IBR-028 which are not. Although all three viruses were engineered by similar approaches, the distinguishing difference of S- IBR-027 is the deletion of the US2 gene. We have also shown that the Nasalgen virus, which was generated by independent methods and is also safe for use in IBRsusceptible pregnant cows, has been deleted in the US2 gene.
Although the S-IBR-027 and Nasalgen have the similar property of fetal safety, S-IBR-027 offers additional advantages. The major portion of the US2 gene (251 out of 309 amino acids) has been deleted in the Nasalgen virus. This deletion would clearly inactivate the gene, however the remaining portion of the gene may make it more likely to revert to virulence via recombination with other viruses. The complete coding region of the US2 has been deleted from S-IBR-027 making it less likely that this gene could be restored and revert the virus to virulence. The S-IBR-027 construct also carries an important deletion in the repeat region, which is not present in the Nasalgen virus. A deletion in the analogous region of the pseudorabius virus (PRV) has been shown to be valuable in attenuating PRV for swine (see U.S. Patent No. 4,877,737). This deletion has also been shown to attenuate IBR for cattle as seen in the testing of S-IBR-002 (see Example 1).
WO 93/02104 PCr/US92/06034 -86- Example 4 S-IBR-028 S-IBR-028 is an IBR virus that has a deletion of approximately 800 bp in the repeat regions and approximately 250 bp in the TK region of the genome. The deletion in the TK region inactivates the TK gene. The repeat deletion was derived from the parental virus S- IBR-002 and is described in Example 2.
To construct this virus, the HOMOLOGOUS RECOMBINATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS was performed. A homology vector containing the bacterial transposon Tn5 NEO (aminoglycosidase 3'phosphotransferase) gene under the control of the HSV-1 a4 gene promoter flanked by sequences from the IBR virus TK gene was constructed. The IBR virus homology regions were derived from the TK gene. The upstream homology included amino acids 1 to 62 of the TK gene (15) and extended approximately 674 base pairs upstream of the TK coding region. The downstream homology included amino acids 156 to 357 and extended downstream of the TK coding region approximately 1138 base pairs. S-IBR-002 DNA was mixed with the homology vector 129-71.5 and transfected into rabbit skin cells as indicated in the methods. The transfection stock was selected according to the SELECTION OF G418 RESISTANT IBR VIRUS.
Individual clones were picked after two rounds of selection and analyzed by the SOUTHERN BLOTTING OF DNA procedure. Several clones were assayed for TK activity by a 14 C-thymidine incorporation assay One clone which was negative for TK activity was chosen and characterized by digestion with HindIII and XbaI. The restriction endonuclease analysis confirmed that the NEO WO 93/02104 PCT/US92/06034 -87gene had been inserted into the TK gene. This clone, designated S-IBR-028, was deposited on May 14, 1991 pursuant to the Budapest Treaty on the Internationa'l Deposit of Microorganisms for the Purposes of Patent Procedure with the Patent Culture Depository of the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852 U.S.A. under ATCC Accession No. VR 2326.
WO 93/02104 PCT/US92/06034 -88- Glvcoprotein G cene Deletion of the PRV gpX gene has been shown to be valuable both as an attenuating lesion and as a negative serological marker (see U.S. Serial No. 192,866, filed May 11, 1988 now U.S. -atent No. 5,047,237 issued September 10, 1991). In the studies described below we show that the unique short region of IBR virus contains a gene homologous to the gpX gene of PRV.
The sequence of an approximately 1400 base pair region of the IBR HindIII K fragment (see Figure located approximately 2800 base pairs downstream of the HindIII K/HindIII 0 junction was determined. This region was found to contain an ORF coding for 441 amino acids translated in the direction away from the HindIII K/HindIII 0 junction (see Figure The ORF is 69% G+C and encodes a protein with a predicted molecular weight of 58,683. Comparison of the sequence of the predicted protein with sequences of gene products of HSV-2 and PRV in the unique short region indicated that this ORF is homologous to the herpesvirus gpG gene (see Figure 9).
The complete gpG gene resides on an approximately 2800 base pair MIul to Ndel sub-fragment of the IBR virus HindIII K fragment. This subfragment has been cloned as a blunt ended fragment into the plasmid pSP64. This plasmid is designated PSY1643. PSY1643 was deposited on July 16, 1991 pursuant to the Budapest Treaty on the International Deposit of Microorganisms for the Purposes of Patent Procedure with the Patent Culture Depository of the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852 U.S.A. under ATCC Accession No. 68652. This plasmid may be used to confirm the sequence of the gpG gene. The sequence of the gpG gene may also be confirmed by c'nparing the appropriate WO 93/02104 IICT/US92/06034 -89- DNA sequence of the wild type virus S-IBR-000 (Cooper strain with the sequence of the gpG deleted virus S-IBR- 037 (ATCC Accession No. 2320).
To confirm the expression of the IBR virus gpG gene product, cells were infected with IBR virus and samples of media from infected cultures were subjected to SDSpolyacrylamide gel electrophoresis. The gel was blotted and analyzed using the WESTERN BLOTTING PROCEDURE. The anti-serum used was a mouse hyper-immune serum raised against chemically-synthesized gpG peptides (amino acids 242-254 and 269-289) linked to keyhole limpet hemocyanin.
As shown in Figure 10, gpG is prominent in the media of cells infected with wild type virus (S-IBR-000), but is not detected in media of mock infected cells.
WO 93/02104 PCT/US92/06034 Example 6 S-PRV-160 S-PRV-160 is a pseudorabies virus that has a deletion in the TK gene in the long unique region, a deletion in the repeat region, and an approximately 1414 base pair deletion in the gpX coding region. The gene for E.coli 8-galactosidase (lacZ gene) was inserted in the place of the gpX gene and is under the control of the gpX promoter. A chimeric gene coding for an IBR virus gpG, PRV gpIII and PRV gpX fusion protein was inser*ed at the HindIII sites located in each repeat.
S-PRV-160 was constructed utilizing plasmid 459-12.6, pseudorabies virus S-PRV-013 (see U.S. Serial No.
823,102, filed January 27, 1986 now U.S. Patent No.
5,068,192 issued November 26, 1991 and U.S. Serial No.
07/192,866, filed May 11, 1988 now U.S. Patent No.
5,047,237 issued September 10, 1991) and the restriction enzyme HindIII in the DIRECT LIGATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS. Several clones were screened by digestion with HindIII for the presence of the HindIII band containing the chimeric gene insert from plasmid 459-12.6. One clone exhibiting the correct HindIII insert band was chosen and designated S-PRV-160.
S-PRV-160 was constructed So that it would express precisely the gpG specific amino acids that were deleted in S-IBR-037. This allows the gpG fusion protein expressed in S-PRV-160 to be used as an antigen to identify antibodies directed against the wild type virus as opposed to antibodies directed against S-IBR-037.
Note that gpX, the PRV homologue of IBR virus gpG, has been deleted from S-PRV-160 to prevent any confusion resulting from cross reactivity that might exist between the two proteins. To confirm that S-PRV-160 does express WO 93/02104 PCT/US92/06034 -91- -BR virus gpG, a Western blot analysis was performed. As can be seen in Figure 10, gpG specific antibody does react with an appropriately sized media protein from S- PRV-160.
S-PRV-160 may also be utilized as an antigen for the production of gpG specific monoclonal antibodies. Such antibodies are useful in the development of diagnostic tests specific for the gpG protein. Monoclonal antibodies were generated in mice utilizing S-PRV-160 according to the PROCEDURE FOR GENERATING MONOCLONAL ANTIBODIES. One of these antibodies' clone 3-1G7 was shown to react specifically with purified gpG in the gpG ELISA assay.
WO 93/02104 PCTI t'S92/06034 -9.2- Example 7 S-IBR-035 is an IBR Virus that has two deletions in the short unique region of the genome. The first deletion is approximately 2500 base pairs and begins in the HindIII K fragment approximately 1750 base pairs downstream of the HindIII O/HindIII K junction and extends back through that junction. This deletion removes the US2 gene. The second deletion is approximately 294 base pairs and begins in the Hindll K fragment approximately 3900 base pairs downstream of the HindIII K/MindIII 0 junction and extends back toward that junction. This deletion removes amino acids 263 to 361 of the gpG gene. The gene for E.coli B-galactosidase (lacZ gene) was inserted into the deletion in the gpG gene and is under the control of the HCMV immediate early promoter.
S-IBR-035 was derived from S-IBR-000 (Cooper strain).
This was accomplished utilizing the homology vector 439- 01.31 (see Materials and Methods) and virus S-IBR-000 in the HOMOLOGOUS RECOMBINATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS. The transfection stock was screened by the BLUOGAL" SCREEN FOR RECOMBINANT HERPEOVIRUS. The final result of blue plaque purification was the recombinant virus designated S-IBR- 035. This virus was characterized by restriction mapping and the SOUTHERN BLOTTING DNA procedure. This analysis ?0 confirmed the insertion of the B-galactosidase (lacZ) marker gene and the deletion of approximately 294 base ps irs of the gpG gene. It was also confirmed that an approximately 2500 base pair deletion had occurred in the region of the US2 gene.
WO 93/021041 W7 [10C
T
-/2/06S92034 -93- Example 8 S-IBR-036 S-IBR-036 is an IBR virus that has two deletions in the short unique region of the genome. The first deletion is approximately 2500 base pairs and is similar to the deletion in S-IBR-035 (see Example 7) which removes the US2 gene. The second deletion is approximately 1230 base pairs and begins in the HinclIII K fragment approximately 3900 base pairs downstream of the HindIII O/HindIII K junction and extends back toward that junction. This deletion removes amino acids 1 to 361 of the gpG gene.
The gene for E.coli B-galactosidase (lacZ gene) was inserted into the deletion in the gpG gene and is under the control of the HCMV immediate early promoter.
S-IBR-036 was derived from S-IBR-000 (Cooper strain).
This was accomplished utilizing the homology vector 439- 21.69 (see Materials and Methods) and virus S-IBR-000 in the HOMOLOGOUS RECOMBINATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS. The transfection stock was screened by the BLUOGAL SCREEN FOR RECOMBINANT HERPESVIRUS. The final result of blue plaque purification was the recombinant virus designated S-IBR- 036. This virus was characterized by restriction mapping and the SC THERN BLOTTING DNA procedure. This analysis confirmed the insertion of the B-galactosidase (lacZ) marker gene and the deletion of approximately 1230 base pairs of the gpG gene. It was also confirmed that an approximately 2500 base pair deletion had occurred in the refgion of the US2 gene (see above).
WO 93/02104 PC'/US92/06034 -94- Example 9 S-IBR-037 S-IBR-037 is an IBR virus that has two deletions in the short unique region of the genome. The first deletion is approximately 2500 base pairs and begins in the HindIII K fragment approximately 1750 base pairs downstream of the HindIII 0/HindIII K junction and extends back through that junction. This deletion removes the US2 gene. The second deletion is approximately 1230 base pairs and begins in the HindIII K fragment approximately 3900 base pairs downstream of the HindIII O/HindIII K junction and extends back toward that junction. This deletion removes amino acids 1 to 361 of the gpG gene.
S-IBR-037 was derived from S-IBR-035. This was accomplished utilizing the homology vector 439-70.4 (see Materials and Methods) and virus S-IBR-035 in the HOMOLOGOUS RECOMBINATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS. The transfection stock was screened by the BLUOGAL" SCREEN FOR RECOMBINANT HERPESVIRUS. The result of white plaque purification was the recombinant virus designated S-IBR-037. This virus was characterized by restriction mapping and the SOUTHERN BLOTTING DNA procedure. This analysis confirmed the deletion of the B-galactosidase (lacZ) marker gene and the deletion of approximately 1230 base pairs of the gpG gene. It was also confirmed that an approximately 2500 base pair deletion had occurred in the region of the US2 gene (see above). S-IBR-037 was deposited on April 16, 1991 pursuant to the Budapest Treaty on the International Deposit of Microorganisms for the Purposes of Patent Procedure with the Patent Culture Depository of the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852 U.S.A. under ATCC Accession No. VR 2320.
WO 93/02104 PCI'! LS92/06034 To test the efficacy of S-IBR-037 as an inactivated IBR virus vaccine in protecting susceptible calves against virulent IBR virus challenge, a study was performed according to the VACCINATION STUDIES IN CALVES WITH INACTIVATED IBR VIRUS. The following results were observed.
Virus neutralization antibody titers were elicited in animals after the first vaccination (see Table 3).
Antibody titers were not significantly different between animals that received a vaccine dose of 107.3 virus and animals vaccinated with 108.0 virus. After the second vaccination, mean antibody titers increased to 1:19 and 1:32, respectively, for the 107.3 and 108.0 vaccine groups. Control animals remained seronegative to IBR virus throughout the vaccination period. Antibody titers in boh vaccinate groups showed an increase typical of an anamnestic response after challenge with virulent IBR virus. By 13 days post challenge, mean antibody titers were 1:152 and 1:215 for the 107.3 and 108.0 vaccinate groups respectively. In contrast, mean antibody titers in challenged control animals were 1:4 at 7 days and 1:8 at 13 days post challenge.
Nasal swabs were collected from challenged animals to determine whether vaccination decreased the time of virus shedding (Table The most dramatic difference between vaccinates and control animals was observed at 12 days post challenge. At this time, seventy-five percent of control animals continue to shed, whereas, only twentyfive percent of both vaccinate groups shed virus. Virus was not isolated from control or vaccinated groups at days post challenge.
WO 93/02104 1PCFI/US92/06034 -96- Table 3. Generation of virus neutralizing antibody in animals vaccinated with inactivated S-IIBR-037 vaccine.
Antibo~dy titer' on days: Animal No. Post Vaccination Post Challenge 7 21 28 42 7 13 Controls 9 :s2 52 s2 :S2 4 4 22 :52 52 s2 :52 4 8 32 s2 52 :s2 :52 4 16 64 52 52 -e.2 52 4 8 GMT 2 2 2 52 4 8 Vaccinates dose 1i7-3 1 :52 8 32 64 64 128 52 8 32 64 64 256 2 8 16 8 64 512 36 2 4 16 4 16 a32 GMT 52 6.7 22.6* 19.00 45.34o 152.2* Vaccinates dose 10&o 7 r.2 4 32 8 64 256 2 a8 64 128 128 .>128 33 52 16 32 128 128 256 69 52 4 16 8 128 256 GMT 52 6.7 32* 32* 107.6' 215S Statistically greater than controls 0.05) "Expressed as reciprocal of dilution.
WO 93/02104 WO 93/21()4 CrI'US92/O6034 -97- Table 4. Isolation of EBR virus from vaccinated and unvaccinated control animals after challenge with virulent EBR virus.
EBR virus isolated from animals Animal No. on days post challenge 3 6 9 12 Controls 9 22 32 64 Vaccinates dose 1 36 Vaccinates dose 7 33 69 WO 93/02104 WO 93/2104 CI'/US92/06034 '-98- Table 5. Vaccinated animals demonstrate reduced clinical signs of IBR.
Clinical scores post challenge Animal NO. Attitude' Ulcers b Serious Mucopurulent Temperature' _______Discharge' Discharge' Controls__ 9 5 3 11 5 3 22 2 2 12 3 1 32 5 3 11 0 4 64 6 3 11 1 1 GMS 4.5 2.8 11.3 2.3 2.3 Vaccinates dose 1P~ 1 0 2 1 0 0 0 1 3 0 0 0 2 -6 2 0 36' 6 2 1 13 0 GMS 1.5 1.8 2.8* 2.3 0 Vaccinates dose 108.0 7 1 2 1 0 0 1 2 2 2 0 33 1 2 0 0 0 69 1 2 0 0 0 GMS 1 2 0.8* 0.5 0 a Days with depressed attitude.
b Number of ulcers.
C Days with serous discharge.
d Days with mucopurulent discharge.
C Days with 2: 2 0 F above baseline temperature.
f Animal exhibited mucopurulent discharge on the day of challenge and for 13 days post challenge.
Statistically greater than controls (p:50.05) WO 93/02104 PCT/US92/06034 -99- Animals were observed daily for 13 days post challenge for clinical signs of IBR infection. Clinical disease was evaluated with respect to attitude, the number of ulcers, extent of serious and mucopurulent discharge and the number of days with elevated temperature. The results presented in Table 5 show that vaccinated animals exhibited less severe disease than did unvaccinated control animals. Control animals showed clinical depression ("Attitude" in Table 5) for 4.5 days compared with 1 to 1.5 days for vaccinated animals. The amount and extent of serous discharge was substantially reduced in both vaccinate groups compared with controls. The extent of mucopurulent discharge was also reduced in vaccinated animals, although to a lesser degree.
However, vaccinate animal #36 did have mucopurulent discharge on the day of challenge and is not consistent with the results for other vaccinates. None of the vaccinates exhibited temperatures of 22 0 F above baseline.
In contrast, all control animals exhibited elevated temperatures of ;2 0 F over baseline and 2 of 4 control animals had temperatures of 104°F and above.
Vaccination of calves with inactivated S-IBR-037 vaccine protected the animals against virulent wild-type IBR virus challenge. Virus neutralization titers were statistically greater in vaccinated than in control animals. An anamnestic response in antibody titer was observed 7 days post challenge, indicating the development of humoral memory response. Except for 7 days post challenge, neutralization titers between the 107.3 and 108.0 vaccinate groups were not statistically different. Fewer vaccinated animals shed virulent challenge virus than control animals. These results suggest that virulent.IBR virus is cleared more rapidly in vaccinated than in unvaccinated animals. Clinical symptoms of IBR virus infection were also reduced in WO 93/02104 PC1JVUS92/06034 -100vaccinated animals. After challenge, both vaccinate groups exhibited fewer days of depressed attitude, reduced serous discharge, and no elevated temperature compared with controls.
In order to show that gpG antibody is produced in vaccinated calves following exposure to wild-type virus, serum samples taken pre- and post-exposure to wild-type viruses were subjected to the ELISA assay. Samples taken at the day of challenge and at 13 days post-challenge were analyzed. As seen in Table 6, the post-challenge absorbance readings for gpG increase for each animal (ratio of indicating that within 13 days of infection a detectable immune response to gpG is present.
WO 9'3/012104- PCT/US92/06034 -101- Table 6. Detection of antibody to gpG in serum of animals vaccinated with S-IBR-037 and challenged with wild type.
Animal No. Ratio of pre- vs. post challenge" Controls 9 1.22 22 1.96 32 1.87 64 2.19 Vaccinates dose 3 1 139 1.40 1.84 36 1.18 Vaccinates dose 108.o 7 1.19 1.29 33 1.52 69 2.66 ,Animals were challenged with 107.6 PFU of wild type IBR virus. Pre-challenge serum from day of challenge, post-challenge serum from 13 days post challenge. Data reflects the average of the ratio of absorbance readings for three independent ELISA determinations.
WVO 93/02104 I'WT/ MUS92/06034 -102- Example S-IBR-038 S-IBR-038 is an IBR virus that has two deletions in the short unique region of the genome. The first deletion is approximately 2500 base pairs and begins in the HindIII K fragment approximately 1750 base pairs downstream of the HindIII O/HindIII K junction and extends back through that junction. This deletion removes the US2 gene. The second deletion is approximately 294 base pairs and begins in the HindIII K fragment approximately 3900 base pairs downstream of the HindIII K/HindIII 0 junction and extends back toward that junction. This deletion removes amino acids 261 to 359 of the gpG gene.
S-IBR-038 resulted from the removal of the marker gene from S-IBR-035 (see above). This was accomplished by digestion of S-IBR-035 with Xbal as described in the DIRECT LIGATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS. The structure of S-IBR-035 was confirmed by restriction enzyme analysis with HindIII, BamHI and XbaI.
WO 93/02104 "C717 LIS2/0603 1 -103- Example 11 Glycoprotein E gene Deletion of the PRV gI gene has been shown to be valuable both as an attenuating lesion and a negative serological marker In the studies described below we show that the unique short region of IBV virus contains a gene homologous to the gI gene of PRV.
The sequence of 2038 base pairs of the IBR unique short region, starting approximately 1325 base pairs upstream of the HindIII K/HindIII F junction in the HindIII K fragment was determined. This region was found to contain an ORF coding for 617 amino acids translated in the direction away from the HindIII K/HindIII 0 junction (see Figure The ORF is 70.5% G+C and encodes a protein with a predicted molecular weight of approximately 88,980. Comparison of the sequence of the predicted protein with sequences of gene products of HSV- 1, VZV, and PRV in the unique short region indicated that this ORF is homologous to the herpesvirus gpE gene (see Figure 16).
The DNA encoding the gpE gene has been cloned in two plasmids, PSY1644 and PSY1645. The amino-terminal half of the gene (encoding amino acids 1-276) was cloned as an approximately 2300 base pair fragment resulting from a partial SmaI digest of wild type S-IBR-000 (Cooper Strain) DNA. This fragment was inserted into the plasmid pSP64 to yield PSY1644. This plasmid, designated PSY1644, was deposited on July 16, 1991 pursuant to the Budapest Treaty on the International Deposit of Microorganisms for the Purposes of Patent Procedure with the Patent Culture Depository of the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852 U.S.A. under ATCC Accession No. 68651.
WO 93/02104 )3 4CT/ lUS92/06034 -104- The carboxyl-terminal half of the gene (encoding amino acids 277-617) was cloned as an approximately 2400 base pair SmaI fragment. The fragment was inserted into the plasmid pSP64 to yield PSY1645. This plasmid, designated PSY1645, was deposited on July 16, 1991 pursuant to the Budapest Treaty on the International Deposit of Microorganisms for the Purposes of Patent Procedure with the Patent Culture Depository of the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852 U.S.A. under ATCC Accession No. 68650.
These plasmids may be used to confirm the sequence of the gpE gene.
W) 93/02104 Pff/ US92/060343 -105- Examlpe 12 Pseudorabies virus expressing IBR virus opE A pseudorabies virus analogous to S-PRV-160 may be constructed for the purpose of expressing the 3BR virus gpE. This may be accomplished by inserting the gene coding for IBR virus gpE into S-PRV-002 Patent No.
4,877,737).
Such an expression vector may be constructed utilizing the IBR virus gpE plasmid described in the methods section, pseudorabies virus S-PRV-002 and the restriction enzyme bal in the DIRECT LIGATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS. Viruses resulting from this procedure may be screened by digestion with XbaI for the presence of the Xbal band containing the IBR virus gpE gene.
The gpE protein expressed from this vector may be used as an antigen to identify antibodies directed against the wild type virus as opposed to antibodies directed against gpE deleted viruses. This virus may also be utilized as an antigen for the production of gpE specific monoclonal antibodies. Such antibodies are useful in the development of diagnostic tests specific for the gpE protein. Monoclonal antibodi, y be generated in mice utilizing this virus accordi.g to the PROCEDURE FO GENERATING MONOCLONAL ANTIBODIES.
W()93/02104 PCT/US92/06034 -106- Example 13 GiycoDrotein E deleted IBR viruses The HOMOLOGY VECTOR 536-03.5 was used to generate various gpE-deleted IBR viruses. Utilizing the general strategy described in CONSTRUCTION OF DELETION VIRUSES, a gpE deletion of approximately 1410 base pairs (amino acids 77-547) was introduced into two different IBR virus backbones, S-IBR-000 (Cooper Strain) and S-iBR-037. The vrus resulting from the S-IBR-000 parent contains the cjpE deletion alone. The virus resulting from the S-IBR- C03 parent contains the gpE deletion in conjunction with the US2 and qpG deletions. The lacZ marker gene may be removed from these viruses utilizing the procedures outlined in the methods section.
These gpE-deleted viruses are of great value as IBR vaccines. Their combination of different deletions will provide the varying degrees of attenuation which are required for a superior vaccine. These viruses will also provide a negative s-rological marker waich -1ay be used to distinguish vaccinated from infected animals. The virus containing both gpG and gpE deletions should be of even greater value by having two negative markers. The availability of two negative markers permits one marker to be used as a confirmatory test, greatly increasing the reliability of such a diagnostic determination.
WO 93/02104 PCf/US92/06034 -107- Example 14 S-IBR-004 S-IBR-004 is an IBR recombinant virus carrying an inserted foreign gene, Tn5 NEO (aminoglycoside 3'phosphotransferase) gene, under the control of the pseudorabies virus (PRV) glycoprotein X promoter.
To construct this virus, the HindIII K DNA fragment from wild type IBR virus was cloned into the plasmid pSP64 at the HindIII site. This plasmid was designated pSY524.
A map of the HindIII K fragment is shown in Figure 19.
The DNA from the XhoI site to t.ie HindIII site and containing the Ndel site from pSY524 was cloned into plasmid pSP65 and called pSY846. The Ndel to EcoRI fragment was removed from pSY846 by digastion with NdeI and EcoRI restriction enzymes, followed by POLYMERASE FILL-IN REACTION and LIGATION. The resulting plasmid was called pSY862. The plasmid pNEO Biochemicals, Inc.) contains the aminoglycoside 3'-phosphotransferase (NEO) gene and confers resistance to ampicillin and neomycin E. li hosts. The coding region of this gene (BglII-BamHI fragment) was iiolated and cloned netweep-; te PRV gpX promoter and the HSV-TK poly A r n a plasmid called pSY845.
The NEO gene construct in pSY845 was excised with HindIII, made blunt ended by the POLYMERASE FILL-IN REACTION, and cloned into the SacI site of plasmid pSY862. The final product was called pSY868.
Wild type IBR DNA was mixed with pSY868 DNA and the mixture was transfected into rabbit skin cells to generate recombinant IBR. The recombinant IBR virus carrying a functional NEO gene was then isolated and WO 93/02104 PCT/US92/06034 -108purified according to the SELECTION OF G418 RESISTANT IBR VIRUS method.
S-IBR-004 recombinant IBR was shown to express the NEO gene by the fact that cells infected with this virus were resistant to the toxicity of G418. A detailed map of the plasmid construction is shown in Figure 19. The structure of S-IBR-004 is also shown in Figure 19. S- IB1'-004 was deposited on May 23, 1986 pursuant to the Budapest Treaty on the International Deposit of Microorganisms for the Purposes of Patent Procedure with the Patent Culture Depository of the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852 U.S.A. under ATCC Accession No. VR 2134.
WO 93/02104 PCfIUS92/06034 -109- Example S-IBR-008 S-IBR-008 is an IBR virus that has a deletion in the short unique region, and an insertion of the bovine rotavirus glycoprotein 38 (gp38) gene in the XbaI site in the long unique region.
The bovine rotavirus gp38 gene was cloned utilizing the METHOD FOR cDNA CLONING BOVINE ROTAVIRUS gp38 GENE, The bovine rotavirus gp38 gene was then engineered to contain herpesvirus regulatory signals as shown in Figure This was accomplished by cloning the gp38 gene BamHI fragment contained in pSY1053 between the BamHI and BglII sites in pSY1052. The resulting plasmid, pSY1023, contained the PRV gpX promoter in front of the gp38 gene, and the HSV-1 TK polyadenylation signal behind the gp38 gene. The entire construct was flanked by XbaI sites to allow for the insertion of the XbaI fragment into IBR by direct ligation.
S-IBR-004 was the sttting virus for the generation of S- IBR-008. S-IBR-004 DNA and pSY1023 DNA were mixed together, cut with XbaI, and transfected into rabbit skin cells according to the DIRECT LIGATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS. The transfection stock was screened for recombinant virus by the ANTIBODY SCREEN FOR RECOMBINANT HERPESVIRUS procedure using antibodies prepared against the rotavirus gp 38 protein.
One of the viruses purified by this screen was S-IBR-008, which has the following characteristics. It contains the rotavirus gp38 gene plus the plasmid DNA inserted into the Xbal site in the long unique region of the virus genome, but no longer contains the NEO gene of parent S- IBR-004 in the unique short region. In fact, a small WO 93/02104 PCT/US92/06034 -110deletion was created in the unique short region at the location of the NEO gene, as evidenced by the absence of an XbaI site at this location in S-IBR-008.
S-IBR-008 was shown to be expressing the rotavirus gp38 gene by analysis of RNA transcription in infected cells, and by the ANTIBODY SCREEN FOR RECOMBINANT HERPESVIRUS procedure using antibodies specific for the gp38 gene.
S-IBR-008 was deposited on June 18, 1986 pursuant to the Budapest Treaty on the International Deposit of Microorganisms for the Purposes of Patent Procedure with the Patent Culture Depository of the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852 U.S.A. under ATCC Accession No. VR 2141.
The structure of S-IBR-008 is shown in Figure WO 93/02104 rIICT US92/06034 -111- Example 16 S-IBR--18 S-IBR-018 is an IBR virus that has three foreign genes inserted: the E.coli beta-galactosidase gene and the neomycin resistance gene in the XbaI site in the nlique long region, and the parainfluenza type 3 (PI-3) vi' is hemagglutinin gene (HN) in the HindIII site in the unique long region immediately adjacent to the XbaI site.
For cloning the PI-3 HN gene, the SF-4 strain of PI-3 was grown in MADIN-DARBY bovine kidney (MDBK) cells in culture and RNA was extracted from infected cells. The RNA was used in a reverse transcription protocol as outlined in the cDNA CLONING procedure using poly-dT as primer for reverse transcriptase. From this procedure, a series of clones was obtained that comprised parts of the genome of the PI-3 virus. The location of the gene for the human PI-3 HN gene has been published (25,26) and this information was used to locate the gene in applicants' bovine PI-3 clones. The entire open reading frame of the bovine PI-3 HN gene was sequenced by applicants and is given in Figure 21.
The HSV ICP4 promoter was used to express the PI-3 HN gene and the HSV TK poly-A signal was used to terminate transcription. The engineering of this construct was done as shown in Figure 22 A and B. The construct contained to the HSV ICP4 promoter, the ICP4 TATA box, the ICP4 cap site, a fusion within the ICP4 untranslated region to the PI-3 HN gene at the Hhal site, the HN gene start codon, the HN structural gene, the HN stop codon, a fusion within the HN 3' untranslated region to the HSV TK untranslated 3' region, and the HSV TK poly-A signal sequence.
WO 93/02104 PCT/US92/)6034 -112- This plasmid also contained the beta-galactosidase (lacZ) gene under the control of the PRV gpX promoter with the gpX poly-A termination signal, as well as the neomycin resistance gene under the control of the gpX promoter with the TK poly-A termination signal. These latter two genes were cloned in tandem at the XbaI site in BamHI-C fragment (Figure 22 A and This BamHI-C fragment contained the homology regions for use in the DNA TRANSFECTION FOR GENERATING RECOMBINANT VIRUS procedure.
After the transfection step in the procedure, the resulting recombinant virus from the transfection stock was selected for by the SELECTION OF G418 RESISTANT IBR VIRUS procedure, followed by the BLUOGAL" SCREEN FOR RECOMBINANT HERPESVIRUS procedure, and subsequently analyzed for the insertion of the PI-3 HN gene by the SOUTHERN BLOTTING OF DNA procedure. The virus that resulted from this screening was designated S-IBR-018.
S-IBR-018 was deposited on July 21, 1987 pursuant to the Budapest Treaty on the International Deposit of Microorganisms for the Purposes of Patent Procedure with the Patent Culture Depository of the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852 U.S.A. under ATCC Accession No. VR 2180.
The structure of S-IBR-018 is shown in Figure 22 C.
WO 93/02104 PCT/US92/06034 -113- Examnle 17 S-IBR-019 S-IBR-019 is an IBR virus that has three foreign genes inserted, the E.coli beta-galactosidase (lacZ) gene and the neomycin resistance gene in the XbaI site in the unique long region, and the parainfluenza type 3 (PI-3) virus fusion gene in the HindIII site in the long unique region adjacent to the Xbal site.
For cloning the PI-3 F gene, the SF-4 strain of PI-3 was grown in MDBK cells in culture and RNA was extracted from infected cells. The RNA was used in a reverse transcription protocol as outlined in the cDNA CLONING procedure using poly-dT as primer for reverse transcriptase. From this procedure, a series of clones was obtained that comprised parts of the genome of the PI-3 virus. The location of the gene for the Sendai virus F gene has been published (27) and this comparative sequence information was used to locate the homologous gene in applicants' bovine PI-3 clones.
The HSV alpha-4 promoter was used to express the PI-3 F gene and the HSV TK poly-A signal was used to terminate transcription. The construct contained to the HSV alpha-4 promoter, the alpha-4 TATA box, the alpha-4 cap site, a fusion in the alpha-4 5' untranslated region to the PI-3 F gene, the F start codon, the F structural gene, the F stop codon, a fusion in the F 3' untranslated region to the HSV TK 3' untranslated region, and the TK poly-A signal sequence.
This plasmid also contained the beta-galactosidase (lacZ) gene under the control of the PRV gpX promoter with the gpX poly-A termination signal, as well as the neomycin resistance gene under the control of the gpX promoter WO) 93/0321041 PCT/US92/06034 -114with the TK poly-A termination signal. These latter two genes were cloned in tandem at the XbaI site in BamHI-C fragment (Figure 23 A and This BamHI-C fragment contained the homology regions for use in the DNA TRANSFECTION FOR GENERATING RECOMBINANT VIRUS procedure.
After the transfection step in the procedure, the resulting recombinant virus from the transfection stock was selected for by the SELECTION OF G418 RESISTANT HERPESVIRUS procedure, followed by the BLUOGAL" SCREEN FOR RECOMBINANT HERPESVIRUS procedure, and subsequently analyzed for the insertion of the PI-3 F gene by SOUTHERN BLOTTING OF DNA procedure. The virus that resulted from this screening was designated S-IBR-019.
The structure of S-IBR-019 is shown in Figure 23 C.
WO 93/02104 WOcr US92/06034 -115- Example 18 S-IBR-032 S-IBR-032 is an IBR virus that has two foreign genes inserted: the Escherichia coli beta-galactosidase (lacZ) gene with the bovine viral diarrhea virus (BVDV) gp53 gene fused to the lacZ C-terminus and inserted in the long unique region at the XbaI restriction endonuclease site.
For cloning the BVDV gp53 gene, the Singer strain of BVDV was grown in MADIN-DARBY bovine kidney (MDBK) cells in culture and the RNA was extracted from infected cells.
The RNA was used in a reverse transcriptase procedure as outlined in the cDNA CLONING procedure using random primers for reverse transcriptase. From this procedure, a series of clones was obtained that comprised parts of the genome of BVDV. The location of the gene for BVDV gp53 has been published (66) and this comparative sequence information was used to locate the homologous gene in the applicant's BVDV clones.
The PRV gpX promoter was used to express lacZ with a region of BVDV gp53 fused to the C-terminus, and the PRV poly-A signal was used to terminate transcription. A plasmid construct was engineered that contained to the PRV gpX promoter and then the coding region consisting of amino acid codons 1-7 of the PRV gpX gene, 10-1024 of the Escherichia coli lacZ gene, and 684-758 of the BVDV major open reading frame, and the PRV poly-A sequence. This lacZ fusion gene cassette was then excised from the plasmid vector at the flanking XbaI sites and cloned into the unique XbaI site in IBR-002 using the in vitro ligation method described in CONSTRUCTION OF DELETION VIRUSES. After the transfection step in DNA TRANSFECTION FOR GENERATING RECOMBINANT VIRUS WO 93/02104 PCT/US92/06034 -116procedure, the resulting recombinant virus was screened and isolated from the transfection stock using the BLUOGAL" SCREEN FOR RECOMBINANT HERPESVIRUS procedure, and subsequently analyzed for the insertion of the BVDV gp53 region by SOUTHERN BLOTTING OF DNA procedure. The virus that resulted from this screening was designated S- IBR-032.
WO 93/02104 PCT/US92/06034 -117- 'Example 19 S-IBR-039 S-IBR-039 is an IBR virus that has three deletions in the short unique region of the genome. The first deletion is approximately 2500 base pairs and begins in the HindIII K fragment approximately 1750 base pairs downstream of the HindIII 0/HindIII K junction and extends back through that junction. This deletion removes the US2 gene. The second deletion is approximately 1230 base pairs and begins in the HindIII K fragment approximately 3900 base pairs downstream of the HindIII O/Hind K junction and extends back toward that junction. This deletion removes amino acids 1 to 361 of the gpG gene. The third deletion is approximately 1410 base pairs and removes amino acids 77-547 of the gpE gene.
S-IER-039 was derived from S-IBR-037. This was accomplished utilizing the homology vector 536-03.5 (see MATERIALS AND METHODS) and virus S-IBR-037 in the HOMOLOGOUS RECOMBINATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS. The transfection stock was screened by the SCREEN FOR RECOMBINANT HERPESVIRUS EXPRESSING ENZYMATIC MARKER GENES. The result of blue plaque purification was the recombinant virus designated S-IBR-039. This virus was characterized by restriction mapping and the SOUTHERN BLOTTING DNA procedure. This analysis confirmed the insertion of the B-galactosidase (lacZ) marker gene and the deletion of approximately 1230 base pairs of the gpG gene. It was also confirmed that an approximately 1410 base pair deletion has occurred in the region of the gpE gene (see above). This virus will be useful as a vaccine to protect cattle from infection with IBR virus. The deletions of the glycoproteins G and E genes from this virus also provides two negative IWO 93/02104 PCr/ US92/06034 serological markers for differentiating it from wild type
IBR.
WO 93/02104 PCI'/ VUS92/06034 -119- Example S-IBR-045 S-IBR-045, a recombinant IBR virus with deletions in the Tk, US2, gpG and gpE genes may be constructed in the following manner. S-IBR-045 would be derived from S-IBR- 039 (see example 19) through the construction of two intermediate viruses. The first intermediate virus, S- IBR-043, would be constructed utilizing the homology vector 591-46.12 (see MATERIALS AND METHODS) and virus S- IBR-039 in the HCMOLOGOUS RECOMBINATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS. The transfection stock would be screened by the SCREEN FOR RECOMBINANT HERPESVIRUS EXPRESSING ENZYMATIC MARKER GENES for a white plaque recombinant virus (uidA substrate). The resulting virus would have deletions of the Tk, US2, gpG and gpE gens and insertion of lacZ gene in the gE gene deletion.
Finally, S-IBR-045 would be constructed, utilizing the homology vector 523-'8.72 (see MATERIALS AND METHODS) and virus S-IBR-044 in the HOMOLOGOUS RECOMBINATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS. The transfection stock would be screened by the SCREEN FOR RECOMBINANT HERPESVIRUS EXPRESSING ENZYMATIC MARKER GENES for a white plaque recombinant virus (lacZ substrate). This virus will be useful as a vaccine to protect cattle from infection with IBR. The combination of deletions will provide the appropriate attenuatioh which is required for a superior vaccine. This virus will also provides two negative serological markers which may be used to distinguish vaccinated from infected animals. The availability of two negative markers permits one marker to be used as a confirmatory test, greatly increasing the reliability of such a diagnostic determination.
WO 93/02104 WO 93/2104 11070tS92/06034l -120- S-IBR-046, a rir*ombinant IBR virus with dleetions in the Tk, US2, gpG and gpE genes and the bovine viral diarrhea virus gp53 gene inserted in place of the gpE (gene, may be construc'ed in the following manner. S-IBR-046 would be derived from S-IBR-044 (see example 20). It woulC be conptructed utilizing the homology vector 523-78.72, into which the bovine viral diarrhea virus gp53 gene has been insertcd, and virus S-IBR-044 in the HOMOLOGOUS RECOMBINATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS. Note that the bov~in~e diarrhea virus gene would be cloned using techniques described in the met:hods section. The 2 gp53 ge~ne would be placed under the control of the HCXV iimed.L 'te early promot ar. The transfect ion stceck would be screkined by the SCR14EN FUR RECOMBINANT HERPEISVIRUS EXPRESSIN3 ENZY11A51C M~ARKER GLEUES for a white plague recombinant virus (1a.-Z substrate). This virus will be useful ac? a va(;cine to protect cattle from intection with IBR virus and bovine viral diarr.~ea virus.
WO 93/02104 WO 9302104rcriUS92/0603-1 -121- Elx Myl 22 S-IBR-047 S-IBR-047, a recombinant IBR virus with deletions in the Tk, US2, gpG and y9pE genes and the parainfluenza type 3 genes for hemagglutinin and fusion protein inserteIA in place of the gpE geria may be constructed in the following manner. S-IBR-047 would be derived from S-IBR-044 (see example 20) It would be constructed utilizing the homology vector 523-78.72, into which the parainfluenza type 3 virus hemagglutinin and fusiorn genes hae. been inserted, and virus S-IBR-044 in the HOMOLOGOUS RECOMBINATION PROCEDURE FOR GENERPATING RECOMBINANT HERPESVIRUS. Note that the parainfluenza type 3 vir us genes would be cloned using techniques described in the methods section. The transfection stock would be screpned by the SCREEN FOR RECOMBINANT HERPESVIRUS EXPRESSING ENZYMATIC MARKER GENES for a white plaque recombinant virus (lacZ substrate). This virus will be useful as a vaccine to protect cattle from infection wit~h IBR virus and parainfluenza type 3 viras.
WO 93/02 104 Pcr/US92/06034 -122- Example 23 R09 iS-IBR-049, a recombinant IBR virus with deletions in the Tk, US2, gpG and 9pE genes and the bovine respiratory syncytial virus genes for the attachment, nucleocapsid and fusion proteins inserted in place of the gpE gene may be constructed in the following manner. S-IBR-049 would be derived from S-IBR-044 (see example 20). It would be constructed utilizing the homology vector 523-78.72, into which the bovine respiratory syncytial virus attachment nucleocapsid and fusion genes had been inserted and virus S-IBR-044 in the HOMOLOGOUS RECOMBINATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS. Note that the bovine respiratory syncytial virus genes would be cloned using techniques described in the methods section. The attachment protein gene would be placed under tne control of the HCaV immediate early promoter and the fusion and nucleocapsid protein genes would be placed under the PRV gpX promoter. The transfection stock would be screened by the SCREEN FOR RECOMBINANT HERPESVIRUS EXPRESSING ENZYMATIC MARKER GENES for a white plaque recombinant virus (lacZ substrate). This viru wi".ll be useful as a vaccine to protect cattle from inf :'.ion with IBR virus and bovine respiratory syncytial.
WO 93/02104 PC1/US92/06034 -123- Examls -2-4 S-IBR-051 S-IBR-051, a recombinant IBR virus with deletions in the Tk, US2, gpG and gpE genes and the Pasteurella haemolyt.ca genes for the leukotoxin and iron regulated outer membrane proteins inserted in place of the gpE gene, may be constructed in the following manner. S-IBR- 051 would be derived from S-IBR-044 (see example 20). It would be constructed utilizing the homology vector 523- 78.72, into which the Pasteurella haemolytica leukotoxin and iron regulated outer membrane protein genes had kt en inserted, and virus S-IBR-044 in the HOMOLO.OUS RECOMBINATION PROCEDURE FOR GENERATING RECOMBINAI HERPESVIRUS. Note that the Pasteurella haemolytica genes would be cloned using the techniques described in the methods section. The leukotoxin gene would be placed under the control of the HCMV immediate early promoter and the iron regulated outer membrane protein genes would be placed under the PRV gpX promoter. The transfection stock would be screened by the SCREEN FOR RECOMBINANT HERPESVIRUS EXPRESSING ENZYMATIC MARKER GENES for a white plaque recombinant virus (lacZ substrate). This virus will be useful as a vaccine to protect cattle from infection with IBR virus and Pasteurella haemolytica.
WO 93/02104 PCr/US92/06034 -124- Example Shipnina Fever Vaccine Shipping fever or bovine respiratory disease (BRD) complex is manifested as a result of a combination of infectious diseases of cattle and additional stress related factors Respiratory virus infections, augmented by pathophysiological effects of stress, alter the susceptibility of cattle to Pasteurella organisms that are normally present in the upper respiratory tract by a number of mechanisms. Control of the viral infections that initiate BRD as well as control of the terminal bacterial pneumonia is essential to preventing the disease syndrome (71).
The major infectious diseases that contribute to BRD are: infectious bovine rhinotracheitis virus, parainfluenza type 3 virus, bovine viral diarrhea virus, bovine respiratory syncytial virus, and Pasteurella haemolytica The applicants' examples 1 through 24 describe vaccine inventions that individually immunize against the various components of BRD. An extension of the applicants' approach is to combine vaccines in a manner so as to control the array of disease pathogens with a single immunization. To this end, at least two approaches can be taken: first, mixing of the various IBR vectored antigens (BRSV, PI-3, BVDV and P.
Haemolytica) in a single vaccine dose, and secondly, the individual antigens (BRSV, BVDV, PI-3 and P. haemolytica) can be simultaneously cloned into the same IBR backbone virus. Note that a combination of antigens could be included in one or more IBR backbone viruses so as to limit the number of IBR viruses required for BRD protection. Also, .conventionally derived vaccines (killed virus, inactivated bacterins and modified live viruses) could be included as part of the BRD vaccine WO 93/02104 PCT/ US92/06034 -125formulation should such vaccine components prove to be more effective.
WO 93/02104 WO 93/0210 tIS92/06034 -126- 1. J.L. Cantello et al., Journal of Virology 1584- 1588 (1991).
2. U.K. Laernnli, Nature 2217, 680-685 (1970).
3. B. Lornniczi et al., Journal of Virology 970-979 (1984).
4. R. Longnecker and B. Roizrnan, Science 236, 573-576 (1987).
S. Macken and B. Roizrnan, Proc. Natl. Acad. Sci. USA 79, 4917-4921 (1982).
6. T. Maniatis et al., Molecular Cloninr:--A- Laboratory Manual, cold Spring Harbor Press (1982).
7. J.E. Mayfield et al., Journal of Virology 47, 259- 264 (1983).
8. D.J. McGeoch et al., Journal of Molecular Biology 111 1-13 (1985).
9. D.J. McGeoch et al., Journal of General Virology, 19-38 (1987).
D.J. McGeoch et al., Journal of General Virology 69., 1531-1574 (1988).
11. E.A. Petrovskis et al., Journal of Virology 60, 116- 169 (1986).
12. T.J. Rea et al. Journal of Virology 54, 21-29 (1985).
WO 93/02 104 ~cr/ US92/06034 -127- 13. A.K. Robbins et al., Journal of Virology 58 339-347 (1986).
14. J. Sambrook et al., Molecular Coninc: A Laboratorv Msnual, second Edition, Cold Spring Harbor Press (1989).
G.A. Smith et al., Journal of General Virology ZJ1, 2417-2424 (1990).
16. D.R. Thomsen et al., Gene 16, 207-217, (1981) 17. S.K. Tikoo et al., Journal of Virology 64j, 5132-5142 (1990).
18. C.E. Aronson, ed., Veterinary Pharmacex;ti~als and Bilgias Veterinary Medicine Pubi. Co., Lenexa, KS, pp. 138-139 (1982-1983).
19. P.C. Weber et al., Science 236 576-579 (1987).
U.S. Wirth et al., Journal of Virology 195-205 (1991).
21. M. Zijil et al., Journal of Virology fl,, 1747-1755 (1990).
22. L. Villarreal and P. Berg, Science 1 ,S 183-185 (1977).
23. U. Gubler and B.J. Hoffman, Gene 25, 263-269 (1983).
24. F.L. Graham and A. Van 'der Eb, Virology ~JE, 556-567 (1973).
N. Elango et al., Journal of Virology 2,481-489 (1986).
WO 93/02104 PI'! U/LS92/06034 -128- 26. M.K. Spriggs and P.L. Collins, Journal' of Virology 646-654 (1986).
27. B.M. Blumnberg et al., Journal of General Virology 66, 317-331 (1985).
28. R. W. Price and A. Kahn, Infection and Immunity 2A, 571-580 (1981).
29. P. B. Tenser et al., J. of General, Virology 1369-1373 (1983).
B. Roizman et al., Cold Spring Harbor Conference on New Approaches to Viral Vaccines (September, 1983).
31. R. L. Thompson et al., Virology 131 180-192 (1983) 32. K. Fukuchi et al., Proc. Natl. Acad. Sci. U.S.A. §Z, 751-754, 1985.
33. J. M. Koomey et al. J. of Virology 662-665, 1984.
34. S.B. Mohanty and S.K. Dutta, VeterinaryVrooy Lea and Febiger, Philadelphia (1981).
R. Crandell in Current Veterinary Therapy, pages 543-546, W.B. Saunders, Philadelphia (1981).
36. H. Ludwig in The Hery-esyiruseg, Vol. 2, B. Roizman, ed., Plenum Press (1983).
37. A.J. Davison, EMIBO Journal, a, 2203-2209 (1983).
38. F.A. Ferrari et al., J. -of Bacteriology J.U, 556-562 1985.
WO) 93/02 104 CT S9/10.
I"C['/US92/06034 -129- 39. V.T. Ci and L.A. Herzenberg, Selected Methods in Cellular Inunnolocry, Freeman Pubi. Co., San Francisco (1980). pp. 351-372.
S. Ihara et al., Virology 268-278 (1982).
41. D. Hanahan, Molecular Biology 166, 557-580 (1983).
42. M.W. Mellencamp, et al., J. of Clinical Microbiology .27, 2208-2213 (1989).
43. Kit et al., U.S. Patent No. 4,824,667, issued April 1989.
44. Kit et al., U.S. Patent 4,703,011, issued October 27, 1987.
Kit et al., The Veterinary Record .12Z, 363-364 (1990).
46. European Patent Publication EP 0 326 127 A2, published August 2, 1989.
47. Federal Register, Vol. 55, No. 90, pp. 19245-19253 (May 9, 1990).
48. Fitzpatrick et al., J. of Virol. Q,4239-4288 (1988).
49. T. Ben-Porat et al., Virol. 154 325-334 (1986).
F. Zuckerman et al., in Vaccination and Control of Auieszky's Disease, Ed. J. van Oirschot, Kluwer, London (1989). pp. 107-117.
51. L.E. Post et al., J. Reprod. Fert. Suppl. Al 97-104 (1990).
WO 93/0210-4 'CT/S92/06034 -130- 52. Wirth et al., J. of Virol. 63, 4882-4889 (1989).
53. B. Moss, Science 52, 1662-1667 (1991).
54. R.W. Honess, J. of General Virology 65, 2077-2107 (1984).
Cook Stevens, J. of General Virology 31, 75-80 (1976).
56. Desrosiers et al., Molecular and Cellular Biology 2796-2803 (1985).
57. Thomsen et al., Gene 57, 261-265 (1987).
58. Weir and Narayanan, Nucleic Acids Research a, 10267-10282 (1988).
59. Spaete and Mocarski, Proceedings of the National Academy of Sciences U.S.A. 9A, 7213-7217 (1987).
Whealy et al., Journal of Virology 62, 4185-4194 (1988).
61. Shih et al,, Proceedings of the National Academy of Sciences U.S.A. 81, 5867-5870 (1984).
62. Edwards et al., in Technological Advances in Vaccine Development, pp. 223-234, Alan Riss Inc. (1988).
63. Proceeding of the 94th Annual Meeting of the United States Animal Health Association, pp. 66-75 (1990).
64. E.A. Petrovskis et al., Journal of Virology 60, 185- 193 (1986).
WO 93/02104 PCIT/JS92/06034 -131- Toda et al., U.S. Patent No. 4,132,775, issued January 2, 1979.
66. M.S. Collett et al., Journal of Virology 65, 200- 208, (1988).
67. M.A. Innis et al., PCR Protocols: A Guide to Methods and Applications, 84-91, Academic Press, Inc. San Diego (1990).
68. R.D. Walker, et al., Am. J. vet Res. 65, 1230-1234 (1984) 69. E. Harlow, and D. Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Press, New York (1988).
C.A. Hjerpe, The Bovine Respiratory Disease Complex.
In: Current Veterinary Therapy 2: Food Animal Practice. Ed. by J.L. Howard, Philadelphia, W.B.
Saunders Co., 1986, pp 670-680.
71. F. Fenner, et al., "Mechanisms of Disease Production: Acute Infections", Veterinar Viroloy.
Academic Press, Inc., Orlando, Florida, 1987, pp 183-202.
72. T. Inque, et al., Journal of General Virology 919-934 (1989).
Claims (21)
1. A live recombinant infectious bovine rhinotracheitis virus comprising a viral genome of a naturally-occurring infectious bovine rhinotracheitis virus from which DNA encoding US2 gene has been deleted.
2. The live recombinant infectious bovine rhinotracheitis virus of claim 1, further comprising a deletion in at least a portion of both repeat regions of the genome.
3. The live recombinant infectious bovine rhinotracheitis virus of claim 2, wherein a deletion in each repeat region is 800 base pairs in size and removes the only EcoRV restriction side in each repeat region and a BglII site adjacent to the EcoRV site.
4. The live recombinant infectious bovine rhinotracheitis virus of claim 3, designated S-IBR-027. The live recombinant infectious bovine rhinotracheitis virus of claim 1, further comprising a deletion in the glycoprotein G (gG) gene of the infectious bovine rhinotracheitis viral genome.
6. The live recombinant infectious bovine rhinotracheitis virus of claim 5, designated S-IBR-037.
7. The live recombinant infectious bovine rhinotracheitis virus of claim 5, designated S-IBR-038.
8. The live recombinant infectious bovine rhinotracheitis virus of claim 1, further comprising a deletion in the glycoprotein E (gE) gene of the infectious bovine rhinotracheitis viral genome. P:\OI'P RUMS\23932.92.1V7- 10196 133
9. The live recombinant infectious bovine rhinotracheitis virus of claim 1, further comprising of a foreign DNA sequence inserted within the glycoprotein G (gG) gene of the infectious bovine rhinotracheitis virus genome.
10. The live recombinant infectious bovine rhinotracheitis virus of claim 1, further comprising of a foreign DNA sequence is inserted within the glycoprotein E (gE) gene of the infectious bovine rhinotracheitis virus genome. Of C\,tA Q \O
11. The live recombinant infectious bovine rhinctracheitis virus of claim 9 wherein the foreign DNA encodes an antigenic polypeptide.
12. The live recombinant infectious bovine rhinotracheitis virus of claim 11, wherein the foreign DNA encodes E. coli beta-galactosidase.
13. The live recombinant infectious bovine rhinotracheitis virus of claim 11, wherein the foreign DNA encodes E. coli B-glucuronidase.
14. The live recombinant infectious bovine rhinotracheitis virus of claim 11, wherein the antigenic polypeptide is selected from a group consisting of bovine respiratory virus fusion protein, bovine respiratory syncytial virus attachment protein, bovine respiratory syncytial virus nucleocapsid protein, parainfluenza type 3 fusion protein, bovine diarrhea virus glycoprotein 53, bovine rotavirus glycoprotein 38, and P Haemolytica Leukotoxin. The live recombinant infectious bovine rhinotracheitis virus of claim 12, designated S-IBR-035.
16. The live recombinant infectious bovine rhinotracheitis virus of claim 12, designated S-IBR-036. A 17. The live recombinant infectious bovine rhinotracheitis virus of claim 1, further P:\OPER MS\23932-92.187 10796 -134- comprising of a foreign DNA inserted within the XbaI site in the unique long region of the infectious bovine rhinotracheitis viral genume.
18. A method of producing a live recombinant infectious bovine rhinotracheitis virus that is fetal-safe in bovine, which comprises treating the viral genome of a naturally-occurring infectious bovine rhinotracheitis virus so as to delete from it DNA corresponding to the US2 gene of the naturally-occurring virus.
19. A vaccine for infectious bovine rhinotracheitis disease which comprises the live recombinant infectious bovine rhinotracheitis virus of claims 1 4 and 17 a suitable carrier. A vaccine for infectious bovine rhinotracheitis disease which comprises the live recombinant infectious bovine rhi, -tracheitis virus of claims 5 16 and a suitable cairier.
21. The vaccine of claim 19, wherein the suitable carrier is a physiologically balanced culture medium containing stabilizing agents. 22, The vaccine of claim 19, wherein the effective immunizing amount is from about 106 to about 109 PPU/dose.
23. The vaccine of claim 22, wherein the effective immunizing amount is from about 107 to about 10 8 PFU/dose.
24. A method of immunizing a bovine against a disease caused by an infectious bovine rhinotracheitis virus which comprises administering to the bovine an effective immunizing dose of the vaccine of claim 19. The method of claim 24, wherein the vaccine is administered by intramuscular, subcutaneous, intraperitoneal intranasally, orally or intravenous injection. r:oPAI3wMs23932*92,187 .2MI96
135- 26. A method of distinguishing a bovine vaccinated with i vaccine whic comprises the live recombinant infectious rhinotracheitis virus of claim 5, 'rom an animal infected with a wild-type infectious bovine rhinotracheitis virus which comprises detecting the presence or absence of the infectious bovine rhinotracheitis glycoprotein G (gG) in a body fluid of the bovine. 27. The method of claim 26, wherein th ,e or absence of the glycoprotein G (gG) in the body fluid is determined by detecting in the body fluid antibodies specific for glycoprotein G (gG). 28. A method of distinguishing a bovine vaccinated with a vaccine which comprises the live recombinant infectious rhinotracheitis virus of claim 8, from an animal infected with a S wild-type infectious bovine rhinotracheitis virus which comprises detecting the presence or absence of the infectious bovine rhinotracheitis glycoprotein E (gE) in a body fluid of the bovine. 29. The method of claim 28, wherein the presence or absence of the glycoprotein E (gE) in the body fluid is deiermined by detecting in the body fluid antibodies specific for glycoprotein E (gE). 30. The vaccine of claim 20, wherein the suitable carrier is a physiologically balanced culture medium containing stabilizing agents. 31. The vaccine of claim 20, wherein the effective immunizing amount is from about 106 to about 109 PFU/dose. 32. The vaccine of claim 31, w' rein the effective immunizing amount is from about 10 7 to about 108 PFU/dose. S33. A method of immunizing a bovine against a disease caused by an infectious bovine P:\O'ERU MS23932-92.,17 2/8/96
136- rhinotracheitis virus which comprises administering to the bovine an effective immunizing dose of the vaccine of claim 34. The method of claim 33, wherein the vaccine is administered by intramuscular, subcutaneous, intraperitoneal intranasally, orally or intravenous injection. DATED this 2nd day of August 1996. Syntro Corporation By DAVIES COLLISON CAVE Patent Attorneys For the Applicant(s) C
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73258491A | 1991-07-18 | 1991-07-18 | |
| US732584 | 1991-07-18 | ||
| PCT/US1992/006034 WO1993002104A1 (en) | 1991-07-18 | 1992-07-20 | Recombinant infectious bovine rhinotracheitis virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2393292A AU2393292A (en) | 1993-02-23 |
| AU672583B2 true AU672583B2 (en) | 1996-10-10 |
Family
ID=24944128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU23932/92A Ceased AU672583B2 (en) | 1991-07-18 | 1992-07-20 | Recombinant infectious bovine rhinotracheitis virus |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP0598759A4 (en) |
| AU (1) | AU672583B2 (en) |
| CA (1) | CA2113641A1 (en) |
| WO (1) | WO1993002104A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410033B1 (en) | 1987-07-27 | 2002-06-25 | Syntro Corporation | Recombinant infectious bovine rhinotracheitis virus |
| US5783195A (en) * | 1991-07-18 | 1998-07-21 | Syntro Corporation | Recombinant infectious bovine rhinotracheitis virus S-IBR-052 and uses thereof |
| FR2693472B1 (en) * | 1992-06-26 | 1994-12-23 | Rhone Merieux | Mutants of the infectious bovine rhinotracheitis virus, deleted in one of the genes of minor glycoproteins, vaccines prepared from these strains, production methods and methods of use. |
| WO1994024296A2 (en) * | 1993-04-19 | 1994-10-27 | University Of Saskatchewan | Recombinant bovine herpesvirus type 1 vaccines |
| CA2136381A1 (en) * | 1993-11-23 | 1995-05-24 | Gunther Keil | Vector vaccines of bovine herpesvirus 1 |
| EP0663403A1 (en) * | 1993-11-23 | 1995-07-19 | Akzo Nobel N.V. | Vector vaccines of bovine herpesvirus I |
| ES2074965B1 (en) * | 1994-01-31 | 1996-05-01 | Hipra Lab Sa | RECOMBINANT MUTANT VIRUSES OF INFECTIOUS BOVINE RHINOTRACHEITIS AND VACCINES THAT CONTAIN IT. |
| US6284251B1 (en) | 1996-02-26 | 2001-09-04 | Kansas State University Research Foundation | BHV-1 gene-deleted virus vaccine |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4132775A (en) * | 1973-12-03 | 1979-01-02 | Richardson-Merrell Inc. | Infectious bovine rhinotracheitis virus vaccine and method of preparing and using the same |
| CA1339735C (en) * | 1984-04-27 | 1998-03-17 | Ian Hamilton Holmes. | Cloning and sequencing of the major outer capsid gylcoprotein gene of a human rotavirus |
| DE3677494D1 (en) * | 1985-07-29 | 1991-03-14 | Upjohn Co | VIRUS VACCINE. |
| US4877737A (en) * | 1985-09-06 | 1989-10-31 | Prutech Research And Development Partnership | Attenuated pseudorabies virus which has a deletion in at least a portion of a repeat sequence and vaccine containing same |
| US4703011A (en) * | 1985-11-12 | 1987-10-27 | Novagene, Inc. | Thymidine kinase deletion mutants of bovine herpesvirus-1 |
| WO1987004463A1 (en) * | 1986-01-27 | 1987-07-30 | Syntro Corporation | Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino acid sequence and vaccine containing same |
| WO1989001040A1 (en) * | 1987-07-27 | 1989-02-09 | Syntro Corporation | Attenuated herpes viruses, herpes viruses which include foreign dna encoding an amino acid sequence and vaccines containing same |
| US4992051A (en) * | 1987-11-03 | 1991-02-12 | Novagene, Inc. | Infectious bovine rhinotracheitis virus mutants, methods for the production of same and methods for the use of same |
| AU2888089A (en) * | 1988-01-26 | 1989-07-27 | Baylor College Of Medicine | Infectious bovine rhinotracheitis virus insertion mutants, vaccines containing same, and methods for the production and use of same |
| ZA915593B (en) * | 1990-07-24 | 1993-03-31 | Novagene Inc | Herpesvirus-based viral vector which expresses a foot and mounth disease virus epitope on the surface of virus-infected cells and on the surface of virus particles,and vaccine against foot and mounth disease containing the same |
| NL9100989A (en) * | 1991-06-07 | 1993-01-04 | Stichting Centr Diergeneeskund | BOVINE HERPESVIRUS TYPE 1 DELETION MUTANTS, VACCINES BASED ON THESE, DIAGNOSTIC KITS FOR DETECTION OF BOVINE HERPESVIRUS TYPE 1. |
-
1992
- 1992-07-20 CA CA002113641A patent/CA2113641A1/en not_active Abandoned
- 1992-07-20 EP EP92916108A patent/EP0598759A4/en not_active Withdrawn
- 1992-07-20 WO PCT/US1992/006034 patent/WO1993002104A1/en not_active Application Discontinuation
- 1992-07-20 AU AU23932/92A patent/AU672583B2/en not_active Ceased
Non-Patent Citations (2)
| Title |
|---|
| J. CLINICAL MICROBIOLOGY VOL 21 PP 546-552 * |
| J. VIROLOGY VOL 63 PP 4882-4889 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0598759A1 (en) | 1994-06-01 |
| WO1993002104A1 (en) | 1993-02-04 |
| AU2393292A (en) | 1993-02-23 |
| EP0598759A4 (en) | 1998-06-03 |
| CA2113641A1 (en) | 1993-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5451499A (en) | Attenuated, genetically-engineered pseudorabies virus S-PRV-155 and uses thereof | |
| JP4339835B2 (en) | Recombinant turkey herpesvirus and use thereof | |
| US5599544A (en) | Recombinant infectious bovine rhinotracheitis virus | |
| EP0332677B1 (en) | Attenuated herpes viruses, herpes viruses which include foreign dna encoding an amino acid sequence and vaccines containing same | |
| US5853733A (en) | Recombinant herpesvirus of turkeys and uses thereof | |
| US5874279A (en) | Recombinant infectious bovine rhinotracheitis virus | |
| US5928648A (en) | Recombinant herpesvirus of turkeys and uses thereof | |
| US5741696A (en) | Recombinant equine herpesviruses | |
| US5961982A (en) | Recombinant herpesvirus of turkeys and uses thereof | |
| US5047237A (en) | Attenuated pseudorabies virus having a deletion of at least a portion of a gene encoding an antigenic, nonessential protein, vaccine containing same and methods of identifying animals vaccinated with the vaccine | |
| CA2166371A1 (en) | Avian herpesvirus-based live recombinant avian vaccine, in particular against gumboro disease | |
| AU672583B2 (en) | Recombinant infectious bovine rhinotracheitis virus | |
| US5731188A (en) | Recombinant equine herpesviruses | |
| US6410033B1 (en) | Recombinant infectious bovine rhinotracheitis virus | |
| US5783195A (en) | Recombinant infectious bovine rhinotracheitis virus S-IBR-052 and uses thereof | |
| JP3964458B2 (en) | Recombinant infectious laryngotracheitis virus and use thereof | |
| EP0654089B1 (en) | Recombinant equine herpesviruses | |
| EP0794257A1 (en) | Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino aced sequence and vaccine containing same | |
| US5068192A (en) | Attenuated pseudorabies virus which includes foreign DNA encoding an amino acid sequence | |
| US6225111B1 (en) | Recombinant equine herpesviruses | |
| JPH09505726A (en) | Recombinant infectious laryngotracheitis virus and their use | |
| AU684046C (en) | Recombinant herpesvirus of turkeys and uses thereof | |
| AU727278B2 (en) | Recombinant fowlpox viruses and uses thereof II |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |